

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : <b>C12N 15/24, C07K 14/54, A61K 38/20, C07K 16/24, G01N 33/68, C12Q 1/68</b>		A1	(11) International Publication Number: <b>WO 00/42187</b>
			(43) International Publication Date: 20 July 2000 (20.07.00)
(21) International Application Number: <b>PCT/US00/00005</b>		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: <b>10 January 2000 (10.01.00)</b>			
(30) Priority Data: <b>09/229,402 11 January 1999 (11.01.99) US</b>			
(71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).			
(72) Inventors: GORMAN, Daniel, M.; 6371 Central Avenue, Newark, CA 94560 (US). BAZAN, J., Fernando; 775 University Drive, Menlo Park, CA 94025 (US). KASTELEIN, Robert, A.; 463 Summit Drive, Redwood City, CA 94062 (US).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(74) Agents: THAMPOE, Immac, J. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).			
(54) Title: INTERLEUKIN-17 RELATED MAMMALIAN CYTOKINE (IL-171). POLYNUCLEOTIDES ENCODING THEM. USES			
(57) Abstract			
CTLA-8 related antigens from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigens. Methods of using said reagents and diagnostic kits are also provided.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BC	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

INTERLEUKIN-17 RELATED MAMMALIAN CYTOKINE (IL-171). POLYNUCLEOTIDES ENCODING THEM. USES

This application is a PCT filing claiming priority to  
5 U.S. Patent Application USSN 09/229,402, filed January 11,  
1999.

FIELD OF THE INVENTION

The present invention relates to compositions related to  
10 proteins which function in controlling physiology,  
development, and differentiation of mammalian cells, e.g.,  
cells of a mammalian immune system. In particular, it  
provides nucleic acids, proteins, antibodies, and mimetics  
which regulate cellular physiology, development,  
15 differentiation, or function of various cell types, including  
hematopoietic cells.

BACKGROUND OF THE INVENTION

The immune system of vertebrates consists of a number of  
20 organs and several different cell types. Two major cell types  
include the myeloid and lymphoid lineages. Among the lymphoid  
cell lineage are B cells, which were originally characterized  
as differentiating in fetal liver or adult bone marrow, and T  
cells, which were originally characterized as differentiating  
25 in the thymus. See, e.g., Paul (ed. 1998) Fundamental  
Immunology (4th ed.) Raven Press, New York.

In many aspects of the development of an immune response  
or cellular differentiation, soluble proteins known as  
cytokines play a critical role in regulating cellular  
30 interactions. These cytokines apparently mediate cellular  
activities in many ways. They have been shown, in many cases,  
to modulate proliferation, growth, and differentiation of  
hematopoietic stem cells into the vast number of progenitors  
composing the lineages responsible for an immune response.

35 However, the cellular molecules which are expressed by  
different developmental stages of cells in these maturation  
pathways are still incompletely identified. Moreover, the

roles and mechanisms of action of signaling molecules which induce, sustain, or modulate the various physiological, developmental, or proliferative states of these cells is poorly understood. Clearly, the immune system and its response to various stresses had relevance to medicine, e.g., infectious diseases, cancer related responses and treatment, allergic and transplantation rejection responses. See, e.g., Thorn, et al. Harrison's Principles of Internal Medicine McGraw/Hill, New York.

Medical science relies, in large degree, to appropriate recruitment or suppression of the immune system in effecting cures for insufficient or improper physiological responses to environmental factors. However, the lack of understanding of how the immune system is regulated or differentiates has blocked the ability to advantageously modulate the normal defensive mechanisms to biological challenges. Medical conditions characterized by abnormal or inappropriate regulation of the development or physiology of relevant cells thus remain unmanageable. The discovery and characterization of specific cytokines will contribute to the development of therapies for a broad range of degenerative or other conditions which affect the immune system, hematopoietic cells, as well as other cell types. The present invention provides solutions to some of these and many other problems.

25

#### SUMMARY OF THE INVENTION

The present invention is based, in part, upon the discovery of cDNA clones encoding various cytokine-like proteins which exhibit significant sequence similarity to the cytokine designated CTLA-8.

The invention embraces isolated genes encoding the proteins of the invention, variants of the encoded proteins, e.g., mutations (mutants) of the natural sequences, species and allelic variants, fusion proteins, chemical mimetics, antibodies, and other structural or functional analogs. Various uses of these different nucleic acid or protein compositions are also provided.

In certain nucleic acid embodiments, the invention provides an isolated or recombinant polynucleotide comprising sequence from: a) a mammalian IL-171, which: encodes at least 8 contiguous amino acids of SEQ ID NO: 3 or 5; encodes at least two distinct segments of at least 5 contiguous amino acids of SEQ ID NO: 3 or 5; or comprises one or more segments at least 21 contiguous nucleotides of SEQ ID NO: 1 or 4; or b) a mammalian IL-175, which: encodes at least 8 contiguous amino acids of SEQ ID NO: 8; encodes at least two distinct segments of at least 5 contiguous amino acids of SEQ ID NO: 8; or comprises one or more segments at least 21 contiguous nucleotides of SEQ ID NO: 6. Other embodiments include such a polynucleotide in an expression vector, comprising sequence: a) (IL-171) which: encodes at least 12 contiguous amino acids of SEQ ID NO: 3 or 5; encodes at least two distinct segments of at least 7 and 10 contiguous amino acids of SEQ ID NO: 3 or 5; or comprises at least 27 contiguous nucleotides of SEQ ID NO: 1 or 4; or b) (IL-175) which: encodes at least 12 contiguous amino acids of SEQ ID NO: 8; encodes at least two distinct segments of at least 7 and 10 contiguous amino acids of SEQ ID NO: 8; or comprises at least 27 contiguous nucleotides of SEQ ID NO: 6. Certain embodiments will include those polynucleotides: a) (IL-171) which: encode at least 16 contiguous amino acids of SEQ ID NO: 3 or 5; encode at least two distinct segments of at least 10 and 14 contiguous amino acid residues of SEQ ID NO: 3 or 5; comprise at least 33 contiguous nucleotides of SEQ ID NO: 1 or 4; or comprise SEQ ID NO: 1 or 4; or b) (IL-175) which: encode at least 16 contiguous amino acid residues of SEQ ID NO: 8; encode at least two distinct segments of at least 10 and 13 contiguous amino acid residues of SEQ ID NO: 8; or comprise at least 33 contiguous nucleotides of SEQ ID NO: 6.

Various methods are provided, e.g., making: a) a polypeptide comprising expressing the described expression vector, thereby producing the polypeptide; b) a duplex nucleic acid comprising contacting a described polynucleotide with a complementary nucleic acid, thereby resulting in production of

the duplex nucleic acid; or c) a described polynucleotide comprising amplifying using a PCR method.

Alternatively, the invention provides an isolated or recombinant polynucleotide which hybridizes under stringent wash conditions of at least 55° C and less than 400 mM salt to: a) the described (IL-171) polynucleotide which consists of SEQ ID NO: 1 or 4; or b) the described (IL-175) polynucleotide which consists of SEQ ID NO: 6 or 7. Other embodiments include such described polynucleotide: a) wherein the wash conditions are at least 65° C and less than 300 mM salt; or b) which comprises at least 50 contiguous nucleotides of the coding portion of: SEQ ID NO: 1 or 4 (IL-171); or SEQ ID NO: 6 or 7 (IL-175).

Certain kits are provided, e.g., comprising a described polynucleotide, and: a) instructions for the use of the polynucleotide for detection; b) instructions for the disposal of the polynucleotide or other reagents of the kit; or c) both a and b.

Various cells are provided also, e.g., a cell containing the described expression vector, wherein the cell is: a prokaryotic cell; a eukaryotic cell; a bacterial cell; a yeast cell; an insect cell; a mammalian cell; a mouse cell; a primate cell; or a human cell.

Polypeptide embodiments include, e.g., an isolated or recombinant antigenic polypeptide: a) (IL-171) comprising at least: i) one segment of 8 identical contiguous amino acids from SEQ ID NO: 3 or 5; or ii) two distinct segments of at least 5 contiguous amino acids from SEQ ID NO: 3 or 5; or b) (IL-175) comprising at least: i) one segment of 8 identical contiguous amino acids from SEQ ID NO: 8; or ii) two distinct segments of at least 5 contiguous amino acids from SEQ ID NO: 8. Additional embodiments include such a described polypeptide, wherein: a) the segment of 8 identical contiguous amino acids is at least 14 contiguous amino acids; or b) one of the segments of at least 5 contiguous amino acids comprises at least 7 contiguous amino acids. Other embodiments include a described polypeptide, wherein: A) (IL-171) the polypeptide:

a) comprises SEQ ID NO: 3 or 5; b) binds with selectivity to a polyclonal antibody generated against an immunogen of SEQ ID NO: 3 or 5; c) comprises a plurality of distinct polypeptide segments of 10 contiguous amino acids of SEQ ID NO: 3 or 5; d) 5 is a natural allelic variant of SEQ ID NO: 3 or 5; e) has a length at least 30 amino acids; or f) exhibits at least two non-overlapping epitopes which are selective for SEQ ID NO: 3 or 5; or B) (IL-175) the polypeptide: a) comprises SEQ ID NO: 8; b) binds with selectivity to a polyclonal antibody 10 generated against an immunogen of SEQ ID NO: 8; c) comprises a plurality of distinct polypeptide segments of 10 contiguous amino acids of SEQ ID NO: 8; d) has a length at least 30 amino acids; or e) exhibits at least two non-overlapping epitopes which are selective for SEQ ID NO: 8. Various other 15 embodiments include such a described polypeptide, which: a) is in a sterile composition; b) is not glycosylated; c) is denatured; d) is a synthetic polypeptide; e) is attached to a solid substrate; f) is a fusion protein with a detection or purification tag; g) is a 5-fold or less substitution from a 20 natural sequence; or h) is a deletion or insertion variant from a natural sequence.

Methods of using described polypeptides are also provided, e.g.,: a) to label the polypeptide, comprising labeling the polypeptide with a radioactive label; b) to 25 separate the polypeptide from another polypeptide in a mixture, comprising running the mixture on a chromatography matrix, thereby separating the polypeptides; c) to identify a compound that binds selectively to the polypeptide, comprising incubating the compound with the polypeptide under appropriate 30 conditions; thereby causing the compound to bind to the polypeptide; or d) to conjugate the polypeptide to a matrix, comprising derivatizing the polypeptide with a reactive reagent, and conjugating the polypeptide to the matrix.

Antibodies are also provided, including a binding 35 compound comprising an antigen binding portion from an antibody which binds with selectivity to such a described polypeptide, wherein the polypeptide: a) (IL-171) comprises

SEQ ID NO 3 or 5; or b) (IL-175) comprises SEQ ID NO 8. Certain embodiments embrace such a binding compound, wherein the antibody is a polyclonal antibody which is raised against: a) (IL-171) of SEQ ID NO: 3 or 5; or b) (IL-175) SEQ ID NO: 8.

5 Other embodiments include such a described binding compound, wherein the: a) antibody: i) is immunoselected; ii) binds to a denatured protein; or iii) exhibits a Kd to the polypeptide of at least 30 mM; or b) the binding compound: i) is attached to a solid substrate, including a bead or plastic membrane; ii)

10 is in a sterile composition; or iii) is detectably labeled, including a radioactive or fluorescent label.

Methods are provided, e.g., producing an antigen:antibody complex, comprising contacting a polypeptide comprising sequence from SEQ ID NO: 3, 5, or 8 with a described binding compound under conditions which allow the complex to form. Preferably, the binding compound is an antibody, and the polypeptide is in a biological sample.

Kits are provided, e.g., comprising a described binding compound and: a) a polypeptide of SEQ ID NO: 3, 5, or 8; b) instructions for the use of the binding compound for detection; or c) instructions for the disposal of the binding compound or other reagents of the kit.

And a method if provided of evaluating the selectivity of binding of an antibody to a protein of SEQ ID NO: 3, 5, or 8, comprising contacting a described antibody to the protein and to another cytokine; and comparing binding of the antibody to the protein and the cytokine.

30 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

I. General

The present invention provides DNA sequence encoding various mammalian proteins which exhibit structural features characteristic of cytokines, particularly related to the cytokine designated CTLA-8 (also referred to as IL-17). Rat, mouse, human forms and a viral homolog of the CTLA-8 have been described and their sequences available from GenBank. See

Rouvier, et al. (1993) J. Immunol. 150:5445-5456; Yao, et al. (1995) Immunity 3:811-821; Yao, et al. (1995) J. Immunol. 155:5483-5486; and Kennedy, et al. (1996) J. Interferon and Cytokine Res. 16:611-617. The CTLA-8 has activities implicated in arthritis, kidney graft rejection, tumorigenicity, virus-host interactions, and innate immunity; and appears to exhibit certain regulatory functions similar to IL-6. See PubMed (search for IL-17); Chabaud, et al. (1998) J. Immunol. 63:139-148; Amin, et al. (1998) Curr. Opin. Rheumatol. 10:263-268; Van Kooten, et al. (1998) J. Am. Soc. Nephrol. 9:1526-1534; Fossiez, et al. (1998) Int. Rev. Immunol. 16:541-551; Knappe, et al. (1998) J. Virol. 72:5797-5801; Seow (1998) Vet. Immunol. Immunopathol. 63:139-48; and Teunissen, et al. (1998) J. Invest. Dermatol. 111:645-649. A report on the signaling through the NF $\kappa$ B transcription factor implicates a signal pathway which is used in innate immunity. Shalom-Barak, et al. (1998) J. Biol. Chem. 273:27467-27473.

The newly presented cDNA sequences exhibit various features which are characteristic of mRNAs encoding cytokines, growth factors, and oncogenes. Because the IL-17 is the first member of this newly recognized family of cytokines related to TGF- $\beta$ , Applicants have designated the family IL-170, with the new members IL-171 and IL-175; and IL-172, IL-173, IL-174, IL-176, and IL-177. The fold for this family is predicted to be that of the TGF- $\beta$  family of cytokines. The TGF- $\beta$  family of cytokines, and the IL-170 family share the common feature of a cystine knot motif, characterized by a particular spacing of cysteine residues. See, e.g., Sun and Davies (1995) Ann. Rev. Biophys. Biomolec. Struct. 24:269-291; McDonald, et al. (1993) Cell 73:421-424; and Isaacs (1995) Curr. Op. Struct. Biol. 5:391-395. In particular, the structures suggest a number of conserved cysteines, which correspond to, and are numbered, in human IL-172 (SEQ ID NO: 10), cysteines at 101, 103, 143, 156, and 158. The first cysteine corresponds to the position in Table 7 of human IL-175 (SEQ ID NO: 8) cys17. The fourth cysteine corresponds to that at human IL-171 ((SEQ ID NO: 3) cys50; at mouse IL-172 (SEQ ID NO: 12) cys141; at human IL-173

(SEQ ID NO: 14) cys119; and mouse IL-174 (SEQ ID NO: 24) cys104. The disulfide linkages should be cysteines 2 with 5; and 3 with 6; and 1 with 4. Functional significance of the fold similarity suggests formation of dimers for the IL-170 family. As a consequence, IL-170 dimers would bring together two cell surface receptors, through which signal transduction will occur.

These new proteins are designated CTLA-8 related, or generally IL-170, proteins. The natural proteins should be capable of mediating various physiological responses which would lead to biological or physiological responses in target cells, e.g., those responses characteristic of cytokine signaling. Initial studies had localized the message encoding this protein to various cell lines of hematopoietic cells. Genes encoding the original CTLA-8 (IL-17) antigen have been mapped to mouse chromosome 1A and human chromosome 2q31. Murine CTLA-8 was originally cloned by Rouvier, et al. (1993) J. Immunol. 150:5445-5456. The human IL-173 has been mapped to chromosome 13q11. Similar sequences for proteins in other mammalian species should also be available.

Purified CTLA-8, when cultured with synoviocytes, is able to induce the secretion of IL-6 from these cells. This induction is reversed upon the addition of a neutralizing antibody raised against human CTLA-8. Endothelial, epithelial, fibroblast and carcinoma cells also exhibit responses to treatment with CTLA-8. This data suggests that CTLA-8 may be implicated in inflammatory fibrosis, e.g., psoriasis, sclerodermia, lung fibrosis, or cirrhosis. CTLA-8 may also cause proliferation of carcinomas or other cancer cells inasmuch as IL-6 often acts as a growth factor for such cells. As such, the newly discovered other related family members are likely to have similar or related biological activities.

The descriptions below are directed, for exemplary purposes, to a murine or human IL-170 proteins, but are likewise applicable to related embodiments from other species.

## II. Nucleic Acids

Tables 1-6 disclose the nucleotide and amino acid sequences of various new IL-170 family member sequences. The described nucleotide sequences and the related reagents are useful in constructing DNA clones useful for extending the clones in both directions for full length or flanking sequence determination, expressing IL-170 polypeptides, or, e.g., isolating a homologous gene from another natural source. Typically, the sequences will be useful in isolating other genes, e.g., allelic variants, from mouse, and similar procedures will be applied to isolate genes from other species, e.g., warm blooded animals, such as birds and mammals. Cross hybridization will allow isolation of genes from other species. A number of different approaches should be available to successfully isolate a suitable nucleic acid clone from other sources.

Table 1: Nucleotide sequence encoding a primate, e.g., human, IL-171 under IUPAC code. Also can use complementary nucleic acid sequences for many purposes. SEQ ID NO: 1:

20	GACACGGATG AGGACCAGCTA TCCACAGAAAG CTGGCCCTCG CCGAGTCGCCT GTGCAGAGGC	60
25	TGTATCGATG CACGGACGGG CCCGCGAGACA GCTGCGCTCA ACTCCGTGCG GCTGCTCCAG	120
	AGCCTGCTGG TGCTGCGCCG CCAGGCCCTGC TCCCGCGACG GCTCGGGGCT CCCCCACACCT	180
30	GGGGCCTTTG CCTTCCACAC CGAGTTCATC CACGTCCCCG TCGGCTGCAC CTGCGTGCTG	240
	CCCCGTTCAA GTGTGACCGC CAAGGCCGTG GGGCCCTTAG NTGACACCGT GTGCTCCCCA	300
35	GAGGGACCCC TATTATGGG AATTATGGTA TTATATGCTT CCCACATACT TGGGGCTGGC	360
	ATCCCCNGCT GAGACAGCCC CCTGTTCTAT TCAGCTATAT GGGGAGAAGA GTAGACTTTC	420
	AGCTAAGTGA AAAGTGNAAC GTGCTGACTG TCTGCTGTCG TNCTACTNAT GCTAGCCGA	480
40	GTGTTCACTC TGAGCCTGTT AAATATAGGC GGTTATGTAC C	521

SEQ ID NO: 2 and 3 are PATENTIN translatable cDNA and polypeptide sequences:

45	GAC ACG GAT GAG GAC CGC TAT CCA CAG AAG CTG GCC TTC GCC GAG TGC Asp Thr Asp Glu Asp Arg Tyr Pro Gln Lys Leu Ala Phe Ala Glu Cys	48
	1 5 10 15	
50	CTG TGC AGA GGC TGT ATC GAT GCA CGG ACG GGC CGC GAG ACA GCT GCG Leu Cys Arg Gly Cys Ile Asp Ala Arg Thr Gly Arg Glu Thr Ala Ala	96
	20 25 30	

CTC AAC TCC GTG CGG CTG CTC CAG AGC CTG CTG GTG CTG CGC CGC CGG 144  
 Leu Asn Ser Val Arg Leu Leu Gln Ser Leu Leu Val Leu Arg Arg Arg  
 35 40 45

5 CCC TGC TCC CGC GAC GGC TCG GGG CTC CCC ACA CCT GGG GCC TTT GCC 192  
 Pro Cys Ser Arg Asp Gly Ser Gly Leu Pro Thr Pro Gly Ala Phe Ala  
 50 55 60

10 TTC CAC ACC GAG TTC ATC CAC GTC CCC GTC GGC TGC ACC TGC GTG CTG 240  
 Phe His Thr Glu Phe Ile His Val Pro Val Gly Cys Thr Cys Val Leu  
 65 70 75 80

15 CCC CGT TCA AGT GTG ACC GCC AAG GCC GTG GGG CCC TTA GnT GAC ACC 288  
 Pro Arg Ser Ser Val Thr Ala Lys Ala Val Gly Pro Leu Xaa Asp Thr  
 85 90 95

20 GTG TGC TCC CCA GAG GGA CCC CTA TTT ATG GGA ATT ATG GTA TTA TAT 336  
 Val Cys Ser Pro Glu Gly Pro Leu Phe Met Gly Ile Met Val Leu Tyr  
 100 105 110

25 GCT TCC CAC ATA CTT GGG GCT GGC ATC CCG nGC TGAGACAGCC CCCTGTTCTA 389  
 Ala Ser His Ile Leu Gly Ala Gly Ile Pro Xaa  
 115 120

30 TTCAGCTATA TGGGGAGAAAG AGTAGACTTT CAGCTAAGTG AAAAGTGNAA CGTGCTGACT 449  
 GTCTGCTGTC GTnCTACTnA TGCTAGCCCCG AGTGTTCACT CTGAGCCTGT TAAATATAGG 509  
 CGGTTATGTA CC 521

35 DTDEDRYPQKLAFAECLRGCIDARTGRETAALNSVRLLQSLLVLRRRPCS RDGSGLPTPGAFAFH  
 TEFIHVPVGCTCVLPRSSVTAKAVGPLXDTVCSP EGPLFMGIMVLYASHILGAGIPX

40 45 Supplementary nucleotide sequence encoding a primate, e.g.,  
 human, IL-171 polypeptide and predicted amino acid sequence.  
 Also can use complementary nucleic acid sequences for many  
 purposes. Predicted signal cleavage site indicated, but may be  
 a few residues on either side; putative glycosylation site at  
 residues 55-57. SEQ ID NO: 4 and 5.

45 50 55 60 65 gtgtggcctc aggtataaga gcccgtgctg ccaggtgcac gcccaggatgc acctgtggga 60  
 ttgccgcacatgtgcaggccgctccaagcccgccctgccccgcaccatgc 117  
 Met  
 acg ctc ctc ccc ggc ctc ctg ttt ctg acc tgg ctg cac aca tgc ctg 165  
 Thr Leu Leu Pro Gly Leu Leu Phe Leu Thr Trp Leu His Thr Cys Leu  
 -15 -10 -5 -1  
 gcc cac cat gac ccc tcc ctc agg ggg cac ccc cac agt cac ggt acc 213  
 Ala His His Asp Pro Ser Leu Arg Gly His Pro His Ser His Gly Thr  
 1 5 10 15  
 cca cac tgc tac tcg gct gag gaa ctg ccc ctc ggc cag gcc ccc cca 261  
 Pro His Cys Tyr Ser Ala Glu Glu Leu Pro Leu Gly Gln Ala Pro Pro  
 20 25 30  
 cac ctg ctg gct cga ggt gcc aag tgg ggg cag gct ttg cct gta gcc 309  
 His Leu Leu Ala Arg Gly Ala Lys Trp Gly Gln Ala Leu Pro Val Ala  
 35 40 45  
 ctg gtg tcc agc ctg gag gca gca agc cac agg ggg agg cac gag agg 357  
 Leu Val Ser Ser Leu Glu Ala Ala Ser His Arg Gly Arg His Glu Arg  
 50 55 60

	ccc tca gct acg acc cag tgc ccg gtg ctg cgg ccg gag gag gtg ttg	405		
65	Pro Ser Ala Thr Thr Gln Cys Pro Val Leu Arg Pro Glu Glu Val Leu			
	70	75		
5	gag gca gac acc cac cag cgc tcc atc tca ccc tgg aga tac cgt gtg	453		
	Glu Ala Asp Thr His Gln Arg Ser Ile Ser Pro Trp Arg Tyr Arg Val			
	85	90	95	
10	gac acg gat gag gac cgc tat cca cag aag ctg gcc ttc gcc gag tgc	501		
	Asp Thr Asp Glu Asp Arg Tyr Pro Gln Lys Leu Ala Phe Ala Glu Cys			
	100	105	110	
15	ctg tgc aga ggc tgt atc gat gca cgg acg ggc cgc gag aca gct gcg	549		
	Leu Cys Arg Gly Cys Ile Asp Ala Arg Thr Gly Arg Glu Thr Ala Ala			
	115	120	125	
20	ctc aac tcc gtg cgg ctg ctc cag agc ctg ctg gtg ctg cgc cgc cgg	597		
	Leu Asn Ser Val Arg Leu Leu Gln Ser Leu Leu Val Leu Arg Arg Arg			
	130	135	140	
25	ccc tgc tcc cgc gac ggc tcg ggg ctc ccc aca cct ggg gcc ttt gcc	645		
	Pro Cys Ser Arg Asp Gly Ser Gly Leu Pro Thr Pro Gly Ala Phe Ala			
	145	150	155	160
30	ttc cac acc gag ttc atc cac gtc ccc gtc ggc tgc acc tgc gtg ctg	693		
	Phe His Thr Glu Phe Ile His Val Pro Val Gly Cys Thr Cys Val Leu			
	165	170	175	
35	ccc cgt tca gtg tgaccgccga ggccgtgggg cccctagact ggacacgtgt	745		
	Pro Arg Ser Val			
	180			
	gctccccaga gggcacccccc tatttatgtg tatttattgg tatttatatg cctccccaa	805		
40	cactaccctt ggggtctggg cattcccccgt gtctggagga cagcccccca ctgttctcct	865		
	catctccagc ctcagtagtt gggggtagaa ggagctcagc acctcttcca gcccattaaag	925		
	ctgcagaaaa ggtgtcacac ggctgcctgt accttggtc cctgtcctgc tcccggttc	985		
45	ccttacccta tcactggcct caggcccccg caggctgcct cttcccaacc tccttgaaag	1045		
	tacccctgtt tcttaaacaa ttatthaagt gtacgtgtat tattaaactg atgaacacat	1105		
	cc	1107		
50	MTLLPGLLFLTWLHTCLAHHDPSLRGHPHSHGTPHCHYSAEELPLGQAPPHLARGAKWGOALPVAL VSSLEAAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRYPQKLAFAECLCR GCIDARTGRETAALNSVRLLQSLVLRRRPCSRDGSGLPTPGAFAFHTEFIHPVGCTCVLPRSV			

Table 2: Nucleotide sequence encoding a primate, e.g., human, IL-175 sequence under IUPAC code. Also can use complementary nucleic acid sequences for many purposes. SEQ ID NO: 6:

60	GAGAAAGAGC TTCCTGCACA AAGTAAGCCA CCAGCGAAC ATGACAGTGA AGACCCTGCA	60
	TGGCCCAGCC ATGGTCAAGT ACTTGCTGCT GTCGATATTG GGGCTTGCCT TTCTGAGTGA	120
	GGCGGCAGCT CGGAAAATCC CCAAAGTAGG ACATACTTT TTCCAAAAGC CTGAGAGTTG	180
65	CCCGCCTGTG CCAGGAGGTA GTATGAAGCT TGACATTGGC ATCATCAATG AAAACCAGCG	240

	CGTTTCCATG TCACGTAACA TCGAGAGCCC CTCCACCTCC CCCTGGAATT ACAGTCAC	300
	TTGGGACCCC AACCGGTACC CCTCGAAGTT GTACAGGCC AAGTGTAGGA ACTTGGGCTG	360
5	TATCAATGCT CAAGGAAAGG AAGACATCTN CATGAATTCC GTC	403
10	SEQ ID NO: 7 and 8 are PATENTIN translatable cDNA and polypeptide sequences. Predicted signal cleavage site indicated, but may be a few residues on either side; putative glycosylation site at residues 53-55:	
15	GAGAAAGAGC TTCCTGCACA AAGTAAGCCA CCAGCGAAC ATGACAGTGA AGACCCTGCA	60
	TGGCCCAGCC ATG GTC AAG TAC TTG CTG CTG TCG ATA TTG GGG CTT GCC	109
	Met Val Lys Tyr Leu Leu Ser Ile Leu Gly Leu Ala	
	-20 -15 -10	
20	TTT CTG AGT GAG GCG GCA GCT CGG AAA ATC CCC AAA GTA GGA CAT ACT	157
	Phe Leu Ser Glu Ala Ala Arg Lys Ile Pro Lys Val Gly His Thr	
	-5 1 5	
25	TTT TTC CAA AAG CCT GAG AGT TGC CCG CCT GTG CCA GGA GGT AGT ATG	205
	Phe Phe Gln Lys Pro Glu Ser Cys Pro Pro Val Pro Gly Gly Ser Met	
	10 15 20 25	
30	AAG CTT GAC ATT GGC ATC ATC AAT GAA AAC CAG CGC GTT TCC ATG TCA	253
	Lys Leu Asp Ile Gly Ile Ile Asn Glu Asn Gln Arg Val Ser Met Ser	
	30 35 40	
35	CGT AAC ATC GAG AGC CGC TCC ACC TCC CCC TGG AAT TAC ACT GTC ACT	301
	Arg Asn Ile Glu Ser Arg Ser Thr Ser Pro Trp Asn Tyr Thr Val Thr	
	45 50 55	
40	TGG GAC CCC AAC CGG TAC CCC TCG AAG TTG TAC AGG CCC AAG TGT AGG	349
	Trp Asp Pro Asn Arg Tyr Pro Ser Lys Leu Tyr Arg Pro Lys Cys Arg	
	60 65 70	
45	AAC TTG GGC TGT ATC AAT GCT CAA GGA AAG GAA GAC ATC TnC ATG AAT	397
	Asn Leu Gly Cys Ile Asn Ala Gln Gly Lys Glu Asp Ile Xaa Met Asn	
	75 80 85	
50	TCC GTC	403
	Ser Val	
	90	
55	MVKYLLSILGLAFLSEAAA RKIPKVGHFFQKPESCPVPGGSMKLDIGIINENQRVMSRNIES RSTSPWNYTVTWDPNRYP SKLYRPKCRNLGCINAQGKEDIXMNSV	
60	Particularly interesting segments include, e.g., those which begin or end with arg1; cys17; pro18, pro19; val20; thr49; ser50; arg69; pro70; and the end of the sequence available.	

Table 3: Nucleotide sequence encoding a primate, e.g., human, IL-172 polypeptide and predicted amino acid sequence. Also can use complementary nucleic acid sequences for many purposes. Predicted signal cleavage site indicated, but may be a few residues on either side; putative glycosylation site at residues 55-57. SEQ ID NO: 9 and 10.

10	ATG GAC TGG CCT CAC AAC CTG CTG TTT CTT CTT ACC ATT TCC ATC TTC Met Asp Trp Pro His Asn Leu Leu Phe Leu Leu Thr Ile Ser Ile Phe -20 -15 -10 -5	48
15	CTG GGG CTG GGC CAG CCC AGG AGC CCC AAA AGC AAG AGG AAG GGG CAA Leu Gly Leu Gly Gln Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln 1 5 10	96
20	GGG CGG CCT GGG CCC CTG GTC CCT GGC CCT CAC CAG GTG CCA CTG GAC Gly Arg Pro Gly Pro Leu Val Pro Gly Pro His Gln Val Pro Leu Asp 15 20 25	144
25	CTG GTG TCA CGG ATG AAA CCG TAT GCC CGC ATG GAG GAG TAT GAG AGG Leu Val Ser Arg Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg 30 35 40	192
30	AAC ATC GAG GAG ATG GTG GCC CAG CTG AGG AAC AGC TCA GAG CTG GCC Asn Ile Glu Glu Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala 45 50 55 60	240
35	CAG AGA AAG TGT GAG GTC AAC TTG CAG CTG TGG ATG TCC AAC AAG AGG Gln Arg Lys Cys Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg 65 70 75	288
40	AGC CTG TCT CCC TGG GGC TAC AGC ATC AAC CAC GAC CCC AGC CGT ATC Ser Leu Ser Pro Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile 80 85 90	336
45	CCC GTG GAC CTG CCG GAG GCA CGG TGC CTG TGT CTG GGC TGT GTG AAC Pro Val Asp Leu Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn 95 100 105	384
50	CCC TTC ACC ATG CAG GAG GAC CGC AGC ATG GTG AGC GTG CCG GTG TTC Pro Phe Thr Met Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe 110 115 120	432
55	AGC CAG GTT CCT GTG CGC CGC CTC TGC CCG CCA CCG CCC CGC ACA Ser Gln Val Pro Val Arg Arg Arg Leu Cys Pro Pro Pro Arg Thr 125 130 135 140	480
60	GGG CCT TGC CGC CAG CGC GCA GTC ATG GAG ACC ATC GCT GTG GGC TGC Gly Pro Cys Arg Gln Arg Ala Val Met Glu Thr Ile Ala Val Gly Cys 145 150 155	528
55	ACC TGC ATC TTC TGA Thr Cys Ile Phe 160	543
60	MDWPHNLLFLLTISIFLGLG QPRSPKSKRKGQGRPGPLVPGPHQVPLDLVSRMKPYARMEEYER NIEEMVAQLRNSSELAQRKCEVNLQLWMSNKRSLSPWGY SINHDPSRIPVVDLPEARCLCLGCVNP FTMQEDRSMSVPVFSQPVRRRLCPPPRTGPCRQRAVMETIAVGCTCIF	

Particularly interesting segments include, e.g., those which begin or end with gln1; val19; pro20; pro22; lys34; pro35; leu78; ser79; glu98; ala99; phel10; thr111; cys143; or arg144.

5

Nucleotide sequence encoding a rodent, e.g., mouse, IL-172 polypeptide and predicted amino acid sequence. Also can use complementary nucleic acid sequences for many purposes.

Predicted signal cleavage site indicated, but may be a few residues on either side; putative glycosylation site at residues 53-55. SEQ ID NO: 11 and 12.

15	ATG GAC TGG CCG CAC AGC CTG CTC TTC CTC CTG GCC ATC TCC ATC TTC Met Asp Trp Pro His Ser Leu Leu Phe Leu Leu Ala Ile Ser Ile Phe -22 -20 -15 -10	48
20	CTG GCG CCA AGC CAC CCC CGG AAC ACC AAA GGC AAA AGA AAA GGG CAA Leu Ala Pro Ser His Pro Arg Asn Thr Lys Gly Lys Arg Lys Gly Gln -5 1 5 10	96
25	GGG AGG CCC AGT CCC TTG GCC CCT GGG CCT CAT CAG GTG CCG CTG GAC Gly Arg Pro Ser Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp 15 20 25	144
30	CTG GTG TCT CGA GTA AAG CCC TAC GCT CGA ATG GAA GAG TAT GAG CGG Leu Val Ser Arg Val Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg 30 35 40	192
35	AAC CTT GGG GAG ATG GTG GCC CAG CTG AGG AAC AGC TCC GAG CCA GCC Asn Leu Gly Glu Met Val Ala Gln Leu Arg Asn Ser Ser Glu Pro Ala 45 50 55	240
40	AAG AAG AAA TGT GAA GTC AAT CTA CAG CTG TGG TTG TCC AAC AAG AGG Lys Lys Lys Cys Glu Val Asn Leu Gln Leu Trp Leu Ser Asn Lys Arg 60 65 70	288
45	AGC CTG TCC CCA TGG GGC TAC AGC ATC AAC CAC GAC CCC AGC CGC ATC Ser Leu Ser Pro Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile 75 80 85 90	336
50	CCT GCG GAC TTG CCC GAG GCG CGG TGC CTA TGT TTG GGT TGC GTG AAT Pro Ala Asp Leu Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn 95 100 105	384
55	CCC TTC ACC ATG CAG GAG GAC CGT AGC ATG GTG AGC GTG CCA GTG TTC Pro Phe Thr Met Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe 110 115 120	432
60	AGC CAG GTG CCG GTG CGC CGC CTC TGT CCT CAA CCT CCT CGC CCT Ser Gln Val Pro Val Arg Arg Leu Cys Pro Gln Pro Pro Arg Pro 125 130 135	480
65	ACC TGC ATC TTC TGA Thr Cys Ile Phe	543

MDWPHSLLFLLAISIFLAPSHP RNTKGKRKGQGRPSPLAPGPHQVPLDLVSRVKPYARMEYERN  
LGEMVAQLRNSSEPAKKCEVNQLWLWSNKRSLSPWGYSINHDPSRIPADLPEARCLCLGCVNPFT  
MQEDRSMVSVPVFSQVPVRRRLCPQQPPRGPCRQRVVMETIAVGCTCIF

Particularly interesting segments include, e.g., those which begin or end with arg1; ala17; pro18; pro20; his21; lys32; pro33; leu76; ser77; glu96; ala97; phe108; thr109; cys141; or arg142.

5

Table 4: Nucleotide sequence encoding a primate, e.g., human, IL-173 polypeptide and predicted amino acid sequence.  
10 Also can use complementary nucleic acid sequences for many purposes. SEQ ID NO: 13 and 14:

15	TGC GCG GAC CGG CCG GAG GAG CTA CTG GAG CAG CTG TAC GGG CGC CTG Cys Ala Asp Arg Pro Glu Glu Leu Leu Glu Gln Leu Tyr Gly Arg Leu 1 5 10 15	48
20	GCG GCC GGC GTG CTC AGT GCC TTC CAC CAC ACG CTG CAG CTG GGG CCG Ala Ala Gly Val Leu Ser Ala Phe His His Thr Leu Gln Leu Gly Pro 20 25 30	96
25	CGT GAG CAG GCG CGC AAC GCG AGC TGC CCG GCA GGG GGC AGG CCC GCC Arg Glu Gln Ala Arg Asn Ala Ser Cys Pro Ala Gly Gly Arg Pro Ala 35 40 45	144
30	GAC CGC CGC TTC CGG ACG CCC ACC AAC CTG CGC AGC GTG TCG CCC TGG Asp Arg Arg Phe Arg Thr Pro Thr Asn Leu Arg Ser Val Ser Pro Trp 50 55 60	192
35	GCC TAC AGA ATC TCC TAC GAC CCG GCG AGG TAC CCC AGG TAC CTG CCT Ala Tyr Arg Ile Ser Tyr Asp Pro Ala Arg Tyr Pro Arg Tyr Leu Pro 65 70 75 80	240
40	GAA GCC TAC TGC CTG TGC CGG GGC TGC CTG ACC GGG CTG TTC GGC GAG Glu Ala Tyr Cys Leu Cys Arg Gly Cys Leu Thr Gly Leu Phe Gly Glu 85 90 95	288
45	GAG GAC GTG CGC TTC CGC AGC GCC CCT GTC TAC ATG CCC ACC GTC GTC Glu Asp Val Arg Phe Arg Ser Ala Pro Val Tyr Met Pro Thr Val Val 100 105 110	336
50	CTG CGC CGC ACC CCC GCC TGC GCC GGC CGT TCC GTC TAC ACC GAG Leu Arg Arg Thr Pro Ala Cys Ala Gly Gly Arg Ser Val Tyr Thr Glu 115 120 125	384
55	GCC TAC GTC ACC ATC CCC GTG GGC TGC ACC TGC GTC CCC GAG CCG GAG Ala Tyr Val Thr Ile Pro Val Gly Cys Thr Cys Val Pro Glu Pro Glu 130 135 140	432
60	AAG GAC GCA GAC AGC ATC AAC T Lys Asp Ala Asp Ser Ile Asn 145 150	454
	CADRPEELLEQLYGRLAAGVLSAFHHTLQLGPREQARNASCPAGGRPADRRFRTPTNLRS VSPWAYRISYDPARYPRYLPEAYCLRGCLTGLFGEEDVFRSAPVYMPVTVLLRTPACA GGRSVYTEAYVTIPVGCTCVPPEKADDSIN	

Supplementary nucleotide sequence encoding a primate, e.g., human, IL-173 polypeptide and predicted amino acid sequence. Also can use complementary nucleic acid sequences for many purposes. Predicted signal cleavage site indicated, but may be a few residues on either side. SEQ ID NO: 15 and 16.

5	gcccgggcag gtggcgacct cgctcagtgc gcttctcggt ccaagtcggc gggctcg 58
10	atg ctg gta gcc ggc ttc ctg ctg gcg ctg ccg ccg agc tgg gcc gcg 106 Met Leu Val Ala Gly Phe Leu Leu Ala Leu Pro Pro Ser Trp Ala Ala -15 -10 -5
15	ggc gcc ccg agg ggc agg cgc ccc gcg cgg ccg cgg ggc tgc gcg 154 Gly Ala Pro Arg Ala Gly Arg Arg Pro Ala Arg Pro Arg Gly Cys Ala -1 1 5 10 15
20	gac cgg ccg gag gag cta ctg gag cag ctg tac ggg cgc ctg gcg gcc 202 Asp Arg Pro Glu Glu Leu Leu Glu Gln Leu Tyr Gly Arg Leu Ala Ala 20 25 30
25	ggc gtg ctc agt gcc ttc cac cac acg ctg cag ctg ggg ccg cgt gag 250 Gly Val Leu Ser Ala Phe His His Thr Leu Gln Leu Gly Pro Arg Glu 35 40 45
30	cag gcg cgc aac gcg agc tgc ccg gca ggg ggc agg ccc gcc gac cgc 298 Gln Ala Arg Asn Ala Ser Cys Pro Ala Gly Gly Arg Pro Ala Asp Arg 50 55 60
35	cgc ttc cgg ccg ccc acc aac ctg cgc agc gtg tcg ccc tgg gcc tac 346 Arg Phe Arg Pro Pro Thr Asn Leu Arg Ser Val Ser Pro Trp Ala Tyr 65 70 75
40	aga atc tcc tac gac ccg gcg agg tac ccc agg tac ctg cct gaa gcc 394 Arg Ile Ser Tyr Asp Pro Ala Arg Tyr Pro Arg Tyr Leu Pro Glu Ala 80 85 90 95
45	tac tgc ctg tgc cgg ggc tgc ctg acc ggg ctg ttc ggc gag gag gac 442 Tyr Cys Leu Cys Arg Gly Cys Leu Thr Gly Leu Phe Gly Glu Asp 100 105 110
50	gtg cgc ttc cgc agc gcc cct gtc tac atg ccc acc gtc gtc ctg cgc 490 Val Arg Phe Arg Ser Ala Pro Val Tyr Met Pro Thr Val Val Leu Arg 115 120 125
55	cgc acc ccc gcc tgc ggc ggc cgt tcc gtc tac acc gag gcc tac 538 Arg Thr Pro Ala Cys Ala Gly Gly Arg Ser Val Tyr Thr Glu Ala Tyr 130 135 140
60	gtc acc atc ccc gtg ggc tgc acc tgc gtc ccc gag ccg gag aag gac 586 Val Thr Ile Pro Val Gly Cys Thr Cys Val Pro Glu Pro Glu Lys Asp 145 150 155
65	gca gac agc atc aac tcc agc atc gac aaa cag ggc gcc aag ctc ctg 634 Ala Asp Ser Ile Asn Ser Ser Ile Asp Lys Gln Gly Ala Lys Leu Leu 160 165 170 175
70	ctg ggc ccc aac gac gcg ccc gct ggc ccc tgaggccggt cctgccccgg 684 Leu Gly Pro Asn Asp Ala Pro Ala Gly Pro 180 185
75	gaggtctccc cggcccccatt cccgaggcgc ccaagctgga gcccctgga gggctcggtc 744
80	ggcgacctct gaagagagtg caccgagcaa accaagtgcc ggagcaccag cgccgccttt 804
85	ccatggagac tcgtaaagcag cttcatctga cacggcatac cctggcttgc ttttagctac 864

aagcaaggcag cgtggctgga agctgatggg aaacgacccg gcacgggcat cctgtgtgcg 924  
 gccccatgg agggtttggaa aagttcacg gaggctccct gaggagcctc tcagatcg 984  
 5 tgctgcgggt gcagggcgtg actcaccgct gggtgcttc caaagagata gggacgcata 1044  
 tgcttttaa agcaatctaa aaataataat aagtatagcg actatataacc tactttaaa 1104  
 10 atcaactgtt ttgaatagag gcagagctat tttatattat caaatgagag ctactctgtt 1164  
 acatttccta acatataaac atcgaaaaacttcttctg gttagaatttt taaaaggcata 1224  
 attggaatcc ttggataaaat tttgttagctg gtacactctg gcctgggtct ctgaattcag 1284  
 15 cctgtcaccg atggctgact gatgaaaatgg acacgtctca tctgacccac tttccttcc 1344  
 actgaaggc ttcacgggcc tccaggcctc gtgccgaatt c 1385  
 20 MLVAGFLLALPPSWAAGAPRAGRPARPRGCADRPEELLEOLYGRILAAGVLSAFHHTLQLGPREQARNAS  
 CPAGGRPADRRFRPPTNLRSVSPWAYRISYDPARYPRYLPEAYCLCRGCLTGLFGEEDVFRSAPVYMPT  
 VVLRRTPACAGGRSVYTEAYVTIPVGCTCVPPEKDADSINSSIDKQGAKLLLGPNDAPAGP  
 25 Important predicted motifs include, e.g., cAMP PK at 50-  
 53, 66-69, 72-75, and 113-116; Ca Phos at 82-84 and 166-168;  
 myristoly sites at 57-61 and 164-166; and phosphorylation  
 sites at 50, 53, 72, 75, 80, 82, 113, and 116.  
 30 Nucleotide sequence encoding a rodent, e.g., rat, IL-173  
 polypeptide and predicted amino acid sequence. Also can use  
 complementary nucleic acid sequences for many purposes. SEQ  
 ID NO: 17 and 18.  
 35 TTT CCG AGA TAC CTG CCC GAA GCC TAC TGC CTG TGC CGA GGC TGT CTG 48  
 Phe Pro Arg Tyr Leu Pro Glu Ala Tyr Cys Leu Cys Arg Gly Cys Leu  
 1 5 10 15  
 40 ACC GGG CTC TAC GGT GAG GAG GAC TTC CGC TTT CGC AGC GCA CCC GTC 96  
 Thr Gly Leu Tyr Gly Glu Glu Asp Phe Arg Phe Arg Ser Ala Pro Val  
 20 25 30  
 TTC TCT CCG GCG GTG GTG CTG CGG CGC ACG GCG GCC T 133  
 Phe Ser Pro Ala Val Val Leu Arg Arg Thr Ala Ala  
 45 35 40  
 FPRYLPEAYCLCRGCLTGLYGEEDFRFRSAPVFSPAVVLRRTAA  
 Supplementary nucleotide sequence encoding a rodent, e.g., mouse,  
 50 IL-173 polypeptide and predicted amino acid sequence. Also can use  
 complementary nucleic acid sequences for many purposes. Predicted  
 signal cleavage site indicated, but may be a few residues on either  
 side. SEQ ID NO: 19 and 20.  
 55 atg ttg ggg aca ctg gtc tgg atg ctc ctc gtc ggc ttc ctg ctg gca 48  
 Met Leu Gly Thr Leu Val Trp Met Leu Leu Val Gly Phe Leu Leu Ala  
 -20 -15 -10  
 60 ctg gcg ccg ggc cgc gcg ggc gcg ctg agg acc ggg agg cgc ccg 96  
 Leu Ala Pro Gly Arg Ala Ala Gly Ala Leu Arg Thr Gly Arg Arg Pro  
 -5 -1 1 5



Important predicted motifs include, e.g., cAMP PK sites at 50-53, 66-69, 72-75, and 113-116; Ca phosphorylation sites at 82-84, 159-161, and 166-168; myristoly sites at 57-61 and 101-105; N-glycosyl sites at 51-53 and 164-166; phosphorylation sites at 50, 53, 72, 75, 80, 82, 113, and 116; and PKC phosphorylation sites at 4-6

10 Table 5: Nucleotide sequence encoding a primate, e.g., human, IL-174 polypeptide and predicted amino acid sequence. Also can use complementary nucleic acid sequences for many purposes. SEQ ID NO: 21 and 22.

15	tgagtgtgca gtgccagc atg tac cag gtg gtt gca ttc ttg gca atg gtc Met Tyr Gln Val Val Ala Phe Leu Ala Met Val -15 -10	51
20	atg gga acc cac acc tac agc cac tgg ccc agc tgc tgc ccc agc aaa Met Gly Thr His Thr Tyr Ser His Trp Pro Ser Cys Cys Pro Ser Lys -5 -1 1 5 10	99
25	ggg cag gac acc tct gag gag ctg ctg agg tgg agc act gtg cct gtg Gly Gln Asp Thr Ser Glu Glu Leu Leu Arg Trp Ser Thr Val Pro Val 15 20 25	147
30	cct ccc cta gag cct gct agg ccc aac cgc cac cca gag tcc tgt agg Pro Pro Leu Glu Pro Ala Arg Pro Asn Arg His Pro Glu Ser Cys Arg 30 35 40	195
35	gcc agt gaa gat gga ccc ctc aac agc agg gcc atc tcc ccc tgg aga Ala Ser Glu Asp Gly Pro Leu Asn Ser Arg Ala Ile Ser Pro Trp Arg 45 50 55	243
40	tat gag ttg gac aga gac ttg aac cgg ctc ccc cag gac ctg tac cac Tyr Glu Leu Asp Arg Asp Leu Asn Arg Leu Pro Gln Asp Leu Tyr His 60 65 70 75	291
45	gcc cgt tgc ctg tgc ccg cac tgc gtc agc cta cag aca ggc tcc cac Ala Arg Cys Leu Cys Pro His Cys Val Ser Leu Gln Thr Gly Ser His 80 85 90	339
50	atg gac ccc cgg ggc aac tcg gag ctg ctc tac cac aac cag act gtc Met Asp Pro Arg Gly Asn Ser Glu Leu Leu Tyr His Asn Gln Thr Val 95 100 105	387
55	ttc tac cgg cgg cca tgc cat ggc gag aag ggc acc cac aag ggc tac Phe Tyr Arg Arg Pro Cys His Gly Glu Lys Gly Thr His Lys Gly Tyr 110 115 120	435
60	tgc ctg gag cgc agg ctg tac cgt gtt tcc tta gct tgt gtg tgt gtg Cys Leu Glu Arg Arg Leu Tyr Arg Val Ser Leu Ala Cys Val Cys Val 125 130 135	483
	cgg ccc cgt gtg atg ggc tag Arg Pro Arg Val Met Gly 140 145	504
	MYQVVAFLAMVMGTHTYSHWPSCCPSKGQDTSEELLRWSTPVPPLEPARPNRHPECRASED GPLNSRAISPWRYELDRDLNRLPQDLYHARCLCPHCVSLQTGSHMDPRGNSELLYHNQTVFYR RPCHGEKGTHKGYCLERRLYRVSLACVCVRPRVMG	

- Important predicted motifs include, e.g., cAMP PK sites at 21-24, 53-56, and 95-98; Ca phosphorylation sites at 15-17, 16-18, and 45-47; myristoly sites at 12-16, 115-119, and 118-122; N-glycosyl site at 104-107; phosphorylation sites at 21, 23, 43, 53, 56, 95, 98, and 131; PKC phosphorylation sites at 41-43 and 119-121; and tyrosine kinase site at 95-102.
- 10 Nucleotide sequence encoding a rodent, e.g., mouse, IL-174 polypeptide and predicted amino acid sequence. Also can use complementary nucleic acid sequences for many purposes. SEQ ID NO: 23 and 24.
- 15 CGG CAC AGG CGG CAC AAA GCC CGG AGA GTG GCT GAA GTG GAG CTC TGC 48  
Arg His Arg Arg His Lys Ala Arg Arg Val Ala Glu Val Glu Leu Cys  
1 5 10 15
- 20 ATC TGT ATC CCC CCC AGA GCC TCT GAG CCA CAC CCA CGC AGA ATC 96  
Ile Cys Ile Pro Pro Arg Ala Ser Glu Pro His Pro Pro Arg Arg Ile  
20 25 30
- 25 CTG CAG GGC CAG CAA GGA TGG CCT CTC AAC AGC AGG GCC ATC TCT CCT 144  
Leu Gln Gly Gln Gly Trp Pro Leu Asn Ser Arg Ala Ile Ser Pro  
35 40 45
- 30 TGG AGC TAT GAG TTG GAC AGG GAC TTG AAT CGG GTC CCC CAG GAC TGG 192  
Trp Ser Tyr Glu Leu Asp Arg Asp Leu Asn Arg Val Pro Gln Asp Trp  
50 55 60
- 35 TAC CAC GCT CGA TGC CTG TGC CCA CAC TGC GTC ACG CTA CAG ACA GGC 240  
Tyr His Ala Arg Cys Leu Cys Pro His Cys Val Thr Leu Gln Thr Gly  
65 70 75 80
- 40 TCC CAC ATG GAC CCG CTG GGC AAC TCC GTC CCA CTT TAC CAC AAC CAG 288  
Ser His Met Asp Pro Leu Gly Asn Ser Val Pro Leu Tyr His Asn Gln  
85 90 95
- 45 ACG GTC TTC TAC CCG CGG CCA TGC ATG GCG AGG AAG GTA CCC ATC GCC 336  
Thr Val Phe Tyr Arg Arg Pro Cys Met Ala Arg Lys Val Pro Ile Ala  
100 105 110
- 50 GCT ACT GCT TGG AGC GCA GGT CTA CCG AGT CTC CTT GGC TTG TGT GTG 384  
Ala Thr Ala Trp Ser Ala Gly Leu Pro Ser Leu Leu Gly Leu Cys Val  
115 120 125
- 55 TGT GCG GCC CCG GGT CAT GGC TTA GTC ATG CTC ACC ATC TGC CTG AGG 432  
Cys Ala Ala Pro Gly His Gly Leu Val Met Leu Thr Ile Cys Leu Arg  
130 135 140
- 60 TGAATGCCGG GTGGGAGAGA GGGCCAGGTG TACATCACCT GCCAATGCGG GCCGGGTTCA 492
- 65 AGCCTGAAA GCCTACCTGA ACCAGCAGGT CCCGGGACAG GATGGAGACT TGGGGAGAAA 552
- 70 TCTGACTTTT GCACTTTG GAGCATTTG GGAAGAGCAG GTTCGCTTGT GCTGTAGAGA 612
- 75 TGCTGTTG 620
- 80 RHRRHKARRVAEVELCICIPPRASEPHPPRRILOGQQGWPLNSRAISPWSYELDRDLNRPQDWYHARC  
LCPHCVTLQTGSHMDPLGNSPVLYHNQTVFYRRPCMARKVPIAATAWSAGLPSLLGLCVCAAPGHGLVM  
LTICLR

Supplementary nucleotide sequence encoding a rodent, e.g., mouse, IL-174 polypeptide and predicted amino acid sequence. Also can use complementary nucleic acid sequences for many purposes. SEQ ID NO: 25 and 26.

5	atg tac cag gct gtt gca ttc ttg gca atg atc gtg gga acc cac acc Met Tyr Gln Ala Val Ala Phe Leu Ala Met Ile Val Gly Thr His Thr -15 -10 -5 -1	48
10	gtc agc ttg cgg atc cag gag ggc tgc agt cac ttg ccc agc tgc tgc Val Ser Leu Arg Ile Gln Glu Gly Cys Ser His Leu Pro Ser Cys Cys 1 5 10 15	96
15	ccc agc aaa gag caa gaa ccc ccg gag gag tgg ctg aag tgg agc tct Pro Ser Lys Glu Gln Glu Pro Pro Glu Glu Trp Leu Lys Trp Ser Ser 20 25 30	144
	gca tct gtg tcc ccc cca gag cct ctg agc cac acc cac gca gaa Ala Ser Val Ser Pro Pro Glu Pro Leu Ser His Thr His His Ala Glu 35 40 45	192
20	tcc tgc agg gcc agc aag gat ggc ccc ctc aac agc agg gcc atc tct Ser Cys Arg Ala Ser Lys Asp Gly Pro Leu Asn Ser Arg Ala Ile Ser 50 55 60	240
25	cct tgg agc tat gag ttg gac agg gac ttg aat cgg gtc ccc cag gac Pro Trp Ser Tyr Glu Leu Asp Arg Asp Leu Asn Arg Val Pro Gln Asp 65 70 75 80	288
30	ctg tac cac gct cga tgc ctg tgc cca cac tgc gtc agc cta cag aca Leu Tyr His Ala Arg Cys Leu Cys Pro His Cys Val Ser Leu Gln Thr 85 90 95	336
35	ggc tcc cac atg gac ccg ctg ggc aac tcc gtc cca ctt tac cac aac Gly Ser His Met Asp Pro Leu Gly Asn Ser Val Pro Leu Tyr His Asn 100 105 110	384
	cag acg gtc ttc tac cgg cgg cca tgc cat ggt gag gaa ggt acc cat Gln Thr Val Phe Tyr Arg Arg Pro Cys His Gly Glu Gly Thr His His 115 120 125	432
40	cgc cgc tac tgc ttg gag cgc agg ctc tac cga gtc tcc ttg gct tgt Arg Arg Tyr Cys Leu Glu Arg Arg Leu Tyr Arg Val Ser Leu Ala Cys 130 135 140	480
45	gtg tgt gtg cgg ccc cgg gtc atg gct tagtcatgct caccacctgc Val Cys Val Arg Pro Arg Val Met Ala 145 150	527
50	ctgaggctga tgccccgttg ggagagaggg ccaggtgtac aatcaccttg ccaatgcggg 587 ccgggttcaa gcccctaaaa gcccctacctg aagcagcagg ctcccgac aagatggagg 647 acttggggag aaactctgac tttgcactt tttgaaagca cttttggaa ggagcagg 707	
55	ccgcttgtgc tgcttagagga tgctgttg gcatttctac tcaggaacgg actccaaagg 767 cctgctgacc ctggaaagcca tactcctggc tcctttcccc tgaatcccc aactcctggc 827	
60	acaggcactt tctccacctc tcccccttg ccttttttg tgtttggaa tgcatgccaa 887 ctctgcgtgc agccagggtgt aattgccttg aaggatggtt ctgaggtgaa agctgttatac gaaagtgaag agatttatcc aaataaacat ctgtgttt	947
		985

MYQAVAFLAMIVGTHTVSLRIOEGCSHLPSCCPSKEQEPPEWLKWSSASAVSPPEPLSHTHAESCRA  
KDGPLNSRAISPWSYELDRDLNRVPQDLYHARCLCPHCVSLQTGSHMDPLGNVPLOYHNQTVFYRRPCH  
GEEGTHRRYCLERRLYRVSLACVCVRPRVMA

5

Important predicted motifs include, e.g., cAMP PK sites at 29-32 and 61-64; Ca phosphorylation sites at 18-20, 53-55, and 67-69; myristoly site at 123-127; N-glycosylation site at 112-114; and phosphorylation sites at 29, 31, 51, 53, 61, 64, 10 139, and 141; and PKC phosphorylation sites at 2-4, 49-51, and 127-129.

15 Table 6: Nucleotide sequence encoding a primate, e.g., human, IL-176. Also can use complementary nucleic acid sequences for many purposes. SEQ ID NO: 27 and 28:

20	tc gtg ccg tat ctt ttt aaa aaa att att ctt cac ttt ttt gcc tcc Val Pro Tyr Leu Phe Lys Lys Ile Ile Leu His Phe Phe Ala Ser 1 5 10 15	47
25	tat tac ttg tta ggg aga ccc aat ggt agt ttt att cct tgg gga tac Tyr Tyr Leu Leu Gly Arg Pro Asn Gly Ser Phe Ile Pro Trp Gly Tyr 20 25 30	95
30	ata gta aat act tca tta aag tcg agt aca gaa ttt gat gaa aag tgt Ile Val Asn Thr Ser Leu Lys Ser Ser Thr Glu Phe Asp Glu Lys Cys 35 40 45	143
35	gga tgt gtg gga tgt act gcc gcc ttc aga agt cca cac act gcc tgg Gly Cys Val Gly Cys Thr Ala Ala Phe Arg Ser Pro His Thr Ala Trp 50 55 60	191
40	agg gag aga act gct gtt tat tca ctg att aag cat ttg ctg tgt acc Arg Glu Arg Thr Ala Val Tyr Ser Leu Ile Lys His Leu Leu Cys Thr 65 70 75	239
45	aac tac ttt tca tgt ctt atc tta att ctc ata aca gtc att Asn Tyr Phe Ser Cys Leu Ile Leu Ile Leu Ile Thr Val Ile 80 85 90	281
50	tatatattta aaaaacccca gaaatctgag aaagagataa agtggtttgc tcaaggttat ttgttcgctt gccagggtac cccacaaaaa tgccaggcag ggcattttca tgatgcactt gagatacctg aaatgacagg gtagcatcac acctgagagg ggtaaaggat gggAACCTAC cttccatggc cgctgcttgg cagtcttttgc ctgcatttca gcagagccac tgttatatgt ccgaggctct gagaattaac tgcttaaaga actgccttct ggagggagaa gagcacaaga 55 581	341 401 461 521
60	tcacaattaa ccatatacac atcttactgt gcgagggtcat tgagcaatac aggagggatt ttatacattt tagcaactat cttcaaaacc tgagctatac ttgtattctg ccccccttc ctggggcaaaa gtgtaaaagt ttg	701 761 784

VPYLFKKIIILHFFASYYLLGRPNGSFIPWGYIVNTSLKSSTEFDEKCGCVGCTAAFRSPHTAWRERTAVYS  
LIKHLLCTNYFSCLILILITVI

Nucleotide sequence encoding a primate, e.g., human, IL-177. Also can use complementary nucleic acid sequences for many purposes. SEQ ID NO: 29 and 30:

35

Table 7: Alignment of various CTLA-8/IL-170 family members. The rat CTLA-8 sequence is SEQ ID NO: 31 (see GB L13839; 293329/30); mouse CTLA-8 sequence is SEQ ID NO: 32 (see GB 1469917/8); human CTLA-8 is SEQ ID NO: 33 (see GB U32659; 115222/3); and Herpes Saimiri virus ORF13 is SEQ ID NO: 34 (see GB Y13183; 2370235). CLUSTAL X (1.64b) multiple sequence alignment

45

```

IL-74_Mu      -----MYQAVAFLAMIVGHTVSLRI----QEGCSHLPSCCPSTEQEPPPEEWLKWS
IL-74_Hu      -----MYQVVAFLAMVMGHTTY-----S---HWPSCCPSPKGQDTSEELLRWS
IL-72_Hu      -----MDWPHNLLFLLTISIFLGLQPRSPKSKRKGQGRPGPLVPGPHQVPLDLVSRMK
IL-72_Mu      -----MDWPHSSLFLLAISIFLAPSHPRNTKGKRGKQGRPSPLAPGPHQVPLDLVSRVK
IL-73_Mu      --MLGTLVWMLLVGFLLALAPGRAAGALRT--GRRP--ARPRDCADRPEELLEQLYYGRILA
IL-73_Hu      -----MLVAGFLLALPPSWAAGAPRA--GRRP--ARPRGCADRPEELLEQLYYGRILA
IL-17_Hu      --MTPGKTSVLVSLLLLLSLEAIVKAGITIP-----RNPGCPNSDEKDKNFPRTVMVNL
IL-17_HS      --MTFRKTSVL-LLLLLSSIDCIVKSEITSA-----QTPRCLAAANN-SFPRSVMVTL
IL-17_Rt      -----MCLMLLLLNLNEATVKAALVTP-----QSSVCVPNAEANNFLQNVKVNL
IL-17_Mu      -----MLLLLLSLAATVKAALIIP-----QSSACPNTAEAKDFLQNVKVNL
IL-75_Hu      -----MVKYLLLSILGLAFLSEAAARKIPIVKVGHFFFQKPESCPVPGGSMKLDIGIIN
IL-71_Hu      MTLLPGPLLFTLWLTCAHHDPSLRGHPHSHTPHCYSAEELPLGQAPPHLARGAKWGQ

```

	IL-74_Mu	S-----ASVSPP-EPLSHTHHAES---CRASKD-GPLNSRAISPWSYELDRDLNRV
	IL-74_Hu	T-----VPVPPPL-EPARPNRHPEs---CRASEd-GPLNSRAISPWRYELDRDLNRl
5	IL-72_Hu	P-YARMEEYERNIEEMVAQLRNSSELAQ-RKCEVNLQLWMSNKRSLSPWGYSINHDPsRI
	IL-72_Mu	P-YARMEEYERNLGEtVAQLRNSSEPAK-KKCEVNLQLWLSNKRSLSPWGYSINHDPsRI
	IL-73_Mu	AGVLSAFHHTLQLGPR-EQARNASC PAGGRAADRRFR-PPTNLRSVSPWAYRISyDPARF
	IL-73_Hu	AGVLSAFHHTLQLGPR-EQARNASC PAGGRPADRRFR-PPTNLRSVSPWAYRISyDPARF
	IL-17_Hu	N-----IHNRNTNTN-----P-KRSSDYYNRSTSPWNLHRNEDPERY
10	IL-17_Hs	S-----IRNWNTSS-----KRASDYYNRSTSPWTLHRNEDQDRY
	IL-17_Rt	K-----VINSSLSSKA-----SSRRPSDYLNRSTSPWTLSRNEDPDRY
	IL-17_Mu	K-----VFNSLGAKV-----SSRRPSDYLNRSTSPWTLHRNEDPDRY
	IL-75_Hu	E-----N--QRVSMS-----R--NIESRSTSPWNYTWTWDPNRY
	IL-71_Hu	ALPVALVSSLEAASHRGRHERPSATTQCPVLRPEEVLEADTHQRSISPWRYRVDTDEDRY
		* : * * *
15		
	IL-74_Mu	PQDLYHARCLCPHCVSLQTGSHMDPLGNSVPLYHNQTVFYRR--PCHGEEGTHRYCLER
	IL-74_Hu	PQDLYHARCLCPHCVSLQTGSHMDPRGNSELLYHNQTVFYRR--PCHGEKGTHKGYCLER
20	IL-72_Hu	PVDLPEARCLCCLGCVCNPFTM-QEDRSMSVPVFS-QVPVRRR--LCPPPP--RTGPCRQR
	IL-72_Mu	PADLPEARCLCCLGCVCNPFTM-QEDRSMSVPVFS-QVPVRRR--LCPPPP--RPGPCRQR
	IL-73_Mu	PRYLPEAYCLCRGCLTGLYG-EEDFRFRSTPVFS-PAVVLRRTAACAG-----GRSVYA
	IL-73_Hu	PRYLPEAYCLCRGCLTGLFG-EEDVFRFRSAPVYM-PTVVLRRTPACAG-----GRSVYT
	IL-17_Hu	PSVIWEAKCRHLGCINADGN--VDYHMNSVPIQQEILVLRREPPHCPN-----SFR
25	IL-17_Hs	PSVIWEAKCRYLGCVNADGN--VDYHMNSVPIQQEILVVRKGHQPCPN-----SFR
	IL-17_Rt	PSVIWEAQCRHQRQCVNAEGK--LDHHMNSVLIQQEILVKREPEKCPF-----TFR
	IL-17_Mu	PSVIWEAQCRHQRQCVNAEGK--LDHHMNSVLIQQEILVKREPEKCPF-----TFR
	IL-75_Hu	PSEVVQAQCRLNLCINAQGK--EDISMNSVPIQQETLVVRRKHQGCSV-----SFQ
	IL-71_Hu	PQKLAFAECLCRGCIDARTG-RETAALNSVRLLQSSLVRRRPCSRDGSGLPTPGAFAFH
		* : * * * : * : . :
30		
	IL-74_Mu	RLYR-VSLACVCVRPRVMA-----
	IL-74_Hu	RLYR-VSLACVCVRPRVMG-----
	IL-72_Hu	AVMETIAVGCTCIF-----
35	IL-72_Mu	VVMETIAVGCTCIF-----
	IL-73_Mu	EHYITIPVGCTCVPEDPKSADSANSSMDK---LLLGPADRPAGR
	IL-73_Hu	EAYVTIPVGCTCVPPEPEKDADSINSSIDKQGAKLLLGPNDAPAGP
	IL-17_Hu	LEKILVSVGCTCVTPIVHHVA-----
	IL-17_Hs	LEKMLVTVGCTCVTPIVHNVD-----
40	IL-17_Rt	VEKMLVGVGCTCVSSIVRHAs-----
	IL-17_Mu	VEKMLVGVGCTCVASIVRQAA-----
	IL-75_Hu	LEKVLVTVGCTCVTPVIHHVQ-----
	IL-71_Hu	TEFIHVPVGCTCVLPRSV-----
		: . * . :

45           Particularly interesting segments include, e.g., those corresponding to the segments of IL-172 or IL-175, indicated above, with the other family members.

50           Purified protein or polypeptides are useful for generating antibodies by standard methods, as described above. Synthetic peptides or purified protein can be presented to an immune system to generate a specific binding composition, e.g., monoclonal or polyclonal antibodies. See, e.g., Coligan (1991) Current Protocols in Immunology Wiley/Greene; and Harlow and Lane (1989) Antibodies: A Laboratory Manual Cold Spring Harbor Press.

For example, the specific binding composition could be used for screening of an expression library made from a cell line which expresses an IL-170 protein. The screening can be standard staining of surface expressed protein, or by panning.

5 Screening of intracellular expression can also be performed by various staining or immunofluorescence procedures. The binding compositions could be used to affinity purify or sort out cells expressing the protein.

This invention contemplates use of isolated DNA or

10 fragments to encode a biologically active corresponding IL-170 protein or polypeptide. In addition, this invention covers isolated or recombinant DNA which encodes a biologically active protein or polypeptide and which is capable of hybridizing under appropriate conditions with the DNA

15 sequences described herein. Said biologically active protein or polypeptide can be an intact antigen, or fragment, and have an amino acid sequence as disclosed in Tables 1-6. Further, this invention covers the use of isolated or recombinant DNA, or fragments thereof, which encode proteins which are

20 homologous to an IL-170 protein or which were isolated using cDNA encoding an IL-170 protein as a probe. The isolated DNA can have the respective regulatory sequences in the 5' and 3' flanks, e.g., promoters, enhancers, poly-A addition signals, and others.

25

An "isolated" nucleic acid is a nucleic acid, e.g., an RNA, DNA, or a mixed polymer, which is substantially separated from other components which naturally accompany a native sequence, e.g., ribosomes, polymerases, and flanking genomic

30 sequences from the originating species. The term embraces a nucleic acid sequence which has been removed from its naturally occurring environment, and includes recombinant or cloned DNA isolates and chemically synthesized analogs or analogs biologically synthesized by heterologous systems. A

35 substantially pure molecule includes isolated forms of the molecule. Alternatively, a purified species may be separated from host components from a recombinant expression system.

The size of homology of such a nucleic acid will typically be less than large vectors, e.g., less than tens of kB, typically less than several kB, and preferably in the 2-6 kB range.

An isolated nucleic acid will generally be a homogeneous composition of molecules, but will, in some embodiments, contain minor heterogeneity. This heterogeneity is typically found at the polymer ends or portions not critical to a desired biological function or activity.

A "recombinant" nucleic acid is defined either by its method of production or its structure. In reference to its method of production, e.g., a product made by a process, the process is use of recombinant nucleic acid techniques, e.g., involving human intervention in the nucleotide sequence, typically selection or production. Alternatively, it can be a nucleic acid made by generating a sequence comprising fusion of two fragments which are not naturally contiguous to each other, but is meant to exclude products of nature, e.g., naturally occurring mutants. Thus, for example, products made by transforming cells with any unnaturally occurring vector is encompassed, as are nucleic acids comprising sequence derived using any synthetic oligonucleotide process. Such is often done to replace a codon with a redundant codon encoding the same or a conservative amino acid, while typically introducing or removing a sequence recognition site. Alternatively, it is performed to join together nucleic acid segments of desired functions to generate a single genetic entity comprising a desired combination of functions not found in the commonly available natural forms. Restriction enzyme recognition sites are often the target of such artificial manipulations, but other site specific targets, e.g., promoters, DNA replication sites, regulation sequences, control sequences, or other useful features may be incorporated by design. A similar concept is intended for a recombinant, e.g., fusion, polypeptide. Specifically included are synthetic nucleic acids which, by genetic code redundancy, encode polypeptides similar to fragments of these antigens, and fusions of sequences from various different species variants.

A significant "fragment" in a nucleic acid context is a contiguous segment of at least about 17 nucleotides, generally at least 20 nucleotides, more generally at least 23 nucleotides, ordinarily at least 26 nucleotides, more 5 ordinarily at least 29 nucleotides, often at least 32 nucleotides, more often at least 35 nucleotides, typically at least 38 nucleotides, more typically at least 41 nucleotides, usually at least 44 nucleotides, more usually at least 47 nucleotides, preferably at least 50 nucleotides, more 10 preferably at least 53 nucleotides, and in particularly preferred embodiments will be at least 56 or more nucleotides. Said fragments may have termini at any location, but especially at boundaries between structural domains.

In other embodiments, the invention provides 15 polynucleotides (or polypeptides) which comprise a plurality of distinct, e.g., nonoverlapping, segments of the specified length. Typically, the plurality will be at least two, more usually at least three, and preferably 5, 7, or even more. While the length minima are provided, longer lengths, of 20 various sizes, may be appropriate, e.g., one of length 7, and two of length 12.

A DNA which codes for an IL-170 protein will be particularly useful to identify genes, mRNA, and cDNA species which code for related or homologous proteins, as well as DNAs 25 which code for homologous proteins from different species. There are likely homologues in other species, including primates. Various CTLA-8 proteins should be homologous and are encompassed herein. However, even proteins that have a more distant evolutionary relationship to the antigen can 30 readily be isolated under appropriate conditions using these sequences if they are sufficiently homologous. Primate CTLA-8 protein proteins are of particular interest.

This invention further covers recombinant DNA molecules and fragments having a DNA sequence identical to or highly 35 homologous to the isolated DNAs set forth herein. In particular, the sequences will often be operably linked to DNA segments which control transcription, translation, and DNA

replication. Alternatively, recombinant clones derived from the genomic sequences, e.g., containing introns, will be useful for transgenic studies, including, e.g., transgenic cells and organisms, and for gene therapy. See, e.g., Goodnow 5 (1992) "Transgenic Animals" in Roitt (ed.) Encyclopedia of Immunology Academic Press, San Diego, pp. 1502-1504; Travis (1992) Science 256:1392-1394; Kuhn, et al. (1991) Science 254:707-710; Capecchi (1989) Science 244:1288; Robertson (ed. 10 1987) Teratocarcinomas and Embryonic Stem Cells: A Practical Approach IRL Press, Oxford; Rosenberg (1992) J. Clinical Oncology 10:180-199; and Cournoyer and Caskey (1993) Ann. Rev. Immunol. 11:297-329.

Homologous nucleic acid sequences, when compared, exhibit significant similarity. The standards for homology in nucleic acids are either measures for homology generally used in the art by sequence comparison or based upon hybridization conditions. The hybridization conditions are described in greater detail below.

Substantial homology in the nucleic acid sequence 20 comparison context means either that the segments, or their complementary strands, when compared, are identical when optimally aligned, with appropriate nucleotide insertions or deletions, in at least about 50% of the nucleotides, generally at least 56%, more generally at least 59%, ordinarily at least 62%, more ordinarily at least 65%, often at least 68%, more often at least 71%, typically at least 74%, more typically at least 77%, usually at least 80%, more usually at least about 85%, preferably at least about 90%, more preferably at least about 95 to 98% or more, and in particular embodiments, as 30 high at about 99% or more of the nucleotides. Alternatively, substantial homology exists when the segments will hybridize under selective hybridization conditions, to a strand, or its complement, typically using a sequence derived from Table 1, 2, or 3. Typically, selective hybridization will occur when 35 there is at least about 55% homology over a stretch of at least about 14 nucleotides, preferably at least about 65%, more preferably at least about 75%, and most preferably at

- least about 90%. See, Kanehisa (1984) Nuc. Acids Res. 12:203-213. The length of homology comparison, as described, may be over longer stretches, and in certain embodiments will be over a stretch of at least about 17 nucleotides, usually at least
- 5 about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 40 nucleotides, preferably at least about 50 nucleotides, and more preferably at least about 75 to 100 or more nucleotides.
- 10 Stringent conditions, in referring to homology in the hybridization context, will be stringent combined conditions of salt, temperature, organic solvents, and other parameters, typically those controlled in hybridization reactions. Stringent temperature conditions will usually include
- 15 temperatures in excess of about 30° C, more usually in excess of about 37° C, typically in excess of about 45° C, more typically in excess of about 55° C, preferably in excess of about 65° C, and more preferably in excess of about 70° C. Stringent salt conditions will ordinarily be less than about
- 20 1000 mM, usually less than about 500 mM, more usually less than about 400 mM, typically less than about 300 mM, preferably less than about 200 mM, and more preferably less than about 150 mM. However, the combination of parameters is much more important than the measure of any single parameter.
- 25 See, e.g., Wetmur and Davidson (1968) J. Mol. Biol. 31:349-370. Hybridization under stringent conditions should give a background of at least 2-fold over background, preferably at least 3-5 or more.

30 Alternatively, for sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The

35 sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the

reference sequence, based on the designated program parameters.

Optical alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc. Nat'l Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (see generally Ausubel, et al., *supra*).

One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a tree or dendrogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng and Doolittle (1987) J. Mol. Evol. 35:351-360. The method used is similar to the method described by Higgins and Sharp (1989) CABIOS 5:151-153. The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. For example, a reference sequence can be compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default

gap weight (3.00), default gap length weight (0.10), and weighted end gaps.

Another example of algorithm that is suitable for determining percent sequence identity and sequence similarity 5 is the BLAST algorithm, which is described Altschul, et al. (1990) J. Mol. Biol. 215:403-410. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first 10 identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold 15 (Altschul, et al., *supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension of the word hits 20 in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The 25 BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a wordlength (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Nat'l Acad. Sci. USA 89:10915) alignments (B) of 50, expectation (E) of 30 10, M=5, N=4, and a comparison of both strands.

In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul (1993) Proc. Nat'l Acad. Sci. USA 90:5873-5787). One 35 measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or

amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 5 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

A further indication that two nucleic acid sequences of polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is 10 immunologically cross reactive with the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two 15 nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions, as described below.

CTLA-8-like proteins from other mammalian species can be cloned and isolated by cross-species hybridization of closely 20 related species, e.g., human, as disclosed in Tables 1-5. Homology may be relatively low between distantly related species, and thus hybridization of relatively closely related species is advisable. Alternatively, preparation of an antibody preparation which exhibits less species specificity 25 may be useful in expression cloning approaches.

### III. Purified IL-170 protein

The predicted sequence of primate, e.g., human, IL-171 polypeptide sequence is shown in Table 1. Similarly, in Table 30 2, is provided primate, e.g., human, IL-175 sequence, and is assigned SEQ ID NO: 8. The peptide sequences allow preparation of peptides to generate antibodies to recognize such segments. Table 3 provides sequences of primate and murine IL-172; Table 4 provides sequence of primate and murine IL-35 173; Table 5 provides sequence of primate and murine IL-174; and Table 6 provides sequence of primate IL-176 and IL-177. Table 7 compares various IL-170 family members.

As used herein, the terms "primate IL-170 protein" and "rodent IL-170 protein" shall encompass, when used in a protein context, a protein having amino acid sequences shown in Tables 1-5, or a significant fragment of such a protein.

- 5 It also refers to a primate or rodent derived polypeptide which exhibits similar biological function or interacts with IL-170 protein specific binding components. These binding components, e.g., antibodies, typically bind to an IL-170 protein with high affinity, e.g., at least about 100 nM,  
10 usually better than about 30 nM, preferably better than about 10 nM, and more preferably at better than about 3 nM. Homologous proteins would be found in mammalian species other than rat or humans, e.g., mouse, primates, and in the herpes virus genome, e.g., ORF13. Non-mammalian species should also  
15 possess structurally or functionally related genes and proteins.

The term "polypeptide" as used herein includes a significant fragment or segment, and encompasses a stretch of amino acid residues of at least about 8 amino acids, generally  
20 at least 10 amino acids, more generally at least 12 amino acids, often at least 14 amino acids, more often at least 16 amino acids, typically at least 18 amino acids, more typically at least 20 amino acids, usually at least 22 amino acids, more usually at least 24 amino acids, preferably at least 26 amino  
25 acids, more preferably at least 28 amino acids, and, in particularly preferred embodiments, at least about 30 or more amino acids. The specific ends of such a segment will be at any combinations within the protein, preferably encompassing structural domains.

30 The term "binding composition" refers to molecules that bind with specificity to IL-170 protein, e.g., in a ligand-receptor type fashion, an antibody-antigen interaction, or compounds, e.g., proteins which specifically associate with IL-170 protein, e.g., in a natural physiologically relevant  
35 protein-protein interaction, either covalent or non-covalent. The molecule may be a polymer, or chemical reagent. No implication as to whether IL-170 protein is either the ligand

or the receptor of a ligand-receptor interaction is represented, other than the interaction exhibit similar specificity, e.g., specific affinity. A functional analog may be a protein with structural modifications, or may be a wholly 5 unrelated molecule, e.g., which has a molecular shape which interacts with the appropriate binding determinants. The proteins may serve as agonists or antagonists of a receptor, see, e.g., Goodman, et al. (eds. 1990) Goodman & Gilman's: The Pharmacological Bases of Therapeutics (8th ed.), Pergamon 10 Press.

Solubility of a polypeptide or fragment depends upon the environment and the polypeptide. Many parameters affect polypeptide solubility, including temperature, electrolyte environment, size and molecular characteristics of the 15 polypeptide, and nature of the solvent. Typically, the temperature at which the polypeptide is used ranges from about 4° C to about 65° C. Usually the temperature at use is greater than about 18° C and more usually greater than about 22° C. For diagnostic purposes, the temperature will usually 20 be about room temperature or warmer, but less than the denaturation temperature of components in the assay. For therapeutic purposes, the temperature will usually be body temperature, typically about 37° C for humans, though under certain situations the temperature may be raised or lowered in 25 situ or in vitro.

The electrolytes will usually approximate in situ physiological conditions, but may be modified to higher or lower ionic strength where advantageous. The actual ions may be modified, e.g., to conform to standard buffers used in 30 physiological or analytical contexts.

The size and structure of the polypeptide should generally be in a substantially stable state, and usually not in a denatured state. The polypeptide may be associated with other polypeptides in a quaternary structure, e.g., to confer 35 solubility, or associated with lipids or detergents in a manner which approximates natural lipid bilayer interactions.

The solvent will usually be a biologically compatible buffer, of a type used for preservation of biological activities, and will usually approximate a physiological solvent. Usually the solvent will have a neutral pH,  
5 typically between about 5 and 10, and preferably about 7.5. On some occasions, a detergent will be added, typically a mild non-denaturing one, e.g., CHS or CHAPS, or a low enough concentration as to avoid significant disruption of structural or physiological properties of the antigen.  
10 Solubility is reflected by sedimentation measured in Svedberg units, which are a measure of the sedimentation velocity of a molecule under particular conditions. The determination of the sedimentation velocity was classically performed in an analytical ultracentrifuge, but is typically  
15 now performed in a standard ultracentrifuge. See, Freifelder (1982) Physical Biochemistry (2d ed.), W.H. Freeman; and Cantor and Schimmel (1980) Biophysical Chemistry, parts 1-3, W.H. Freeman & Co., San Francisco. As a crude determination, a sample containing a putatively soluble polypeptide is spun  
20 in a standard full sized ultracentrifuge at about 50K rpm for about 10 minutes, and soluble molecules will remain in the supernatant. A soluble particle or polypeptide will typically be less than about 30S, more typically less than about 15S, usually less than about 10S, more usually less than about 6S,  
25 and, in particular embodiments, preferably less than about 4S, and more preferably less than about 3S.

#### IV. Making IL-170 protein; Mimetics

DNA which encodes the IL-170 protein or fragments thereof  
30 can be obtained by chemical synthesis, screening cDNA libraries, or by screening genomic libraries prepared from a wide variety of cell lines or tissue samples.

This DNA can be expressed in a wide variety of host cells for the synthesis of a full-length protein or fragments which  
35 can in turn, for example, be used to generate polyclonal or monoclonal antibodies; for binding studies; for construction and expression of modified molecules; and for

- structure/function studies. Each antigen or its fragments can be expressed in host cells that are transformed or transfected with appropriate expression vectors. These molecules can be substantially purified to be free of protein or cellular
- 5 contaminants, other than those derived from the recombinant host, and therefore are particularly useful in pharmaceutical compositions when combined with a pharmaceutically acceptable carrier and/or diluent. The antigen, or portions thereof, may be expressed as fusions with other proteins.
- 10 Expression vectors are typically self-replicating DNA or RNA constructs containing the desired antigen gene or its fragments, usually operably linked to suitable genetic control elements that are recognized in a suitable host cell. These control elements are capable of effecting expression within a
- 15 suitable host. The specific type of control elements necessary to effect expression will depend upon the eventual host cell used. Generally, the genetic control elements can include a prokaryotic promoter system or a eukaryotic promoter expression control system, and typically include a
- 20 transcriptional promoter, an optional operator to control the onset of transcription, transcription enhancers to elevate the level of mRNA expression, a sequence that encodes a suitable ribosome binding site, and sequences that terminate transcription and translation. Expression vectors also
- 25 usually contain an origin of replication that allows the vector to replicate independently of the host cell. Methods for amplifying vector copy number are also known, see, e.g., Kaufman, et al. (1985) Molec. and Cell. Biol. 5:1750-1759.
- The vectors of this invention contain DNA which encodes
- 30 an IL-170 protein, or a fragment thereof, typically encoding a biologically active polypeptide. The DNA can be under the control of a viral promoter and can encode a selection marker. This invention further contemplates use of such expression vectors which are capable of expressing eukaryotic cDNA coding
- 35 for an IL-170 protein in a prokaryotic or eukaryotic host, where the vector is compatible with the host and where the eukaryotic cDNA coding for the antigen is inserted into the

vector such that growth of the host containing the vector expresses the cDNA in question. Usually, expression vectors are designed for stable replication in their host cells or for amplification to greatly increase the total number of copies 5 of the desirable gene per cell. It is not always necessary to require that an expression vector replicate in a host cell, e.g., it is possible to effect transient expression of the antigen or its fragments in various hosts using vectors that do not contain a replication origin that is recognized by the 10 host cell. It is also possible to use vectors that cause integration of an IL-170 protein gene or its fragments into the host DNA by recombination, or to integrate a promoter which controls expression of an endogenous gene.

Vectors, as used herein, comprise plasmids, viruses, 15 bacteriophage, integratable DNA fragments, and other vehicles which enable the integration of DNA fragments into the genome of the host. Expression vectors are specialized vectors which contain genetic control elements that effect expression of operably linked genes. Plasmids are the most commonly used 20 form of vector but all other forms of vectors which serve an equivalent function and which are, or become, known in the art are suitable for use herein. See, e.g., Pouwels, et al. (1985 and Supplements) Cloning Vectors: A Laboratory Manual, Elsevier, N.Y., and Rodriguez, et al. (eds. 1988) Vectors: A 25 Survey of Molecular Cloning Vectors and Their Uses, Butterworth, Boston, MA.

Transformed cells include cells, preferably mammalian, that have been transformed or transfected with vectors containing an IL-170 gene, typically constructed using 30 recombinant DNA techniques. Transformed host cells usually express the antigen or its fragments, but for purposes of cloning, amplifying, and manipulating its DNA, do not need to express the protein. This invention further contemplates culturing transformed cells in a nutrient medium, thus 35 permitting the protein to accumulate in the culture. The protein can be recovered, either from the culture or from the culture medium.

For purposes of this invention, DNA sequences are operably linked when they are functionally related to each other. For example, DNA for a presequence or secretory leader is operably linked to a polypeptide if it is expressed as a 5 preprotein or participates in directing the polypeptide to the cell membrane or in secretion of the polypeptide. A promoter is operably linked to a coding sequence if it controls the transcription of the polypeptide; a ribosome binding site is operably linked to a coding sequence if it is positioned to 10 permit translation. Usually, operably linked means contiguous and in reading frame, however, certain genetic elements such as repressor genes are not contiguously linked but still bind to operator sequences that in turn control expression.

Suitable host cells include prokaryotes, lower 15 eukaryotes, and higher eukaryotes. Prokaryotes include both gram negative and gram positive organisms, e.g., *E. coli* and *B. subtilis*. Lower eukaryotes include yeasts, e.g., *S. cerevisiae* and *Pichia*, and species of the genus *Dictyostelium*. Higher eukaryotes include established tissue culture cell 20 lines from animal cells, both of non-mammalian origin, e.g., insect cells, and birds, and of mammalian origin, e.g., human, primates, and rodents.

Prokaryotic host-vector systems include a wide variety of vectors for many different species. As used herein, *E. coli* 25 and its vectors will be used generically to include equivalent vectors used in other prokaryotes. A representative vector for amplifying DNA is pBR322 or many of its derivatives. Vectors that can be used to express the IL-170 proteins or its fragments include, but are not limited to, such vectors as 30 those containing the lac promoter (pUC-series); trp promoter (pBR322-trp); Ipp promoter (the pIN-series); lambda-pP or pR promoters (pOTS); or hybrid promoters such as ptac (pDR540). See Brosius, et al. (1988) "Expression Vectors Employing Lambda-, trp-, lac-, and Ipp-derived Promoters", in Rodriguez 35 and Denhardt (eds.) Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworth, Boston, Chapter 10, pp. 205-236.

Lower eukaryotes, e.g., yeasts and *Dictyostelium*, may be transformed with vectors encoding IL-170 proteins. For purposes of this invention, the most common lower eukaryotic host is the baker's yeast, *Saccharomyces cerevisiae*. It will 5 be used to generically represent lower eukaryotes although a number of other strains and species are also available. Yeast vectors typically consist of a replication origin (unless of the integrating type), a selection gene, a promoter, DNA encoding the desired protein or its fragments, and sequences 10 for translation termination, polyadenylation, and transcription termination. Suitable expression vectors for yeast include such constitutive promoters as 3-phosphoglycerate kinase and various other glycolytic enzyme 15 gene promoters or such inducible promoters as the alcohol dehydrogenase 2 promoter or metallothionein promoter.

Suitable vectors include derivatives of the following types: self-replicating low copy number (such as the YRp-series), self-replicating high copy number (such as the YEp-series); integrating types (such as the YIp-series), or mini- 20 chromosomes (such as the YCp-series).

Higher eukaryotic tissue culture cells are the preferred host cells for expression of the functionally active IL-170 protein. In principle, many higher eukaryotic tissue culture cell lines are workable, e.g., insect baculovirus expression 25 systems, whether from an invertebrate or vertebrate source. However, mammalian cells are preferred, in that the processing, both cotranslationally and posttranslationally. Transformation or transfection and propagation of such cells has become a routine procedure. Examples of useful cell lines 30 include HeLa cells, Chinese hamster ovary (CHO) cell lines, baby rat kidney (BRK) cell lines, insect cell lines, bird cell lines, and monkey (COS) cell lines. Expression vectors for such cell lines usually include an origin of replication, a promoter, a translation initiation site, RNA splice sites (if 35 genomic DNA is used), a polyadenylation site, and a transcription termination site. These vectors also usually contain a selection gene or amplification gene. Suitable

expression vectors may be plasmids, viruses, or retroviruses carrying promoters derived, e.g., from such sources as from adenovirus, SV40, parvoviruses, vaccinia virus, or cytomegalovirus. Representative examples of suitable expression vectors include pCDNA1; pCD, see Okayama, et al. (1985) Mol. Cell Biol. 5:1136-1142; pMC1neo Poly-A, see Thomas, et al. (1987) Cell 51:503-512; and a baculovirus vector such as pAC 373 or pAC 610, see O'Reilly, et al. (1992) Baculovirus Expression Vectors: A Laboratory Manual Freeman and Co., CRC Press, Boca Raton, Fla.

It will often be desired to express an IL-170 protein polypeptide in a system which provides a specific or defined glycosylation pattern. In this case, the usual pattern will be that provided naturally by the expression system. However, the pattern will be modifiable by exposing the polypeptide, e.g., an unglycosylated form, to appropriate glycosylating proteins introduced into a heterologous expression system. For example, the IL-170 protein gene may be co-transformed with one or more genes encoding mammalian or other glycosylating enzymes. Using this approach, certain mammalian glycosylation patterns will be achievable or approximated in prokaryote or other cells.

The IL-170 protein, or a fragment thereof, may be engineered to be phosphatidyl inositol (PI) linked to a cell membrane, but can be removed from membranes by treatment with a phosphatidyl inositol cleaving enzyme, e.g., phosphatidyl inositol phospholipase-C. This releases the antigen in a biologically active form, and allows purification by standard procedures of protein chemistry. See, e.g., Low (1989) Biochim. Biophys. Acta 988:427-454; Tse, et al. (1985) Science 230:1003-1008; and Brunner, et al. (1991) J. Cell Biol. 114:1275-1283.

Now that the IL-170 protein has been characterized, fragments or derivatives thereof can be prepared by conventional processes for synthesizing peptides. These include processes such as are described in Stewart and Young (1984) Solid Phase Peptide Synthesis, Pierce Chemical Co.,

Rockford, IL; Bodanszky and Bodanszky (1984) The Practice of Peptide Synthesis, Springer-Verlag, New York; and Bodanszky (1984) The Principles of Peptide Synthesis, Springer-Verlag, New York. For example, an azide process, an acid chloride process, an acid anhydride process, a mixed anhydride process, an active ester process (for example, p-nitrophenyl ester, N-hydroxysuccinimide ester, or cyanomethyl ester), a carbodiimidazole process, an oxidative-reductive process, or a dicyclohexylcarbodiimide (DCCD) /additive process can be used.

5 Solid phase and solution phase syntheses are both applicable to the foregoing processes.

The IL-170 protein, fragments, or derivatives are suitably prepared in accordance with the above processes as typically employed in peptide synthesis, generally either by a so-called stepwise process which comprises condensing an amino acid to the terminal amino acid, one by one in sequence, or by coupling peptide fragments to the terminal amino acid. Amino groups that are not being used in the coupling reaction are typically protected to prevent coupling at an incorrect location.

If a solid phase synthesis is adopted, the C-terminal amino acid is bound to an insoluble carrier or support through its carboxyl group. The insoluble carrier is not particularly limited as long as it has a binding capability to a reactive carboxyl group. Examples of such insoluble carriers include halomethyl resins, such as chloromethyl resin or bromomethyl resin, hydroxymethyl resins, phenol resins, tert-alkyloxycarbonyl-hydrazidated resins, and the like.

An amino group-protected amino acid is bound in sequence through condensation of its activated carboxyl group and the reactive amino group of the previously formed peptide or chain, to synthesize the peptide step by step. After synthesizing the complete sequence, the peptide is split off from the insoluble carrier to produce the peptide. This solid-phase approach is generally described by Merrifield, et al. (1963) in J. Am. Chem. Soc. 85:2149-2156.

The prepared protein and fragments thereof can be isolated and purified from the reaction mixture by means of peptide separation, for example, by extraction, precipitation, electrophoresis and various forms of chromatography, and the like. The IL-170 proteins of this invention can be obtained in varying degrees of purity depending upon its desired use. Purification can be accomplished by use of the protein purification techniques disclosed herein or by the use of the antibodies herein described in immunoabsorbant affinity chromatography. This immunoabsorbant affinity chromatography is carried out by first linking the antibodies to a solid support and then contacting the linked antibodies with solubilized lysates of appropriate source cells, lysates of other cells expressing the protein, or lysates or supernatants of cells producing the IL-170 protein as a result of DNA techniques, see below.

#### V. Physical Variants

This invention also encompasses proteins or peptides having substantial amino acid sequence homology with the amino acid sequence of the IL-170 protein. The variants include species or allelic variants.

Amino acid sequence homology, or sequence identity, is determined by optimizing residue matches, if necessary, by introducing gaps as required. This changes when considering conservative substitutions as matches. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. Homologous amino acid sequences are typically intended to include natural allelic and interspecies variations in each respective protein sequence. Typical homologous proteins or peptides will have from 25-100% homology (if gaps can be introduced), to 50-100% homology (if conservative substitutions are included) with the amino acid sequence of the IL-170 protein. Homology measures will be at

least about 35%, generally at least 40%, more generally at least 45%, often at least 50%, more often at least 55%, typically at least 60%, more typically at least 65%, usually at least 70%, more usually at least 75%, preferably at least 80%, and more preferably at least 80%, and in particularly preferred embodiments, at least 85% or more. See also Needleham, et al. (1970) J. Mol. Biol. 48:443-453; Sankoff, et al. (1983) Chapter One in Time Warps, String Edits, and Macromolecules: The Theory and Practice of Sequence Comparison

10 Addison-Wesley, Reading, MA; and software packages from IntelliGenetics, Mountain View, CA; and the University of Wisconsin Genetics Computer Group, Madison, WI.

The isolated DNA encoding an IL-170 protein can be readily modified by nucleotide substitutions, nucleotide deletions, nucleotide insertions, and inversions of nucleotide stretches. These modifications result in novel DNA sequences which encode these antigens, their derivatives, or proteins having similar physiological, immunogenic, or antigenic activity. These modified sequences can be used to produce mutant antigens or to enhance expression. Enhanced expression may involve gene amplification, increased transcription, increased translation, and other mechanisms. Such mutant IL-170 protein derivatives include predetermined or site-specific mutations of the respective protein or its fragments. "Mutant IL-170 protein" encompasses a polypeptide otherwise falling within the homology definition of the murine IL-170 or human IL-170 protein as set forth above, but having an amino acid sequence which differs from that of IL-170 protein as found in nature, whether by way of deletion, substitution, or insertion. In particular, "site specific mutant IL-170 protein" generally includes proteins having significant homology with a protein having sequences of Tables 1-5, and as sharing various biological activities, e.g., antigenic or immunogenic, with those sequences, and in preferred embodiments contain most of the disclosed sequences. Similar concepts apply to different IL-170 proteins, particularly those found in various warm blooded animals, e.g., mammals and

birds. As stated before, it is emphasized that descriptions are generally meant to encompass all IL-170 proteins, not limited to the mouse embodiment specifically discussed.

Although site specific mutation sites are predetermined, 5 mutants need not be site specific. IL-170 protein mutagenesis can be conducted by making amino acid insertions or deletions. Substitutions, deletions, insertions, or any combinations may be generated to arrive at a final construct. Insertions include amino- or carboxy-terminal fusions. Random 10 mutagenesis can be conducted at a target codon and the expressed mutants can then be screened for the desired activity. Methods for making substitution mutations at predetermined sites in DNA having a known sequence are well known in the art, e.g., by M13 primer mutagenesis or 15 polymerase chain reaction (PCR) techniques. See also Sambrook, et al. (1989) and Ausubel, et al. (1987 and Supplements).

The mutations in the DNA normally should not place coding sequences out of reading frames and preferably will not create 20 complementary regions that could hybridize to produce secondary mRNA structure such as loops or hairpins.

The present invention also provides recombinant proteins, e.g., heterologous fusion proteins using segments from these 25 proteins. A heterologous fusion protein is a fusion of proteins or segments which are naturally not normally fused in the same manner. Thus, the fusion product of an immunoglobulin with an IL-170 polypeptide is a continuous protein molecule having sequences fused in a typical peptide linkage, typically made as a single translation product and 30 exhibiting properties derived from each source peptide. A similar concept applies to heterologous nucleic acid sequences.

In addition, new constructs may be made from combining 35 similar functional domains from other proteins. For example, antigen-binding or other segments may be "swapped" between different new fusion polypeptides or fragments. See, e.g., Cunningham, et al. (1989) Science 243:1330-1336; and O'Dowd,

et al. (1988) *J. Biol. Chem.* 263:15985-15992. Thus, new chimeric polypeptides exhibiting new combinations of specificities will result from the functional linkage of biologically relevant domains and other functional domains.

5       The phosphoramidite method described by Beaucage and Carruthers (1981) *Tetra. Letts.* 22:1859-1862, will produce suitable synthetic DNA fragments. A double stranded fragment will often be obtained either by synthesizing the complementary strand and annealing the strand together under  
10 appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence, e.g., PCR techniques.

#### VI. Functional Variants

15       The blocking of physiological response to IL-170 proteins may result from the inhibition of binding of the antigen to its natural binding partner, e.g., through competitive inhibition. Thus, in vitro assays of the present invention will often use isolated protein, membranes from cells  
20 expressing a recombinant membrane associated IL-170 protein, soluble fragments comprising binding segments, or fragments attached to solid phase substrates. These assays will also allow for the diagnostic determination of the effects of either binding segment mutations and modifications, or protein  
25 mutations and modifications, e.g., analogs.

This invention also contemplates the use of competitive drug screening assays, e.g., where neutralizing antibodies to antigen or binding partner fragments compete with a test compound for binding to the protein. In this manner, the  
30 antibodies can be used to detect the presence of any polypeptide which shares one or more antigenic binding sites of the protein and can also be used to occupy binding sites on the protein that might otherwise interact with a binding partner.

35       Additionally, neutralizing antibodies against the IL-170 protein and soluble fragments of the antigen which contain a high affinity receptor binding site, can be used to inhibit

antigen function in tissues, e.g., tissues experiencing abnormal physiology.

"Derivatives" of the IL-170 antigens include amino acid sequence mutants, glycosylation variants, and covalent or aggregate conjugates with other chemical moieties. Covalent derivatives can be prepared by linkage of functionalities to groups which are found in the IL-170 amino acid side chains or at the N- or C- termini, by means which are well known in the art. These derivatives can include, without limitation, aliphatic esters or amides of the carboxyl terminus, or of residues containing carboxyl side chains, O-acyl derivatives of hydroxyl group-containing residues, and N-acyl derivatives of the amino terminal amino acid or amino-group containing residues, e.g., lysine or arginine. Acyl groups are selected from the group of alkyl-moieties including C3 to C18 normal alkyl, thereby forming alkanoyl aroyl species. Covalent attachment to carrier proteins may be important when immunogenic moieties are haptens.

In particular, glycosylation alterations are included, e.g., made by modifying the glycosylation patterns of a polypeptide during its synthesis and processing, or in further processing steps. Particularly preferred means for accomplishing this are by exposing the polypeptide to glycosylating enzymes derived from cells which normally provide such processing, e.g., mammalian glycosylation enzymes. Deglycosylation enzymes are also contemplated. Also embraced are versions of the same primary amino acid sequence which have other minor modifications, including phosphorylated amino acid residues, e.g., phosphotyrosine, phosphoserine, or phosphothreonine.

A major group of derivatives are covalent conjugates of the IL-170 protein or fragments thereof with other proteins or polypeptides. These derivatives can be synthesized in recombinant culture such as N- or C-terminal fusions or by the use of agents known in the art for their usefulness in cross-linking proteins through reactive side groups. Preferred antigen derivatization sites with cross-linking agents are at

free amino groups, carbohydrate moieties, and cysteine residues.

Fusion polypeptides between the IL-170 proteins and other homologous or heterologous proteins are also provided.

- 5 Homologous polypeptides may be fusions between different surface markers, resulting in, e.g., a hybrid protein exhibiting receptor binding specificity. Likewise, heterologous fusions may be constructed which would exhibit a combination of properties or activities of the derivative
- 10 proteins. Typical examples are fusions of a reporter polypeptide, e.g., luciferase, with a segment or domain of an antigen, e.g., a receptor-binding segment, so that the presence or location of the fused antigen may be easily determined. See, e.g., Dull, et al., U.S. Patent No.
- 15 4,859,609. Other gene fusion partners include bacterial  $\beta$ -galactosidase, trpE, Protein A,  $\beta$ -lactamase, alpha amylase, alcohol dehydrogenase, and yeast alpha mating factor. See, e.g., Godowski, et al. (1988) Science 241:812-816.

- 20 The phosphoramidite method described by Beaucage and Carruthers (1981) Tetra. Letts. 22:1859-1862, will produce suitable synthetic DNA fragments. A double stranded fragment will often be obtained either by synthesizing the complementary strand and annealing the strand together under appropriate conditions or by adding the complementary strand
- 25 using DNA polymerase with an appropriate primer sequence.

- Such polypeptides may also have amino acid residues which have been chemically modified by phosphorylation, sulfonation, biotinylation, or the addition or removal of other moieties, particularly those which have molecular shapes similar to phosphate groups. In some embodiments, the modifications will be useful labeling reagents, or serve as purification targets, e.g., affinity ligands.
- 30

- 35 Fusion proteins will typically be made by either recombinant nucleic acid methods or by synthetic polypeptide methods. Techniques for nucleic acid manipulation and expression are described generally, for example, in Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual (2d

- ed.), Vols. 1-3, Cold Spring Harbor Laboratory. Techniques for synthesis of polypeptides are described, for example, in Merrifield (1963) J. Amer. Chem. Soc. 85:2149-2156; Merrifield (1986) Science 232: 341-347; and Atherton, et al. (1989) Solid Phase Peptide Synthesis: A Practical Approach, IRL Press, Oxford.

This invention also contemplates the use of derivatives of the IL-170 proteins other than variations in amino acid sequence or glycosylation. Such derivatives may involve covalent or aggregative association with chemical moieties. These derivatives generally fall into the three classes: (1) salts, (2) side chain and terminal residue covalent modifications, and (3) adsorption complexes, for example with cell membranes. Such covalent or aggregative derivatives are useful as immunogens, as reagents in immunoassays, or in purification methods such as for affinity purification of antigens or other binding proteins. For example, an IL-170 antigen can be immobilized by covalent bonding to a solid support such as cyanogen bromide-activated Sepharose, by methods which are well known in the art, or adsorbed onto polyolefin surfaces, with or without glutaraldehyde cross-linking, for use in the assay or purification of anti-IL-170 protein antibodies or its receptor or other binding partner. The IL-170 antigens can also be labeled with a detectable group, for example radioiodinated by the chloramine T procedure, covalently bound to rare earth chelates, or conjugated to another fluorescent moiety for use in diagnostic assays. Purification of IL-170 protein may be effected by immobilized antibodies or binding partners.

A solubilized IL-170 antigen or fragment of this invention can be used as an immunogen for the production of antisera or antibodies specific for the protein or fragments thereof. The purified antigen can be used to screen monoclonal antibodies or binding fragments prepared by immunization with various forms of impure preparations containing the protein. In particular, the term "antibodies" also encompasses antigen binding fragments of natural

antibodies. The purified IL-170 proteins can also be used as a reagent to detect any antibodies generated in response to the presence of elevated levels of the protein or cell fragments containing the antigen, both of which may be 5 diagnostic of an abnormal or specific physiological or disease condition. Additionally, antigen fragments may also serve as immunogens to produce the antibodies of the present invention, as described immediately below. For example, this invention contemplates antibodies raised against amino acid sequences 10 encoded by nucleotide sequences shown in Table 1 through 5, or fragments of proteins containing them. In particular, this invention contemplates antibodies having binding affinity to or being raised against specific fragments which are predicted to lie outside of the lipid bilayer.

15 The present invention contemplates the isolation of additional closely related species variants. Southern blot analysis established that similar genetic entities exist in other mammals, e.g., rat and human. It is likely that the IL-170 proteins are widespread in species variants, e.g., 20 rodents, lagomorphs, carnivores, artiodactyla, perissodactyla, and primates.

The invention also provides means to isolate a group of related antigens displaying both distinctness and similarities in structure, expression, and function. Elucidation of many 25 of the physiological effects of the antigens will be greatly accelerated by the isolation and characterization of distinct species variants. In particular, the present invention provides useful probes for identifying additional homologous genetic entities in different species.

30 The isolated genes will allow transformation of cells lacking expression of a corresponding IL-170 protein, e.g., either species types or cells which lack corresponding antigens and should exhibit negative background activity. Expression of transformed genes will allow isolation of 35 antigenically pure cell lines, with defined or single specie variants. This approach will allow for more sensitive detection and discrimination of the physiological effects of

IL-170 proteins. Subcellular fragments, e.g., cytoplasts or membrane fragments, can be isolated and used.

Dissection of the critical structural elements which effect the various physiological or differentiation functions provided by the proteins is possible using standard techniques of modern molecular biology, particularly in comparing members of the related class. See, e.g., the homolog-scanning mutagenesis technique described in Cunningham, et al. (1989) Science 243:1339-1336; and approaches used in O'Dowd, et al. (1988) J. Biol. Chem. 263:15985-15992; and Lechleiter, et al. (1990) EMBO J. 9:4381-4390.

In particular, functional domains or segments can be substituted between species variants to determine what structural features are important in both binding partner affinity and specificity, as well as signal transduction. An array of different variants will be used to screen for molecules exhibiting combined properties of interaction with different species variants of binding partners.

Antigen internalization may occur under certain circumstances, and interaction between intracellular components and "extracellular" segments of proteins involved in interactions may occur. The specific segments of interaction of IL-170 protein with other intracellular components may be identified by mutagenesis or direct biochemical means, e.g., cross-linking or affinity methods. Structural analysis by crystallographic or other physical methods will also be applicable. Further investigation of the mechanism of biological function will include study of associated components which may be isolatable by affinity methods or by genetic means, e.g., complementation analysis of mutants.

Further study of the expression and control of IL-170 protein will be pursued. The controlling elements associated with the antigens may exhibit differential developmental, tissue specific, or other expression patterns. Upstream or downstream genetic regions, e.g., control elements, are of interest.

Structural studies of the antigen will lead to design of new variants, particularly analogs exhibiting agonist or antagonist properties on binding partners. This can be combined with previously described screening methods to 5 isolate variants exhibiting desired spectra of activities.

- Expression in other cell types will often result in glycosylation differences in a particular antigen. Various species variants may exhibit distinct functions based upon structural differences other than amino acid sequence.
- 10 Differential modifications may be responsible for differential function, and elucidation of the effects are now made possible.

Thus, the present invention provides important reagents related to antigen-binding partner interaction. Although the 15 foregoing description has focused primarily upon the murine IL-170 and human IL-170 protein, those of skill in the art will immediately recognize that the invention encompasses other antigens, e.g., mouse and other mammalian species or allelic variants, as well as variants thereof.

20

## VII. Antibodies

Antibodies can be raised to the various IL-170 proteins, including species or allelic variants, and fragments thereof, both in their naturally occurring forms and in their 25 recombinant forms. Additionally, antibodies can be raised to IL-170 proteins in either their active forms or in their inactive forms. Anti-idiotypic antibodies are also contemplated.

Antibodies, including binding fragments and single chain 30 versions, against predetermined fragments of the antigens can be raised by immunization of animals with conjugates of the fragments with immunogenic proteins. Monoclonal antibodies are prepared from cells secreting the desired antibody. These antibodies can be screened for binding to normal or defective 35 IL-170 proteins, or screened for agonistic or antagonistic activity, e.g., mediated through a binding partner. These monoclonal antibodies will usually bind with at least a  $K_D$  of

about 1 mM, more usually at least about 300  $\mu$ M, typically at least about 10  $\mu$ M, more typically at least about 30  $\mu$ M, preferably at least about 10  $\mu$ M, and more preferably at least about 3  $\mu$ M or better.

5        An IL-170 polypeptide that specifically binds to or that is specifically immunoreactive with an antibody, e.g., such as a polyclonal antibody, generated against a defined immunogen, e.g., such as an immunogen consisting of an amino acid sequence of SEQ ID NO: 3 or fragments thereof or a polypeptide 10 generated from the nucleic acid of SEQ ID NO: 1 is typically determined in an immunoassay. Included within the metes and bounds of the present invention are those nucleic acid sequences described herein, including functional variants, that encode polypeptides that selectively bind to polyclonal 15 antibodies generated against the prototypical IL-171 polypeptide as structurally and functionally defined herein. The immunoassay typically uses a polyclonal antiserum which was raised, e.g., to a protein of SEQ ID NO: 3 or 5. This antiserum is selected to have low crossreactivity against 20 appropriate other IL-170 family members, preferably from the same species, and any such crossreactivity is removed by immunoabsorption prior to use in the immunoassay. Appropriate selective serum preparations can be isolated, and characterized.

25       In order to produce antisera for use in an immunoassay, the protein, e.g., of SEQ ID NO: 5, is isolated as described herein. For example, recombinant protein may be produced in a mammalian cell line. An appropriate host, e.g., an inbred strain of mice such as Balb/c, is immunized with the protein 30 of SEQ ID NO: 5 using a standard adjuvant, such as Freund's adjuvant, and a standard mouse immunization protocol (see Harlow and Lane). Alternatively, a substantially full length synthetic peptide derived from the sequences disclosed herein can be used as an immunogen. Polyclonal sera are collected 35 and titered against the immunogen protein in an immunoassay, e.g., a solid phase immunoassay with the immunogen immobilized on a solid support. Polyclonal antisera with a titer of  $10^4$

or greater are selected and tested for their cross reactivity against other IL-170 family members, e.g., IL-171, IL-172, IL-173, IL-174, IL-175, IL-176, or IL-177, using a competitive binding immunoassay such as the one described in Harlow and Lane, *supra*, at pages 570-573. Preferably at least two IL-170 family members are used in this determination in conjunction with the target. These IL-170 family members can be produced as recombinant proteins and isolated using standard molecular biology and protein chemistry techniques as described herein.

Thus, antibody preparations can be identified or produced having desired selectivity or specificity for subsets of IL-170 family members.

Immunoassays in the competitive binding format can be used for the crossreactivity determinations. For example, the protein of SEQ ID NO: 5 can be immobilized to a solid support. Proteins added to the assay compete with the binding of the antisera to the immobilized antigen. The ability of the above proteins to compete with the binding of the antisera to the immobilized protein is compared to the protein of SEQ ID NO: 5. The percent crossreactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% crossreactivity with each of the proteins listed above are selected and pooled. The cross-reacting antibodies are then removed from the pooled antisera by immunoabsorption with the above-listed proteins.

The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay as described above to compare a second protein to the immunogen protein. In order to make this comparison, the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is determined. If the amount of the second protein required is less than twice the amount of the protein of, e.g., SEQ ID NO: 5 that is required, then the second protein is said to specifically bind to an antibody generated to the immunogen.

The antibodies, including antigen binding fragments, of this invention can have significant diagnostic or therapeutic value. They can be potent antagonists that bind to a binding partner and inhibit antigen binding or inhibit the ability of 5 an antigen to elicit a biological response. They also can be useful as non-neutralizing antibodies and can be coupled to toxins or radionuclides so that when the antibody binds to the antigen, a cell expressing it, e.g., on its surface, is killed. Further, these antibodies can be conjugated to drugs 10 or other therapeutic agents, either directly or indirectly by means of a linker, and may effect drug targeting.

The antibodies of this invention can also be useful in diagnostic applications. As capture or non-neutralizing antibodies, they can be screened for ability to bind to the 15 antigens without inhibiting binding by a partner. As neutralizing antibodies, they can be useful in competitive binding assays. They will also be useful in detecting or quantifying IL-170 protein or its binding partners. See, e.g., Chan (ed. 1987) Immunoassay: A Practical Guide Academic 20 Press, Orlando, Fla.; Ngo (ed. 1988) Nonisotopic Immunoassay Plenum Press, NY; and Price and Newman (eds. 1991) Principles and Practice of Immunoassay Stockton Press, NY.

Antigen fragments may be joined to other materials, particularly polypeptides, as fused or covalently joined 25 polypeptides to be used as immunogens. An antigen and its fragments may be fused or covalently linked to a variety of immunogens, such as keyhole limpet hemocyanin, bovine serum albumin, tetanus toxoid, etc. See Microbiology, Hoeber Medical Division, Harper and Row, 1969; Landsteiner (1962) 30 Specificity of Serological Reactions, Dover Publications, New York, and Williams, et al. (1967) Methods in Immunology and Immunochimistry, Vol. 1, Academic Press, New York, for descriptions of methods of preparing polyclonal antisera. A typical method involves hyperimmunization of an animal with an 35 antigen. The blood of the animal is then collected shortly after the repeated immunizations and the gamma globulin is isolated.

In some instances, it is desirable to prepare monoclonal antibodies from various mammalian hosts, such as mice, rodents, primates, humans, etc. Description of techniques for preparing such monoclonal antibodies may be found in, e.g.,

5 Stites, et al. (eds.) Basic and Clinical Immunology (4th ed.), Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane (1988) Antibodies: A Laboratory Manual, CSH Press; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.) Academic Press,

10 New York; and particularly in Kohler and Milstein (1975) in Nature 256: 495-497, which discusses one method of generating monoclonal antibodies. Summarized briefly, this method involves injecting an animal with an immunogen. The animal is then sacrificed and cells taken from its spleen, which are

15 then fused with myeloma cells. The result is a hybrid cell or "hybridoma" that is capable of reproducing in vitro. The population of hybridomas is then screened to isolate individual clones, each of which secrete a single antibody species to the immunogen. In this manner, the individual

20 antibody species obtained are the products of immortalized and cloned single B cells from the immune animal generated in response to a specific site recognized on the immunogenic substance.

Other suitable techniques involve in vitro exposure of

25 lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors. See, Huse, et al. (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science 246:1275-1281; and Ward, et al. (1989)

30 Nature 341:544-546. The polypeptides and antibodies of the present invention may be used with or without modification, including chimeric or humanized antibodies. Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a

35 detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include

radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents, teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 5 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced, see Cabilly, U.S. Patent No. 4,816,567.

The antibodies of this invention can also be used for affinity chromatography in isolating the protein. Columns can 10 be prepared where the antibodies are linked to a solid support, e.g., particles, such as agarose, Sephadex, or the like, where a cell lysate may be passed through the column, the column washed, followed by increasing concentrations of a mild denaturant, whereby the purified IL-170 protein will be 15 released.

The antibodies may also be used to screen expression libraries for particular expression products. Usually the 20 antibodies used in such a procedure will be labeled with a moiety allowing easy detection of presence of antigen by antibody binding.

Antibodies raised against each IL-170 protein will also be useful to raise anti-idiotypic antibodies. These will be useful in detecting or diagnosing various immunological conditions related to expression of the respective antigens.

25

## VIII. Uses

The present invention provides reagents which will find use in diagnostic applications as described elsewhere herein, e.g., in the general description for physiological or 30 developmental abnormalities, or below in the description of kits for diagnosis.

This invention also provides reagents with significant therapeutic value. The IL-170 protein (naturally occurring or recombinant), fragments thereof, and antibodies thereto, along 35 with compounds identified as having binding affinity to IL-170 protein, should be useful in the treatment of conditions associated with abnormal physiology or development, including

abnormal proliferation, e.g., cancerous conditions, or degenerative conditions. Abnormal proliferation, regeneration, degeneration, and atrophy may be modulated by appropriate therapeutic treatment using the compositions  
5 provided herein. For example, a disease or disorder associated with abnormal expression or abnormal signaling by an IL-170 antigen should be a likely target for an agonist or antagonist of the protein.

Other abnormal developmental conditions are known in the  
10 cell types shown to possess IL-170 antigen mRNA by Northern blot analysis. See Berkow (ed.) The Merck Manual of Diagnosis and Therapy, Merck & Co., Rahway, N.J.; and Thorn, et al. Harrison's Principles of Internal Medicine, McGraw-Hill, N.Y. These problems may be susceptible to prevention or treatment  
15 using compositions provided herein.

Recombinant antibodies which bind to IL-170 can be purified and then administered to a patient. These reagents can be combined for therapeutic use with additional active or inert ingredients, e.g., in conventional pharmaceutically  
20 acceptable carriers or diluents, e.g., immunogenic adjuvants, along with physiologically innocuous stabilizers and excipients. These combinations can be sterile filtered and placed into dosage forms as by lyophilization in dosage vials or storage in stabilized aqueous preparations. This invention  
25 also contemplates use of antibodies or binding fragments thereof, including forms which are not complement binding.

Screening using IL-170 for binding partners or compounds having binding affinity to IL-170 antigen can be performed, including isolation of associated components. Subsequent  
30 biological assays can then be utilized to determine if the compound has intrinsic biological activity and is therefore an agonist or antagonist in that it blocks an activity of the antigen. This invention further contemplates the therapeutic use of antibodies to IL-170 protein as antagonists. This  
35 approach should be particularly useful with other IL-170 protein species variants.

The quantities of reagents necessary for effective therapy will depend upon many different factors, including means of administration, target site, physiological state of the patient, and other medicants administered. Thus,

5 treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of these reagents. Animal testing of effective doses for treatment of particular disorders will provide further

10 predictive indication of human dosage. Various considerations are described, e.g., in Gilman, et al. (eds. 1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, 17th ed. (1990), Mack Publishing Co., Easton, Penn. Methods for

15 administration are discussed therein and below, e.g., for oral, intravenous, intraperitoneal, or intramuscular administration, transdermal diffusion, and others. See also Langer (1990) Science 249:1527-1533. Pharmaceutically acceptable carriers will include water, saline, buffers, and

20 other compounds described, e.g., in the Merck Index, Merck & Co., Rahway, New Jersey. Dosage ranges would ordinarily be expected to be in amounts lower than 1 mM concentrations, typically less than about 10  $\mu$ M concentrations, usually less than about 100 nM, preferably less than about 10 pM

25 (picomolar), and most preferably less than about 1 fM (femtomolar), with an appropriate carrier. Slow release formulations, or a slow release apparatus will often be utilized for continuous administration.

IL-170 protein, fragments thereof, and antibodies to it

30 or its fragments, antagonists, and agonists, may be administered directly to the host to be treated or, depending on the size of the compounds, it may be desirable to conjugate them to carrier proteins such as ovalbumin or serum albumin prior to their administration. Therapeutic formulations may

35 be administered in any conventional dosage formulation. While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical

formulation. Formulations typically comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof. Each carrier should be both pharmaceutically and physiologically acceptable in the sense of being compatible with the other ingredients and not injurious to the patient. Formulations include those suitable for oral, rectal, nasal, or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. See, e.g., Gilman, et al. (eds. 1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press, Parrytown, NY; Remington's Pharmaceutical Sciences, 17th ed. (1990) Mack Publishing Co., Easton, Penn.; Avis, et al. (eds. 1993) Pharmaceutical Dosage Forms: Parenteral Medications 2d ed., Dekker, NY; Lieberman, et al. (eds. 1990) Pharmaceutical Dosage Forms: Tablets 2d ed., Dekker, NY; and Lieberman, et al. (eds. 1990) Pharmaceutical Dosage Forms: Disperse Systems Dekker, NY. The therapy of this invention may be combined with or used in association with other therapeutic, including cytokine, reagents.

Both the naturally occurring and the recombinant forms of the IL-170 proteins of this invention are particularly useful in kits and assay methods which are capable of screening compounds for binding activity to the proteins. Several methods of automating assays have been developed in recent years so as to permit screening of tens of thousands of compounds in a short period. See, e.g., Fodor, et al. (1991) Science 251:767-773, which describes means for testing of binding affinity by a plurality of defined polymers synthesized on a solid substrate. The development of suitable assays can be greatly facilitated by the availability of large amounts of purified, soluble IL-170 protein as provided by this invention.

This invention is particularly useful for screening compounds by using recombinant antigen in any of a variety of

drug screening techniques. The advantages of using a recombinant protein in screening for specific ligands include: (a) improved renewable source of the antigen from a specific source; (b) potentially greater number of antigen molecules per cell giving better signal to noise ratio in assays; and (c) species variant specificity (theoretically giving greater biological and disease specificity). The purified protein may be tested in numerous assays, typically in vitro assays, which evaluate biologically relevant responses. See, e.g., Coligan 5 Current Protocols in Immunology; Hood, et al. Immunology Benjamin/Cummings; Paul (ed.) Fundamental Immunology; and 10 Methods in Enzymology Academic Press.

One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with 15 recombinant DNA molecules expressing the IL-170 antigens. Cells may be isolated which express an antigen in isolation from other functionally equivalent antigens. Such cells, either in viable or fixed form, can be used for standard protein-protein binding assays. See also, Parce, et al. 20 (1989) Science 246:243-247; and Owicki, et al. (1990) Proc. Nat'l Acad. Sci. USA 87:4007-4011, which describe sensitive methods to detect cellular responses. Competitive assays are particularly useful, where the cells (source of IL-170 protein) are contacted and incubated with a labeled binding 25 partner or antibody having known binding affinity to the ligand, such as  $^{125}\text{I}$ -antibody, and a test sample whose binding affinity to the binding composition is being measured. The bound and free labeled binding compositions are then separated to assess the degree of antigen binding. The amount of test 30 compound bound is inversely proportional to the amount of labeled receptor binding to the known source. Any one of numerous techniques can be used to separate bound from free antigen to assess the degree of binding. This separation step could typically involve a procedure such as adhesion to 35 filters followed by washing, adhesion to plastic followed by washing, or centrifugation of the cell membranes. Viable cells could also be used to screen for the effects of drugs on

IL-170 protein mediated functions, e.g., second messenger levels, i.e., Ca<sup>++</sup>; cell proliferation; inositol phosphate pool changes; and others. Some detection methods allow for elimination of a separation step, e.g., a proximity sensitive 5 detection system. Calcium sensitive dyes will be useful for detecting Ca<sup>++</sup> levels, with a fluorimeter or a fluorescence cell sorting apparatus.

Another method utilizes membranes from transformed eukaryotic or prokaryotic host cells as the source of the IL-10 170 protein. These cells are stably transformed with DNA vectors directing the expression of a membrane associated IL-170 protein, e.g., an engineered membrane bound form. Essentially, the membranes would be prepared from the cells and used in any receptor/ligand type binding assay such as the 15 competitive assay set forth above.

Still another approach is to use solubilized, unpurified or solubilized, purified IL-170 protein from transformed eukaryotic or prokaryotic host cells. This allows for a "molecular" binding assay with the advantages of increased 20 specificity, the ability to automate, and high drug test throughput.

Another technique for drug screening involves an approach which provides high throughput screening for compounds having suitable binding affinity to IL-170 and is described in detail 25 in Geysen, European Patent Application 84/03564, published on September 13, 1984. First, large numbers of different small peptide test compounds are synthesized on a solid substrate, e.g., plastic pins or some other appropriate surface, see Fodor, et al. (1991). Then all the pins are reacted with 30 solubilized, unpurified or solubilized, purified IL-170 binding composition, and washed. The next step involves detecting bound binding composition.

Rational drug design may also be based upon structural studies of the molecular shapes of the IL-170 protein and 35 other effectors or analogs. Effectors may be other proteins which mediate other functions in response to antigen binding, or other proteins which normally interact with the antigen.

One means for determining which sites interact with specific other proteins is a physical structure determination, e.g., x-ray crystallography or 2 dimensional NMR techniques. These will provide guidance as to which amino acid residues form 5 molecular contact regions. For a detailed description of protein structural determination, see, e.g., Blundell and Johnson (1976) Protein Crystallography, Academic Press, New York.

10 Purified IL-170 protein can be coated directly onto plates for use in the aforementioned drug screening techniques. However, non-neutralizing antibodies to these ligands can be used as capture antibodies to immobilize the respective ligand on the solid phase.

15 IX. Kits

This invention also contemplates use of IL-170 proteins, fragments thereof, peptides, and their fusion products in a variety of diagnostic kits and methods for detecting the presence of a binding composition. Typically the kit will 20 have a compartment containing either a defined IL-170 peptide or gene segment or a reagent which recognizes one or the other, e.g., antigen fragments or antibodies.

A kit for determining the binding affinity of a test compound to an IL-170 protein would typically comprise a test 25 compound; a labeled compound, for example an antibody having known binding affinity for the antigen; a source of IL-170 protein (naturally occurring or recombinant); and a means for separating bound from free labeled compound, such as a solid phase for immobilizing the antigen. Once compounds are 30 screened, those having suitable binding affinity to the antigen can be evaluated in suitable biological assays, as are well known in the art, to determine whether they exhibit similar biological activities to the natural antigen. The availability of recombinant IL-170 protein polypeptides also 35 provide well defined standards for calibrating such assays.

A preferred kit for determining the concentration of, for example, an IL-170 protein in a sample would typically

comprise a labeled compound, e.g., antibody, having known binding affinity for the antigen, a source of antigen (naturally occurring or recombinant) and a means for separating the bound from free labeled compound, for example,  
5 a solid phase for immobilizing the IL-170 protein. Compartments containing reagents, and instructions, will normally be provided.

One method for determining the concentration of IL-170 protein in a sample would typically comprise the steps of: (1)  
10 preparing membranes from a sample comprised of a membrane bound IL-170 protein source; (2) washing the membranes and suspending them in a buffer; (3) solubilizing the antigen by incubating the membranes in a culture medium to which a suitable detergent has been added; (4) adjusting the detergent  
15 concentration of the solubilized antigen; (5) contacting and incubating said dilution with radiolabeled antibody to form complexes; (6) recovering the complexes such as by filtration through polyethyleneimine treated filters; and (7) measuring the radioactivity of the recovered complexes.

20 Antibodies, including antigen binding fragments, specific for the IL-170 protein or fragments are useful in diagnostic applications to detect the presence of elevated levels of IL-170 protein and/or its fragments. Such diagnostic assays can employ lysates, live cells, fixed cells, immunofluorescence,  
25 cell cultures, body fluids, and further can involve the detection of antigens related to the protein in serum, or the like. Diagnostic assays may be homogeneous (without a separation step between free reagent and protein-protein complex) or heterogeneous (with a separation step). Various  
30 commercial assays exist, such as radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay (EIA), enzyme-multiplied immunoassay technique (EMIT), substrate-labeled fluorescent immunoassay (SLFIA), and the like. For example, unlabeled antibodies can be employed by  
35 using a second antibody which is labeled and which recognizes the antibody to an IL-170 protein or to a particular fragment thereof. Similar assays have also been extensively discussed

in the literature. See, e.g., Harlow and Lane (1988)

Antibodies: A Laboratory Manual, CSH.

Anti-idiotypic antibodies may have similar use to diagnose presence of antibodies against an IL-170 protein, as 5 such may be diagnostic of various abnormal states. For example, overproduction of IL-170 protein may result in production of various immunological reactions which may be diagnostic of abnormal physiological states, particularly in proliferative cell conditions such as cancer or abnormal 10 differentiation.

Frequently, the reagents for diagnostic assays are supplied in kits, so as to optimize the sensitivity of the assay. For the subject invention, depending upon the nature 15 of the assay, the protocol, and the label, either labeled or unlabeled antibody, or labeled IL-170 protein is provided. This is usually in conjunction with other additives, such as buffers, stabilizers, materials necessary for signal production such as substrates for enzymes, and the like. Preferably, the kit will also contain instructions for proper 20 use and disposal of the contents after use. Typically the kit has compartments for each useful reagent. Desirably, the reagents are provided as a dry lyophilized powder, where the reagents may be reconstituted in an aqueous medium providing appropriate concentrations of reagents for performing the 25 assay.

Any of the aforementioned constituents of the drug screening and the diagnostic assays may be used without modification or may be modified in a variety of ways. For example, labeling may be achieved by covalently or non- 30 covalently joining a moiety which directly or indirectly provides a detectable signal. In any of these assays, the antigen, test compound, IL-170 protein, or antibodies thereto can be labeled either directly or indirectly. Possibilities for direct labeling include label groups: radiolabels such as 35  $^{125}\text{I}$ , enzymes (U.S. Pat. No. 3,645,090) such as peroxidase and alkaline phosphatase, and fluorescent labels (U.S. Pat. No. 3,940,475) capable of monitoring the change in fluorescence

intensity, wavelength shift, or fluorescence polarization. Possibilities for indirect labeling include biotinylation of one constituent followed by binding to avidin coupled to one of the above label groups.

- 5        There are also numerous methods of separating the bound from the free antigen, or alternatively the bound from the free test compound. The IL-170 protein can be immobilized on various matrixes followed by washing. Suitable matrixes include plastic such as an ELISA plate, filters, and beads.
- 10      Methods of immobilizing the IL-170 protein to a matrix include, without limitation, direct adhesion to plastic, use of a capture antibody, chemical coupling, and biotin-avidin. The last step in this approach involves the precipitation of protein-protein complex by any of several methods including
- 15      those utilizing, e.g., an organic solvent such as polyethylene glycol or a salt such as ammonium sulfate. Other suitable separation techniques include, without limitation, the fluorescein antibody magnetizable particle method described in Rattle, et al. (1984) Clin. Chem. 30:1457-1461, and the double
- 20      antibody magnetic particle separation as described in U.S. Pat. No. 4,659,678.

The methods for linking proteins or their fragments to the various labels have been extensively reported in the literature and do not require detailed discussion here. Many 25 of the techniques involve the use of activated carboxyl groups either through the use of carbodiimide or active esters to form peptide bonds, the formation of thioethers by reaction of a mercapto group with an activated halogen such as chloroacetyl, or an activated olefin such as maleimide, for 30 linkage, or the like. Fusion proteins will also find use in these applications.

Another diagnostic aspect of this invention involves use of oligonucleotide or polynucleotide sequences taken from the sequence of an IL-170 protein. These sequences can be used as 35 probes for detecting levels of antigen message in samples from patients suspected of having an abnormal condition, e.g., cancer or developmental problem. The preparation of both RNA

and titered against the immunogen protein in an immunoassay, e.g., a solid phase immunoassay with the immunogen immobilized on a solid support. Polyclonal antisera with a titer of  $10^4$  or greater are selected and tested for their cross reactivity  
5 against other IL-170 family members, e.g., IL-171, IL-172, IL-173, IL-174, IL-175, IL-176, or IL-177, using a competitive binding immunoassay such as the one described in Harlow and Lane, supra, at pages 570-573. Preferably at least two IL-170 family members are used in this determination in conjunction  
10 with the target. These IL-170 family members can be produced as recombinant proteins and isolated using standard molecular biology and protein chemistry techniques as described herein. Thus, antibody preparations can be identified or produced having desired selectivity or specificity for subsets of IL-  
15 170 family members.

Immunoassays in the competitive binding format can be used for the crossreactivity determinations. For example, the protein of SEQ ID NO: 5 can be immobilized to a solid support. Proteins added to the assay compete with the binding of the  
20 antisera to the immobilized antigen. The ability of the above proteins to compete with the binding of the antisera to the immobilized protein is compared to the protein of SEQ ID NO: 5. The percent crossreactivity for the above proteins is calculated, using standard calculations. Those antisera with  
25 less than 10% crossreactivity with each of the proteins listed above are selected and pooled. The cross-reacting antibodies are then removed from the pooled antisera by immunoabsorption with the above-listed proteins.

The immunoabsorbed and pooled antisera are then used in a  
30 competitive binding immunoassay as described above to compare a second protein to the immunogen protein. In order to make this comparison, the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the  
35 immobilized protein is determined. If the amount of the second protein required is less than twice the amount of the protein of, e.g., SEQ ID NO: 5 that is required, then the

second protein is said to specifically bind to an antibody generated to the immunogen.

The antibodies, including antigen binding fragments, of this invention can have significant diagnostic or therapeutic value. They can be potent antagonists that bind to a binding partner and inhibit antigen binding or inhibit the ability of an antigen to elicit a biological response. They also can be useful as non-neutralizing antibodies and can be coupled to toxins or radionuclides so that when the antibody binds to the antigen, a cell expressing it, e.g., on its surface, is killed. Further, these antibodies can be conjugated to drugs or other therapeutic agents, either directly or indirectly by means of a linker, and may effect drug targeting.

The antibodies of this invention can also be useful in diagnostic applications. As capture or non-neutralizing antibodies, they can be screened for ability to bind to the antigens without inhibiting binding by a partner. As neutralizing antibodies, they can be useful in competitive binding assays. They will also be useful in detecting or quantifying IL-170 protein or its binding partners. See, e.g., Chan (ed. 1987) Immunoassay: A Practical Guide Academic Press, Orlando, Fla.; Ngo (ed. 1988) Nonisotopic Immunoassay Plenum Press, NY; and Price and Newman (eds. 1991) Principles and Practice of Immunoassay Stockton Press, NY.

Antigen fragments may be joined to other materials, particularly polypeptides, as fused or covalently joined polypeptides to be used as immunogens. An antigen and its fragments may be fused or covalently linked to a variety of immunogens, such as keyhole limpet hemocyanin, bovine serum albumin, tetanus toxoid, etc. See Microbiology, Hoeber Medical Division, Harper and Row, 1969; Landsteiner (1962) Specificity of Serological Reactions, Dover Publications, New York, and Williams, et al. (1967) Methods in Immunology and Immunochemistry, Vol. 1, Academic Press, New York, for descriptions of methods of preparing polyclonal antisera. A typical method involves hyperimmunization of an animal with an antigen. The blood of the animal is then collected shortly

after the repeated immunizations and the gamma globulin is isolated.

In some instances, it is desirable to prepare monoclonal antibodies from various mammalian hosts, such as mice, 5 rodents, primates, humans, etc. Description of techniques for preparing such monoclonal antibodies may be found in, e.g., Stites, et al. (eds.) Basic and Clinical Immunology (4th ed.), Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane (1988) Antibodies: A 10 Laboratory Manual, CSH Press; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.) Academic Press, New York; and particularly in Kohler and Milstein (1975) in Nature 256: 495-497, which discusses one method of generating monoclonal antibodies. Summarized briefly, this method 15 involves injecting an animal with an immunogen. The animal is then sacrificed and cells taken from its spleen, which are then fused with myeloma cells. The result is a hybrid cell or "hybridoma" that is capable of reproducing in vitro. The population of hybridomas is then screened to isolate 20 individual clones, each of which secrete a single antibody species to the immunogen. In this manner, the individual antibody species obtained are the products of immortalized and cloned single B cells from the immune animal generated in response to a specific site recognized on the immunogenic 25 substance.

Other suitable techniques involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors. See, Huse, et al. (1989) "Generation of a Large 30 Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science 246:1275-1281; and Ward, et al. (1989) Nature 341:544-546. The polypeptides and antibodies of the present invention may be used with or without modification, including chimeric or humanized antibodies. Frequently, the 35 polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation

techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents, teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced, see Cabilly, U.S. Patent No. 4,816,567.

10       The antibodies of this invention can also be used for affinity chromatography in isolating the protein. Columns can be prepared where the antibodies are linked to a solid support, e.g., particles, such as agarose, Sephadex, or the like, where a cell lysate may be passed through the column, 15 the column washed, followed by increasing concentrations of a mild denaturant, whereby the purified IL-170 protein will be released.

20       The antibodies may also be used to screen expression libraries for particular expression products. Usually the antibodies used in such a procedure will be labeled with a moiety allowing easy detection of presence of antigen by antibody binding.

25       Antibodies raised against each IL-170 protein will also be useful to raise anti-idiotypic antibodies. These will be useful in detecting or diagnosing various immunological conditions related to expression of the respective antigens.

#### VIII. Uses

30       The present invention provides reagents which will find use in diagnostic applications as described elsewhere herein, e.g., in the general description for physiological or developmental abnormalities, or below in the description of kits for diagnosis.

35       This invention also provides reagents with significant therapeutic value. The IL-170 protein (naturally occurring or recombinant), fragments thereof, and antibodies thereto, along with compounds identified as having binding affinity to IL-170

### III. Biochemical Characterization of IL-170 proteins

An IL-170 protein is expressed in heterologous cells, e.g., the native form or a recombinant form displaying the FLAG peptide at the carboxy terminus. See, e.g., Crowe, et al. (1992) QIAexpress: The High Level Expression and Protein Purification System QIAGEN, Inc. Chatsworth, CA; and Hopp, et al. (1988) Bio/Technology 6:1204-1210. These two forms are introduced into expression vectors, e.g., pME18S or pEE12, and subsequently transfected into appropriate cells, e.g., COS-7 or NSO cells, respectively. Electroporated cells are cultivated, e.g., for 48 hours in RPMI medium supplemented with 10% Fetal Calf Serum. Cells are then incubated with  $^{35}\text{S}$ -Met and  $^{35}\text{S}$ -Cys in order to label cellular proteins. Comparison of the proteins under reducing conditions on SDS-PAGE should show that cells transfected with full length clones should secret a polypeptide of the appropriate size, e.g., about 15,000 daltons. Treatment with endoglycosidases will demonstrate whether there are N-glycosylated forms.

### 20 IV. Large Scale Production, Purification of IL-170s

For biological assays, mammalian IL-170 is produced in large amounts, e.g., with transfected COS-7 cells grown in RPMI medium supplemented with 1% Nutridoma HU (Boehringer Mannheim, Mannheim, Germany) and subsequently purified.

25 Purification may use affinity chromatography using antibodies, or protein purification techniques, e.g., using antibodies to determine separation properties.

In order to produce larger quantities of native proteins, stable transformants of NSO cells can be prepared according to 30 the methodology developed by Celltech (Slough, Berkshire, UK; International Patent Applications WO86/05807, WO87/04462, WO89/01036, and WO89/10404).

Typically, 1 liter of supernatant containing human IL-171 or IL-171-FLAG is passed, e.g., on a 60 ml column of  $\text{Zn}^{++}$  ions 35 grafted to a Chelating Sepharose Fast Flow matrix (Pharmacia, Upsalla, Sweden). After washing with 10 volumes of binding buffer (His-Bind Buffer kit, Novagen, Madison, WI), the

proteins retained by the metal ions are eluted with a gradient of 20-100 mM Imidazole. The content of human IL-170-FLAG in the eluted fractions is determined by dot blot using the anti-FLAG monoclonal antibody M2 (Eastman Kodak, New Haven, CT),  
5 whereas the content of human IL-172 is assessed, e.g., by silver staining of non-reducing SDS-PAGE. The IL-170 containing fractions are then pooled and dialyzed against PBS, and are either used in biological assays or further purified, e.g., by anion exchange HPLC on a DEAE column. A third step  
10 of gel filtration chromatography may be performed on a SUPERDEX G-75 HRD30 column (Pharmacia Uppsala, Sweden). Purification may be evaluated, e.g., by silver stained SDS-PAGE.

15 V. Preparation of antibodies against IL-171

Inbred Balb/c mice are immunized intraperitoneally, e.g., with 1 ml of purified human IL-171-FLAG emulsified in Freund's complete adjuvant on day 0, and in Freund's incomplete adjuvant on days 15 and 22. The mice are boosted with 0.5 ml  
20 of purified human IL-171 administered intravenously.

Polyclonal antiserum is collected. The serum can be purified to antibodies. The antibodies can be further processed, e.g., to Fab, Fab2, Fv, or similar fragments.

Hybridomas are created using, e.g., the non-secreting  
25 myeloma cells line SP2/0-Ag8 and polyethylene glycol 1000 (Sigma, St. Louis, MO) as the fusing agent. Hybridoma cells are placed in a 96-well Falcon tissue culture plate (Becton Dickinson, NJ) and fed with DMEM F12 (Gibco, Gaithersburg, MD) supplemented with 80 µg/ml gentamycin, 2 mM glutamine, 10%  
30 horse serum (Gibco, Gaithersburg, MD), 1% ADCM (CRTS, Lyon, France) 10<sup>-5</sup> M azaserine (Sigma, St. Louis, MO) and 5 x 10<sup>-5</sup> M hypoxanthine. Hybridoma supernatants are screened for antibody production against human IL-171 by immunocytochemistry (ICC) using acetone fixed human IL-171  
35 transfected COS-7 cells and by ELISA using human IL-171-FLAG purified from COS-7 supernatants as a coating antigen. Aliquots of positive cell clones are expanded for 6 days and

cryopreserved as well as propagated in ascites from pristane (2,6,10,14-teramethylpentadecane, Sigma, St. Louis, MO) treated Balb/c mice who had received an intraperitoneal injection of pristane 15 days before. Typically, about 10<sup>5</sup> hybridoma cells in 1 ml of PBS are given intraperitoneally, and 10 days later, ascites are collected from each mouse.

After centrifugation of the ascites, the antibody fraction is isolated by ammonium sulfate precipitation and anion-exchange chromatography on a Zephyr-D silicium column (IBF Sepracor) equilibrated with 20 mM Tris pH 8.0. Proteins are eluted with a NaCl gradient (ranging from 0 to 1 M NaCl). 2 ml fractions are collected and tested by ELISA for the presence of anti-IL-171 antibody. The fractions containing specific anti-IL-171 activity are pooled, dialyzed, and frozen. Aliquots of the purified monoclonal antibodies may be peroxidase labeled.

Antibody preparations, polyclonal or monoclonal, may be cross absorbed, depleted, or combined to create reagents which exhibit desired combinations of selectivities and specificities. Defined specific antigens can be immobilized to a solid matrix and used to selectively deplete or select for desired binding capacities.

Similar methods will be applicable to IL-175, IL-172, IL-173, IL-174, IL-176, and/or IL-177. Methods to develop antibody preparations which cross react among various subsets of the family may be readily prepared.

#### VI. Quantification of human IL-171

Among the antibodies specific for IL-171, appropriate clonal isolates are selected to quantitate levels of human IL-171 using a sandwich assay. Purified antibodies are diluted, e.g., at 2 µg/ml in coating buffer (carbonate buffer, pH 9.6. 15 mM Na<sub>2</sub>CO<sub>3</sub>, 35 mM NaHCO<sub>3</sub>). This diluted solution is coated onto the wells of a 96-well ELISA plate (Immunoplate Maxisorp F96 certified, NUNC, Denmark) overnight at room temperature. The plates are then washed manually, e.g., with a washing buffer consisting of Phosphate Buffered Saline and 0.05% Tween

20 (Technicon Diagnositics, USA). 110  $\mu$ l of purified human CTLA-8 diluted in TBS-B-T buffer [20 mM Tris, 150 mM NaCl, 1% BSA (Sigma, St. Louis, MO), and 0.05% Tween 20] is added to each well. After 3 hours of incubation at 37° C, the plates  
5 are washed once. 100  $\mu$ l of peroxidase labeled Ab16 diluted to 5  $\mu$ g/ml in TBS-B-T buffer is added to each well, and incubated for 2 hours at 37° C. The wells are then washed three times in washing buffer. 100  $\mu$ l of peroxidase substrate, 2,2'-  
10 Azino-bis(3 ethylbenzthiazoline-6-sulfonic acid) (ABTS), diluted to 1 mg/ml in citrate/phosphate buffer, is added to each well, and the colorimetric reaction read at 405 nm.

#### VII. Distribution of IL-170 genes

The human IL-171 was identified from a sequence derived  
15 from an apoptotic T cell. The gene appears to be quite rare, which suggests the expression distribution would be highly restricted.

The human IL-175 was identified from a sequence derived from a 12 h thiouridine activated T cell. The gene appears to  
20 be quite rare, which suggests the expression distribution would be highly restricted.

The human IL-172 was identified from sequences derived from human fetal heart, liver and spleen, thymus, thymus tumor, and total fetus. Mouse was derived from sequences  
25 derived from mouse, embryo, mammary gland, and pooled organs. Both genes appear to be quite rare, which suggests their expression distribution would be highly restricted.

The human IL-173 was identified from sequence derived from a cDNA library from an epileptic brain frontal cortex.  
30 The rat IL-173 was derived from a cDNA library from cochlea, brain, cerebellum, eye, lung, and kidney. Again, the genes appear to be quite rare, which suggests the expression distributions would be highly restricted.

The mouse IL-174 was identified from sequence derived from a cDNA library derived form a mouse embryo. The gene appears to be quite rare, which suggests the expression distribution would be highly restricted.  
35

### VIII. Chromosome mapping of IL-170 genes

An isolated cDNA encoding the appropriate IL-170 gene is used. Chromosome mapping is a standard technique. See, e.g.,  
5 BIOS Laboratories (New Haven, CT) and methods for using a mouse somatic cell hybrid panel with PCR.

The human IL-173 gene maps to human chromosome 13q11.

### IX. Isolating IL-170 Homologues

10 A binding composition, e.g., antibody, is used for screening of an expression library made from a cell line which expresses an IL-170 protein. Standard staining techniques are used to detect or sort intracellular or surface expressed antigen, or surface expressing transformed  
15 cells are screened by panning. Screening of intracellular expression is performed by various staining or immunofluorescence procedures. See also McMahan, et al.  
(1991) EMBO J. 10:2821-2832.

Similar methods are applicable to isolate either  
20 species or allelic variants. Species variants are isolated using cross-species hybridization techniques based upon a full length isolate or fragment from one species as a probe, or appropriate species.

### 25 X. Isolating receptors for IL-170

Methods are available for screening of an expression library made from a cell line which expresses potential IL-170 receptors. A labeled IL-170 ligand is produced, as described above. Standard staining techniques are used to  
30 detect or sort surface expressed receptor, or surface expressing transformed cells are screened by panning. See also McMahan, et al. (1991) EMBO J. 10:2821-2832.

For example, on day 0, precoat 2-chamber permanox slides with 1 ml per chamber of fibronectin, 10 ng/ml in  
35 PBS, for 30 min at room temperature. Rinse once with PBS. Then plate COS cells at  $2-3 \times 10^5$  cells per chamber in 1.5 ml of growth media. Incubate overnight at 37° C.

- On day 1 for each sample, prepare 0.5 ml of a solution of 66 µg/ml DEAE-dextran, 66 µM chloroquine, and 4 µg DNA in serum free DME. For each set, a positive control is prepared, e.g., of huIL-170-FLAG cDNA at 1 and 1/200 dilution, and a negative mock. Rinse cells with serum free DME. Add the DNA solution and incubate 5 hr at 37° C. Remove the medium and add 0.5 ml 10% DMSO in DME for 2.5 min. Remove and wash once with DME. Add 1.5 ml growth medium and incubate overnight.
- 5 On day 2, change the medium. On days 3 or 4, the cells are fixed and stained. Rinse the cells twice with Hank's Buffered Saline Solution (HBSS) and fix in 4% paraformaldehyde (PFA)/glucose for 5 min. Wash 3X with HBSS. The slides may be stored at -80° C after all liquid is removed. For each chamber, 0.5 ml incubations are performed as follows. Add HBSS/saponin (0.1%) with 32 µl/ml of 1 M NaN<sub>3</sub> for 20 min. Cells are then washed with HBSS/saponin 1X. Soluble antibody is added to cells and incubate for 30 min. Wash cells twice with HBSS/saponin.
- 10 15 20 25 30 35
- Add second antibody, e.g., Vector anti-mouse antibody, at 1/200 dilution, and incubate for 30 min. Prepare ELISA solution, e.g., Vector Elite ABC horseradish peroxidase solution, and preincubate for 30 min. Use, e.g., 1 drop of solution A (avidin) and 1 drop solution B (biotin) per 2.5 ml HBSS/saponin. Wash cells twice with HBSS/saponin. Add ABC HRP solution and incubate for 30 min. Wash cells twice with HBSS, second wash for 2 min, which closes cells. Then add Vector diaminobenzoic acid (DAB) for 5 to 10 min. Use 2 drops of buffer plus 4 drops DAB plus 2 drops of H<sub>2</sub>O<sub>2</sub> per 5 ml of glass distilled water. Carefully remove chamber and rinse slide in water. Air dry for a few minutes, then add 1 drop of Crystal Mount and a cover slip. Bake for 5 min at 85-90° C.
- Alternatively, the labeled ligand is used to affinity purify or sort out cells expressing the receptor. See, e.g., Sambrook, et al. or Ausubel, et al.

All references cited herein are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

- 5        Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited only by the terms  
10      of the appended claims, along with the full scope of equivalents to which such claims are entitled.

## WHAT IS CLAIMED IS:

1. An isolated or recombinant polynucleotide comprising sequence from a mammalian IL-171, which:
  - 5 a) encodes at least 8 contiguous amino acids of SEQ ID NO: 3 or 5;
  - b) encodes at least two distinct segments of at least 5 contiguous amino acids of SEQ ID NO: 3 or 5; or
  - c) comprises one or more segments of at least 21 contiguous nucleotides of SEQ ID NO: 1 or 4.
2. The polynucleotide of Claim 1 in an expression vector, comprising a sequence which:
  - 15 a) encodes at least 12 contiguous amino acids of SEQ ID NO: 3 or 5;
  - b) encodes at least two distinct segments of at least 7 and 10 contiguous amino acids of SEQ ID NO: 3 or 5; or
  - c) comprises at least 27 contiguous nucleotides of SEQ ID NO: 1 or 4.
3. The polynucleotide of Claim 2 which:
  - 25 a) encodes at least 16 contiguous amino acids of SEQ ID NO: 3 or 5;
  - b) encodes at least two distinct segments of at least 10 and 14 contiguous amino acid residues of SEQ ID NO: 3 or 5; or
  - c) comprises at least 33 contiguous nucleotides of SEQ ID NO: 1 or 4.
4. A method of making:
  - 30 a) a polypeptide comprising expressing said expression vector of Claim 2, thereby producing said polypeptide;
  - b) a duplex nucleic acid comprising contacting a polynucleotide of Claim 2 with a complementary

nucleic acid, thereby resulting in production of said duplex nucleic acid; or

- c) a polynucleotide of Claim 2 comprising amplifying using a PCR method.

5

5. An isolated or recombinant polynucleotide which hybridizes under stringent wash conditions of at least 55° C and less than 400 mM salt to:

- 10 a) the (IL-171) polynucleotide of Claim 3 which consists of the entire mature coding portions of SEQ ID NO: 1 or 4.

6. A polynucleotide of Claim 5:

- 15 a) wherein said wash conditions are at least 65° C and less than 300 mM salt; or  
b) which comprises at least 50 contiguous nucleotides of the coding portion of SEQ ID NO: 1 or 4.

7. A kit comprising said polynucleotide of Claim 6, and

- 20 a) instructions for the use of said polynucleotide for detection;  
b) instructions for the disposal of said polynucleotide or other reagents of said kit; or  
c) both a and b.

25

8. A cell containing said expression vector of Claim 3, wherein said cell is:

- 30 a) a prokaryotic cell;  
b) a eukaryotic cell;  
c) a bacterial cell;  
d) a yeast cell;  
e) an insect cell;  
f) a mammalian cell;  
g) a mouse cell;  
35 h) a primate cell; or  
i) a human cell.

9. An isolated or recombinant antigenic polypeptide comprising at least:

- a) one segment of 8 identical contiguous amino acids from SEQ ID NO: 3 or 5; or
- 5 b) two distinct segments of at least 5 contiguous amino acids from SEQ ID NO: 3 or 5.

10. The polypeptide of Claim 9, wherein:

- 10 a) said segment of 8 identical contiguous amino acids is at least 14 contiguous amino acids; or
- b) one of said segments of at least 5 contiguous amino acids comprises at least 7 contiguous amino acids.

11. The polypeptide of Claim 9, wherein said  
15 polypeptide:

- a) comprises a mature sequence of SEQ ID NO: 3 or 5;
- b) binds with selectivity to a polyclonal antibody generated against an immunogen of SEQ ID NO: 3 or 5;
- c) comprises a plurality of distinct polypeptide  
20 segments of 10 contiguous amino acids of SEQ ID NO: 3 or 5;
- d) is a natural allelic variant of SEQ ID NO: 3 or 5;
- e) has a length at least 30 amino acids; or
- f) exhibits at least two non-overlapping epitopes which  
25 are selective for SEQ ID NO: 3 or 5.

12. The polypeptide of Claim 11, which:

- a) is in a sterile composition;
- b) is not glycosylated;
- 30 c) is denatured;
- d) is a synthetic polypeptide;
- e) is attached to a solid substrate;
- f) is a fusion protein with a detection or purification tag;
- 35 g) is a 5-fold or less substitution from a natural sequence; or

h) is a deletion or insertion variant from a natural sequence.

13. A method using said polypeptide of Claim 9:

- 5       a) to label said polypeptide, comprising labeling said polypeptide with a radioactive label;
- b) to separate said polypeptide from another polypeptide in a mixture, comprising running said mixture on a chromatography matrix, thereby separating said polypeptides;
- 10      c) to identify a compound that binds selectively to said polypeptide, comprising incubating said compound with said polypeptide under appropriate conditions; thereby causing said compound to bind to said polypeptide; or
- 15      d) to conjugate said polypeptide to a matrix, comprising derivatizing said polypeptide with a reactive reagent, and conjugating said polypeptide to said matrix.

20

14. A binding compound comprising an antigen binding portion from an antibody which binds with selectivity to said polypeptide of Claim 11, wherein said polypeptide comprises SEQ ID NO 3 or 5.

25

15. The binding compound of Claim 14, wherein said antibody is a polyclonal antibody which is raised against SEQ ID NO: 3 or 5.

30 16. The binding compound of Claim 14, wherein said:

- a) antibody:
  - i) is immunoselected;
  - ii) binds to a denatured protein; or
  - iii) exhibits a Kd to said polypeptide of at least 35      30 mM; or
- 35      b) said binding compound:

- 5           i) is attached to a solid substrate, including a bead or plastic membrane;
- ii) is in a sterile composition; or
- iii) is detectably labeled, including a radioactive or fluorescent label.

17.         A method of producing an antigen:antibody complex, comprising contacting a polypeptide comprising sequence from SEQ ID NO: 3 or 5 with a binding compound of Claim 14 under  
10          conditions which allow said complex to form.

18.         The method of Claim 17, wherein said binding compound is an antibody, and said polypeptide is in a biological sample.  
15

19.         A kit comprising said binding compound of Claim 14 and:  
20            a) a polypeptide of SEQ ID NO: 3 or 5;  
              b) instructions for the use of said binding compound for detection; or  
              c) instructions for the disposal of said binding compound or other reagents of said kit.

20.         A method of evaluating the selectivity of binding of an antibody to a protein of SEQ ID NO: 3 or 5, comprising contacting said antibody to said protein and to another cytokine; and comparing binding of said antibody to said protein and said cytokine.  
25

## SEQUENCE LISTING

SEQ ID NO: 1 is primate IL-171 IUPAC nucleic acid sequence.  
SEQ ID NO: 2 is primate IL-171 nucleic acid sequence.  
SEQ ID NO: 3 is primate IL-171 polypeptide sequence.  
SEQ ID NO: 4 is supp. primate IL-171 nucleic acid sequence.  
SEQ ID NO: 5 is supp. primate IL-171 polypeptide sequence.  
SEQ ID NO: 6 is primate IL-175 IUPAC nucleic acid sequence.  
SEQ ID NO: 7 is primate IL-175 nucleic acid sequence.  
SEQ ID NO: 8 is primate IL-175 polypeptide sequence.  
SEQ ID NO: 9 is primate IL-172 nucleic acid sequence.  
SEQ ID NO: 10 is primate IL-172 polypeptide sequence.  
SEQ ID NO: 11 is murine IL-172 nucleic acid sequence.  
SEQ ID NO: 12 is murine IL-172 polypeptide sequence.  
SEQ ID NO: 13 is primate IL-173 nucleic acid sequence.  
SEQ ID NO: 14 is primate IL-173 polypeptide sequence.  
SEQ ID NO: 15 is supp. murine IL-173 nucleic acid sequence.  
SEQ ID NO: 16 is supp. murine IL-173 polypeptide sequence.  
SEQ ID NO: 17 is murine IL-173 nucleic acid sequence.  
SEQ ID NO: 18 is murine IL-173 polypeptide sequence.  
SEQ ID NO: 19 is supp. murine IL-173 nucleic acid sequence.  
SEQ ID NO: 20 is supp. murine IL-173 polypeptide sequence.  
SEQ ID NO: 21 is primate IL-174 nucleic acid sequence.  
SEQ ID NO: 22 is primate IL-174 polypeptide sequence.  
SEQ ID NO: 23 is murine IL-174 nucleic acid sequence.  
SEQ ID NO: 24 is murine IL-174 polypeptide sequence.  
SEQ ID NO: 25 is supp. murine IL-174 nucleic acid sequence.  
SEQ ID NO: 26 is supp. murine IL-174 polypeptide sequence.  
SEQ ID NO: 27 is primate IL-176 nucleic acid sequence.  
SEQ ID NO: 28 is primate IL-176 polypeptide sequence.  
SEQ ID NO: 29 is primate IL-177 nucleic acid sequence.  
SEQ ID NO: 30 is primate IL-177 polypeptide sequence.  
SEQ ID NO: 31 is rat CTLA-8 polypeptide sequence.  
SEQ ID NO: 32 is mouse CTLA-8 polypeptide sequence.  
SEQ ID NO: 33 is primate CTLA-8 polypeptide sequence.  
SEQ ID NO: 34 is viral CTLA-8 polypeptide sequence.

<110> Schering Corporation

<120> Purified Mammalian Cytokines; Related Reagents and Methods

<130> DX0918K

<140>

<141>

<150> USSN 09/229,402

<151> 1999-01-11

<160> 34

<170> PatentIn Ver. 2.1

<210> 1

<211> 521

<212> DNA

<213> primate

<220>

<221> misc\_feature

<222> (281)..(468)

<223> note= "n may be a, c, g, or t"

<400> 1  
gacacggatg aggaccgcta tccacagaag ctggccttcg ccgagtgcct gtgcagaggc 60  
tgtatcgatg cacggacggg cccgcagaca gctgcgtca actccgtgcg gctgctccag 120  
agcctgtgg tgctgcgccg cccgcctgc tcccgcgacg gctcgggct ccccacacct 180  
ggggcctttg cttccacac cgagttcatc cacgtccccg tcggctgcac ctgcgtgctg 240  
ccccgttcaa gtgtgaccgc caaggccgtg gggcccttag ntgacaccgt gtgctcccc 300  
gagggacccc tatttatggg aattatggta ttatatgtt cccacatact tgggctggc 360  
atcccngct gagacagccc cctgttctat tcagctatat gggagaaga gtagactttc 420  
agctaagtga aaagtgnaac gtgctgactg tctgctgtcg tnctactnat gctagcccg 480  
gtgttcaactc tgagcctgtt aaatataggc ggttatgtac c 521

<210> 2  
<211> 521  
<212> DNA  
<213> primate

<220>  
<221> CDS  
<222> (1)..(369)  
  
<220>  
<221> misc\_feature  
<222> (281)..(468)  
<223> note= "n at 281, 367, 437, 462, and 468 may  
alternatively be a, c, g, or t; translated amino  
acid depends upon genetic code"

<400> 2  
gac acg gat gag gac cgc tat cca cag aag ctg gcc ttc gcc gag tgc 48  
Asp Thr Asp Glu Asp Arg Tyr Pro Gln Lys Leu Ala Phe Ala Glu Cys  
1 5 10 15  
  
ctg tgc aga ggc tgt atc gat gca cgg acg ggc cgc gag aca gct gcg 96  
Leu Cys Arg Gly Cys Ile Asp Ala Arg Thr Gly Arg Glu Thr Ala Ala  
20 25 30  
  
ctc aac tcc gtg cgg ctg ctc cag agc ctg ctg ctg cgc cgg 144  
Leu Asn Ser Val Arg Leu Leu Gln Ser Ile Leu Val Leu Arg Arg Arg  
35 40 45  
  
ccc tgc tcc cgc gac ggc tcg ggg ctc ccc aca cct ggg gcc ttt gcc 192  
Pro Cys Ser Arg Asp Gly Ser Gly Leu Pro Thr Pro Gly Ala Phe Ala  
50 55 60  
  
ttc cac acc gag ttc atc cac gtc ccc gtc ggc tgc acc tgc gtg ctg 240  
Phe His Thr Glu Phe Ile His Val Pro Val Gly Cys Thr Cys Val Leu  
65 70 75 80  
  
ccc cgt tca agt gtg acc gcc aag gcc gtg ggg ccc tta gnt gac acc 288  
Pro Arg Ser Ser Val Thr Ala Lys Ala Val Gly Pro Leu Xaa Asp Thr  
85 90 95  
  
gtg tgc tcc cca gag gga ccc cta ttt atg gga att atg gta tta tat 336  
Val Cys Ser Pro Glu Gly Pro Leu Phe Met Gly Ile Met Val Leu Tyr  
100 105 110  
  
gct tcc cac ata ctt ggg gct ggc atc ccg ngc tgagacagcc ccctgttcta 389  
Ala Ser His Ile Leu Gly Ala Gly Ile Pro Xaa  
115 120  
  
ttcagctata tgggagaag agtagacttt cagctaagtg aaaagtgcaa cgtgctgact 449  
gtctgctgtc gtcctactca tgctagcccg agtgttcaact ctgagcctgt taaatatagg 509  
cggttatgtac cc 521

<210> 3  
<211> 123  
<212> PRT  
<213> primate

<400> 3  
Asp Thr Asp Glu Asp Arg Tyr Pro Gln Lys Leu Ala Phe Ala Glu Cys  
1 5 10 15

Leu Cys Arg Gly Cys Ile Asp Ala Arg Thr Gly Arg Glu Thr Ala Ala  
20 25 30

Leu Asn Ser Val Arg Leu Leu Gln Ser Leu Leu Val Leu Arg Arg Arg  
35 40 45

Pro Cys Ser Arg Asp Gly Ser Gly Leu Pro Thr Pro Gly Ala Phe Ala  
50 55 60

Phe His Thr Glu Phe Ile His Val Pro Val Gly Cys Thr Cys Val Leu  
                     65                      70                      75                      80

Pro Arg Ser Ser Val Thr Ala Lys Ala Val Gly Pro Leu Xaa Asp Thr  
85 90 95

Val Cys Ser Pro Glu Gly Pro Leu Phe Met Gly Ile Met Val Leu Tyr  
           100                 105                 110

Ala Ser His Ile Leu Gly Ala Gly Ile Pro Xaa  
115 120

<210> 4  
<211> 1107  
<212> DNA  
<213> primate

<220>  
<221> CDS  
<222> (115)..(705)

<220>  
<221> mat\_peptide  
<222> (166)..(705)

<400> 4  
gtgtggcctc aggtataaga qcqqactqctg ccaqqtgcac qqccaaqgtqc acctgtqqqa 60

**ttgcccacatgtgcaggccgttccaagccagcttgcccgctgtccgcaccatgt** 117  
Met

```

acg ctc ctc ccc ggc ctc ctg ttt ctg acc tgg ctg cac aca tgc ctg 165
Thr Leu Leu Pro Gly Leu Leu Phe Leu Thr Trp Leu His Thr Cys Leu
-15      -10      -5      -1

```

```

gcc cac cat gac ccc tcc ctc agg ggg cac ccc cac agt cac ggt acc 213
Ala His His Asp Pro Ser Leu Arg Gly His Pro His Ser His Gly Thr
   1      5          10         15

```

cca cac tgc tac tcg gct gag gaa ctg ccc ctc ggc cag gcc ccc cca 261  
 Pro His Cys Tyr Ser Ala Glu Glu Leu Pro Leu Gly Gln Ala Pro Pro  
           20                 25                 30

cac ctg ctg gct cga ggt gcc aag tgg ggg cag gct ttg cct gta gcc 309  
His Leu Leu Ala Arg Gly Ala Lys Trp Gly Gln Ala Leu Pro Val Ala

35	40	45	
ctg gtg tcc agc ctg gag gca gca agc cac agg ggg agg cac gag agg Leu Val Ser Ser Leu Glu Ala Ala Ser His Arg Gly Arg His Glu Arg	50                    55	60	357
ccc tca gct acg acc cag tgc ccg gtg ctg cgg ccg gag gag gtg ttg Pro Ser Ala Thr Thr Gln Cys Pro Val Leu Arg Pro Glu Glu Val Leu	65                    70	75	405
gag gca gac acc cac cag cgc tcc atc tca ccc tgg aga tac cgt gtg Glu Ala Asp Thr His Gln Arg Ser Ile Ser Pro Trp Arg Tyr Arg Val	85                    90	95	453
gac acg gat gag gac cgc tat cca cag aag ctg gcc ttc gcc gag tgc Asp Thr Asp Glu Asp Arg Tyr Pro Gln Lys Leu Ala Phe Ala Glu Cys	100                    105	110	501
ctg tgc aga ggc tgt atc gat gca cgg acg ggc cgc gag aca gct gcg Leu Cys Arg Gly Cys Ile Asp Ala Arg Thr Gly Arg Glu Thr Ala Ala	115                    120	125	549
ctc aac tcc gtg cgg ctg ctc cag agc ctg ctg gtg ctg cgc cgc cgg Leu Asn Ser Val Arg Leu Leu Gln Ser Leu Leu Val Leu Arg Arg Arg	130                    135	140	597
ccc tgc tcc cgc gac ggc tcg ggg ctc ccc aca cct ggg gcc ttt gcc Pro Cys Ser Arg Asp Gly Ser Gly Leu Pro Thr Pro Gly Ala Phe Ala	145                    150	155	645
ttc cac acc gag ttc atc cac gtc ccc gtc ggc tgc acc tgc gtg ctg Phe His Thr Glu Phe Ile His Val Pro Val Gly Cys Thr Cys Val Leu	165                    170	175	693
ccc cgt tca gtg tgaccgcccga ggccgtgggg cccctagact ggacacgtgt Pro Arg Ser Val	180		745
gctccccaga gggcaccccc tatttatgtg tatttattgg tatttatatg cctccccaa caactaccctt ggggtctggg cattccccgt gtctggagga cagccccca ctgttctcct			805
catctccagc ctcagtagtt ggggtagaa ggagctcagc acctcttcca gcccttaaag ctgcagaaaa ggtgtcacac ggctgcctgt accttggctc cctgtcctgc tcccggttc			865
ccttacccta tcactggctt caggcccccg caggctgcctt cttccaaacc tccttggaaag tacccctgtt tcttaaacaa ttatttaagt gtacgtgtat tattaaactg atgaacacat			925
cc			1105
			1107

<210> 5  
<211> 197  
<212> PRT  
<213> primate

<400> 5  
Met Thr Leu Leu Pro Gly Leu Leu Phe Leu Thr Trp Leu His Thr Cys  
-15                    -10                    -5

Leu Ala His His Asp Pro Ser Leu Arg Gly His Pro His Ser His Gly  
-1      1                5                    10                    15

Thr Pro His Cys Tyr Ser Ala Glu Glu Leu Pro Leu Gly Gln Ala Pro

20	25	30
Pro His Leu Leu Ala Arg Gly Ala Lys Trp Gly Gln Ala Leu Pro Val		
35	40	45
Ala Leu Val Ser Ser Leu Glu Ala Ala Ser His Arg Gly Arg His Glu		
50	55	60
Arg Pro Ser Ala Thr Thr Gln Cys Pro Val Leu Arg Pro Glu Glu Val		
65	70	75
Leu Glu Ala Asp Thr His Gln Arg Ser Ile Ser Pro Trp Arg Tyr Arg		
80	85	90
Val Asp Thr Asp Glu Asp Arg Tyr Pro Gln Lys Leu Ala Phe Ala Glu		
100	105	110
Cys Leu Cys Arg Gly Cys Ile Asp Ala Arg Thr Gly Arg Glu Thr Ala		
115	120	125
Ala Leu Asn Ser Val Arg Leu Leu Gln Ser Leu Leu Val Leu Arg Arg		
130	135	140
Arg Pro Cys Ser Arg Asp Gly Ser Gly Leu Pro Thr Pro Gly Ala Phe		
145	150	155
Ala Phe His Thr Glu Phe Ile His Val Pro Val Gly Cys Thr Cys Val		
160	165	170
Leu Pro Arg Ser Val		
180		

<210> 6  
<211> 403  
<212> DNA  
<213> primate

<220>  
<221> misc\_feature  
<222> (1)..(403)  
<223> note= "n may alternatively be a, c, g, or t;  
translated amino acid depends on genetic code"

<400> 6  
gagaaagagc ttccctgcaca aagtaaggca ccagcgcaac atgacagtga agaccctgca 60  
tggcccaagcc atggtaagt acttgctgtct gtgcataattg qggcttgcc ttctgagtga 120  
ggcggcagct cggaaaatcc ccaaaggtagg acataactttt ttccaaaagc ctgagagttg 180  
ccccctgtg ccaggaggtt gtatgaagct tgacattggc atcatcaatg aaaaccagcg 240  
cgtttccatg tcacgtaaca tcgagagccg ctccacctcc cccttggaaatt acactgtcac 300  
ttgggacccc aaccggtacc cctcgaagtt gtacaggccc aagtgttagga acttgggctg 360  
tatcaatgtct caaggaaagg aagacatctn catgaattcc gtc 403

<210> 7  
<211> 403  
<212> DNA  
<213> primate

<220>  
<221> CDS  
<222> (71)..(403)

<220>  
<221> mat\_peptide  
<222> (131)..(403)

<400> 7  
gagaaagagc ttcctgcaca aagtaagcca ccagcgcaac atgacagtga agaccctgca 60  
tggcccagcc atg gtc aag tac ttg ctg ctg tcg ata ttg ggg ctt gcc 109  
Met Val Lys Tyr Leu Leu Ser Ile Leu Gly Leu Ala  
-20 -15 -10  
ttt ctg agt gag gcg gca gct cg<sup>g</sup> aaa atc ccc aaa gta gga cat act 157  
Phe Leu Ser Glu Ala Ala Arg Lys Ile Pro Lys Val Gly His Thr  
-5 -1 1 5  
ttt ttc caa aag cct gag agt tgc cg<sup>g</sup> cct gtg cca gga ggt agt atg 205  
Phe Phe Gln Lys Pro Glu Ser Cys Pro Pro Val Pro Gly Gly Ser Met  
10 15 20 25  
aag ctt gac att ggc atc atc aat gaa aac cag cg<sup>c</sup> gtt tcc atg tca 253  
Lys Leu Asp Ile Gly Ile Ile Asn Glu Asn Gln Arg Val Ser Met Ser  
30 35 40  
cgt aac atc gag agc cg<sup>c</sup> tcc acc tcc ccc tgg aat tac act gtc act 301  
Arg Asn Ile Glu Ser Arg Ser Thr Ser Pro Trp Asn Tyr Thr Val Thr  
45 50 55  
tgg gac ccc aac cg<sup>g</sup> tac ccc tcg aag ttg tac agg ccc aag tgt agg 349  
Trp Asp Pro Asn Arg Tyr Pro Ser Lys Leu Tyr Arg Pro Lys Cys Arg  
60 65 70  
aac ttg ggc tgt atc aat gct caa gga aag gaa gac atc tnc atg aat 397  
Asn Leu Gly Cys Ile Asn Ala Gln Gly Lys Glu Asp Ile Xaa Met Asn  
75 80 85  
tcc gtc 403  
Ser Val  
90

<210> 8  
<211> 111  
<212> PRT  
<213> primate

<400> 8  
Met Val Lys Tyr Leu Leu Ser Ile Leu Gly Leu Ala Phe Leu Ser 5  
-20 -15 -10 -5  
Glu Ala Ala Ala Arg Lys Ile Pro Lys Val Gly His Thr Phe Phe Gln  
1 5 10  
Lys Pro Glu Ser Cys Pro Pro Val Pro Gly Gly Ser Met Lys Leu Asp  
15 20 25  
Ile Gly Ile Ile Asn Glu Asn Gln Arg Val Ser Met Ser Arg Asn Ile  
30 35 40  
Glu Ser Arg Ser Thr Ser Pro Trp Asn Tyr Thr Val Thr Trp Asp Pro  
45 50 55 60  
Asn Arg Tyr Pro Ser Lys Leu Tyr Arg Pro Lys Cys Arg Asn Leu Gly  
65 70 75  
Cys Ile Asn Ala Gln Gly Lys Glu Asp Ile Xaa Met Asn Ser Val  
80 85 90

<210> 9

<211> 543  
 <212> DNA  
 <213> primate  
  
 <220>  
 <221> CDS  
 <222> (1)..(540)  
  
 <220>  
 <221> mat\_peptide  
 <222> (61)..(540)  
  
 <400> 9  
 atg gac tgg cct cac aac ctg ctg ttt ctt ctt acc att tcc atc ttc 48  
 Met Asp Trp Pro His Asn Leu Leu Phe Leu Leu Thr Ile Ser Ile Phe  
 -20 -15 -10 -5  
  
 ctg ggg ctg ggc cag ccc agg agc ccc aaa agc aag agg aag ggg caa 96  
 Leu Gly Leu Gly Gln Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln  
 -1 1 5 10  
  
 ggg cgg cct ggg ccc ctg gtc cct ggc cct cac cag gtg cca ctg gac 144  
 Gly Arg Pro Gly Pro Leu Val Pro Gly Pro His Gln Val Pro Leu Asp  
 15 20 25  
  
 ctg gtg tca cgg atg aaa ccg tat gcc cgc atg gag gag tat gag agg 192  
 Leu Val Ser Arg Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg  
 30 35 40  
  
 aac atc gag gag atg gtg gcc cag ctg agg aac agc tca gag ctg gcc 240  
 Asn Ile Glu Glu Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala  
 45 50 55 60  
  
 cag aga aag tgt gag gtc aac ttg cag ctg tgg atg tcc aac aag agg 288  
 Gln Arg Lys Cys Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg  
 65 70 75  
  
 agc ctg tct ccc tgg ggc tac agc atc aac cac gac ccc agc cgt atc 336  
 Ser Leu Ser Pro Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile  
 80 85 90  
  
 ccc gtg gac ctg ccg gag gca cgg tgc ctg tgt ctg ggc tgt gtg aac 384  
 Pro Val Asp Leu Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn  
 95 100 105  
  
 ccc ttc acc atg cag gag gac cgc agc atg gtg agc gtg ccg gtg ttc 432  
 Pro Phe Thr Met Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe  
 110 115 120  
  
 agc cag gtt cct gtg cgc cgc ctc tgc ccg cca ccg ccc cgc aca 480  
 Ser Gln Val Pro Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr  
 125 130 135 140  
  
 ggg cct tgc cgc cag cgc gca gtc atg gag acc atc gct gtg ggc tgc 528  
 Gly Pro Cys Arg Gln Arg Ala Val Met Glu Thr Ile Ala Val Gly Cys  
 145 150 155  
  
 acc tgc atc ttc tga 543  
 Thr Cys Ile Phe  
 160

<400> 10  
Met Asp Trp Pro His Asn Leu Leu Phe Leu Leu Thr Ile Ser Ile Phe  
-20 -15 -10 -5  
Leu Gly Leu Gly Gln Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln  
1 5 10  
Gly Arg Pro Gly Pro Leu Val Pro Gly Pro His Gln Val Pro Leu Asp  
15 20 25  
Leu Val Ser Arg Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg  
30 35 40  
Asn Ile Glu Glu Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala  
45 50 55 60  
Gln Arg Lys Cys Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg  
65 70 75  
Ser Leu Ser Pro Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile  
80 85 90  
Pro Val Asp Leu Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn  
95 100 105  
Pro Phe Thr Met Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe  
110 115 120  
Ser Gln Val Pro Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr  
125 130 135 140  
Gly Pro Cys Arg Gln Arg Ala Val Met Glu Thr Ile Ala Val Gly Cys  
145 150 155  
Thr Cys Ile Phe  
160

<210> 11  
<211> 543  
<212> DNA  
<213> rodent

<220>  
<221> CDS  
<222> (1)..(540)  
  
<220>  
<221> mat\_peptide  
<222> (67)..(540)

<400> 11  
atg gac tgg ccg cac agc ctg ctc ttc ctc ctg gcc atc tcc atc ttc 48  
Met Asp Trp Pro His Ser Leu Leu Phe Leu Leu Ala Ile Ser Ile Phe  
-20 -15 -10  
ctg gcg cca agc cac ccc cgg aac acc aaa ggc aaa aga aaa ggg caa 96  
Leu Ala Pro Ser His Pro Arg Asn Thr Lys Gly Lys Arg Lys Gly Gln  
-5 -1 1 5 10  
ggg agg ccc agt ccc ttg gcc cct ggg cct cat cag gtg ccg ctg gac 144  
Gly Arg Pro Ser Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp  
15 20 25  
ctg gtg tct cga gta aag ccc tac gct cga atg gaa gag tat gag cgg 192

Leu Val Ser Arg Val Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg		
30	35	40
aac ctt ggg gag atg gtg gcc cag ctg agg aac agc tcc gag cca gcc	240	
Asn Leu Gly Glu Met Val Ala Gln Leu Arg Asn Ser Ser Glu Pro Ala		
45	50	55
aag aag aaa tgt gaa gtc aat cta cag ctg tgg ttg tcc aac aag agg	288	
Lys Lys Lys Cys Glu Val Asn Leu Gln Leu Trp Leu Ser Asn Lys Arg		
60	65	70
agc ctg tcc cca tgg ggc tac agc atc aac cac gac ccc agc cgc atc	336	
Ser Leu Ser Pro Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile		
75	80	85
cct gcg gac ttg ccc gag gcg cgg tgc cta tgt ttg ggt tgc gtg aat	384	
Pro Ala Asp Leu Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn		
95	100	105
ccc ttc acc atg cag gag gac cgt agc atg gtg agc gtg cca gtg ttc	432	
Pro Phe Thr Met Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe		
110	115	120
agc cag gtg ccg gtg cgc cgc ctc tgt cct caa cct cct cgc cct	480	
Ser Gln Val Pro Val Arg Arg Arg Leu Cys Pro Gln Pro Pro Arg Pro		
125	130	135
ggg ccc tgc cgc cag cgt gtc atg gag acc atc gct gtg ggt tgc	528	
Gly Pro Cys Arg Gln Arg Val Val Met Glu Thr Ile Ala Val Gly Cys		
140	145	150
acc tgc atc ttc tga	543	
Thr Cys Ile Phe		
155		
<210> 12		
<211> 180		
<212> PRT		
<213> rodent		
<400> 12		
Met Asp Trp Pro His Ser Leu Leu Phe Leu Leu Ala Ile Ser Ile Phe		
-20	-15	-10
Leu Ala Pro Ser His Pro Arg Asn Thr Lys Gly Lys Arg Lys Gly Gln		
-5	-1	5
10		
Gly Arg Pro Ser Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp		
15	20	25
Leu Val Ser Arg Val Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg		
30	35	40
Asn Leu Gly Glu Met Val Ala Gln Leu Arg Asn Ser Ser Glu Pro Ala		
45	50	55
Lys Lys Lys Cys Glu Val Asn Leu Gln Leu Trp Leu Ser Asn Lys Arg		
60	65	70
Ser Leu Ser Pro Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile		
75	80	85
90		
Pro Ala Asp Leu Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn		
95	100	105

Pro Phe Thr Met Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe  
 110 115 120

Ser Gln Val Pro Val Arg Arg Arg Leu Cys Pro Gln Pro Pro Arg Pro  
 125 130 135

Gly Pro Cys Arg Gln Arg Val Val Met Glu Thr Ile Ala Val Gly Cys  
 140 145 150

Thr Cys Ile Phe  
 155

<210> 13  
 <211> 310  
 <212> DNA  
 <213> primate

<220>  
 <221> CDS  
 <222> (1)..(309)

<400> 13

tgc gcg gac ccg ccg gag gag cta ctg gag cag ctg tac ggg cgc ctg	48
Cys Ala Asp Arg Pro Glu Glu Leu Leu Glu Gln Leu Tyr Gly Arg Leu	
1 5 10 15	

gcg gcc ggc gtg ctc agt gcc ttc cac cac acg ctg cag ctg ggg ccg	96
Ala Ala Gly Val Leu Ser Ala Phe His His Thr Leu Gln Leu Gly Pro	
20 25 30	

cgt gag cag gcg cgc aac gcg agc tgc ccg gca ggg ggc agg ccc gcc	144
Arg Glu Gln Ala Arg Asn Ala Ser Cys Pro Ala Gly Gly Arg Pro Ala	
35 40 45	

gac cgc cgc ttc ccg acg ccc acc aac ctg cgc agc gtg tcg ccc tgg	192
Asp Arg Arg Phe Arg Thr Pro Thr Asn Leu Arg Ser Val Ser Pro Trp	
50 55 60	

gcc tac aga atc tcc tac gac ccg gcg agg tac ccc agg tac ctg cct	240
Ala Tyr Arg Ile Ser Tyr Asp Pro Ala Arg Tyr Pro Arg Tyr Leu Pro	
65 70 75 80	

gaa gcc tac tgc ctg tgc ccg ggc tgc ctg acc ggg ctg ttc ggc gag	288
Glu Ala Tyr Cys Leu Cys Arg Gly Cys Leu Thr Gly Leu Phe Gly Glu	
85 90 95	

gag gac gtg cgc ttc cgc agc g	310
Glu Asp Val Arg Phe Arg Ser	
100	

<210> 14  
 <211> 103  
 <212> PRT  
 <213> primate

<400> 14

Cys Ala Asp Arg Pro Glu Glu Leu Leu Glu Gln Leu Tyr Gly Arg Leu	
1 5 10 15	

Ala Ala Gly Val Leu Ser Ala Phe His His Thr Leu Gln Leu Gly Pro	
20 25 30	

Arg Glu Gln Ala Arg Asn Ala Ser Cys Pro Ala Gly Gly Arg Pro Ala	
35 40 45	

Asp Arg Arg Phe Arg Thr Pro Thr Asn Leu Arg Ser Val Ser Pro Trp  
 50 55 60  
 Ala Tyr Arg Ile Ser Tyr Asp Pro Ala Arg Tyr Pro Arg Tyr Leu Pro  
 65 70 75 80  
 Glu Ala Tyr Cys Leu Cys Arg Gly Cys Leu Thr Gly Leu Phe Gly Glu  
 85 90 95  
 Glu Asp Val Arg Phe Arg Ser  
 100

<210> 15  
<211> 1385  
<212> DNA  
<213> rodent

<220>  
<221> CDS  
<222> (59)..(664)

<220>  
<221> mat\_peptide  
<222> (110)..(664)

<400> 15  
 gcccgggcag gtggcgacct cgctcagtcg gcttctcggt ccaagtcccc gggtctgg 58  
 atg ctg gta gcc ggc ttc ctg ctg gcg ctg ccg agc tgg gcc gcg 106  
 Met Leu Val Ala Gly Phe Leu Leu Ala Leu Pro Pro Ser Trp Ala Ala  
 -15 -10 -5  
 ggc gcc ccg agg gcg ggc agg cgc ccc gcg ccg ccg ggc tgc gcg 154  
 Gly Ala Pro Arg Ala Gly Arg Arg Pro Ala Arg Pro Arg Gly Cys Ala  
 -1 1 5 10 15  
 gac cgg ccg gag gag cta ctg gag cag ctg tac ggg cgc ctg gcg gcc 202  
 Asp Arg Pro Glu Glu Leu Leu Glu Gln Leu Tyr Gly Arg Leu Ala Ala  
 20 25 30  
 ggc gtg ctc agt gcc ttc cac cac acg ctg cag ctg ggg ccg cgt gag 250  
 Gly Val Leu Ser Ala Phe His His Thr Leu Gln Leu Gly Pro Arg Glu  
 35 40 45  
 cag gcg cgc aac gcg agc tgc ccg gca ggg ggc agg ccc gcc gac cgc 298  
 Gln Ala Arg Asn Ala Ser Cys Pro Ala Gly Arg Pro Ala Asp Arg  
 50 55 60  
 cgc ttc cgg ccc acc aac ctg cgc agc gtg tcg ccc tgg gcc tac 346  
 Arg Phe Arg Pro Pro Thr Asn Leu Arg Ser Val Ser Pro Trp Ala Tyr  
 65 70 75  
 aga atc tcc tac gac ccg gcg agg tac ccc agg tac ctg cct gaa gcc 394  
 Arg Ile Ser Tyr Asp Pro Ala Arg Tyr Pro Arg Tyr Leu Pro Glu Ala  
 80 85 90 95  
 tac tgc ctg tgc cgg ggc tgc ctg acc ggg ctg ttc ggc gag gag gac 442  
 Tyr Cys Leu Cys Arg Gly Cys Leu Thr Gly Leu Phe Gly Glu Glu Asp  
 100 105 110  
 gtg cgc ttc cgc agc gcc cct gtc tac atg ccc acc gtc gtc ctg cgc 490  
 Val Arg Phe Arg Ser Ala Pro Val Tyr Met Pro Thr Val Val Leu Arg  
 115 120 125

cgc acc ccc gcc tgc gcc ggc ggc cgt tcc gtc tac acc gag gcc tac	538
Arg Thr Pro Ala Cys Ala Gly Gly Arg Ser Val Tyr Thr Glu Ala Tyr	
130	135
135	140
gtc acc atc ccc gtg ggc tgc acc tgc gtc ccc gag ccg gag aag gac	586
Val Thr Ile Pro Val Gly Cys Thr Cys Val Pro Glu Pro Glu Lys Asp	
145	150
150	155
gca gac agc atc aac tcc agc atc gac aaa cag ggc gcc aag ctc ctg	634
Ala Asp Ser Ile Asn Ser Ser Ile Asp Lys Gln Gly Ala Lys Leu Leu	
160	165
165	170
170	175
ctg ggc ccc aac gac gcg ccc gct ggc ccc tgaggccggt cctgccccgg	684
Leu Gly Pro Asn Asp Ala Pro Ala Gly Pro	
180	185
gaggtctccc cggcccgcat cccgaggcgc ccaagctgga gccgcctgga gggctcggtc	744
ggcgacctct gaagagagtg caccgagcaa accaagtgcc ggagcaccag cgccgccttt	804
ccatggagac tcgtaagcag cttcatctga cacggcattc cctggcttgc ttttagctac	864
aagcaagcag cgtggctgga agctgatggg aaacgaccgg gcacggccat cctgtgtgcg	924
gcccgcattgg agggtttgga aaagttcacg gaggtccct gaggagccctc tcagatcgcc	984
tgctcggtt gcaaggcgtg actcaccgct gggtcttgc caaagagata gggacgcata	1044
tgctttttaa agcaatctaa aaataataat aagtatacg actatataacc tacttttaaa	1104
atcaactgtt ttgaatagag gcagagctat tttatattat caaatgagag ctactctgtt	1164
acatttctta acatataaac atcgaaaaat acttcttctg gtagaatttt ttaaagcata	1224
attggaatcc ttggataaaat tttgttagctg gtacactctg gcctgggtct ctgaattcag	1284
cctgtcaccg atggctgact gatgaaatgg acacgtctca tctgaccac tttccctcc	1344
actgaaggc ttcacgggcc tccaggccctc gtggccatt c	1385

<210> 16  
<211> 202  
<212> PRT  
<213> rodent

<400> 16  
Met Leu Val Ala Gly Phe Leu Leu Ala Leu Pro Pro Ser Trp Ala Ala  
-15                    -10                    -5

Gly Ala Pro Arg Ala Gly Arg Arg Pro Ala Arg Pro Arg Gly Cys Ala  
-1    1                5                    10                    15

Asp Arg Pro Glu Glu Leu Leu Glu Gln Leu Tyr Gly Arg Leu Ala Ala  
20                    25                    30

Gly Val Leu Ser Ala Phe His His Thr Leu Gln Leu Gly Pro Arg Glu  
35                    40                    45

Gln Ala Arg Asn Ala Ser Cys Pro Ala Gly Gly Arg Pro Ala Asp Arg  
50                    55                    60

Arg Phe Arg Pro Pro Thr Asn Leu Arg Ser Val Ser Pro Trp Ala Tyr  
65                    70                    75

Arg Ile Ser Tyr Asp Pro Ala Arg Tyr Pro Arg Tyr Leu Pro Glu Ala

80	85	90	95
Tyr Cys Leu Cys Arg Gly Cys Leu Thr Gly Leu Phe Gly Glu Glu Asp			
100	105		110
Val Arg Phe Arg Ser Ala Pro Val Tyr Met Pro Thr Val Val Leu Arg			
115	120		125
Arg Thr Pro Ala Cys Ala Gly Gly Arg Ser Val Tyr Thr Glu Ala Tyr			
130	135		140
Val Thr Ile Pro Val Gly Cys Thr Cys Val Pro Glu Pro Glu Lys Asp			
145	150		155
Ala Asp Ser Ile Asn Ser Ser Ile Asp Lys Gln Gly Ala Lys Leu Leu			
160	165		175
Leu Gly Pro Asn Asp Ala Pro Ala Gly Pro			
180	185		

<210> 17  
<211> 454  
<212> DNA  
<213> rodent

<220>  
<221> CDS  
<222> (1)..(453)

<400> 17

tgc gcg gac cgg ccg gag gag cta ctg gag cag ctg tac ggg cgc ctg 48  
 Cys Ala Asp Arg Pro Glu Glu Leu Leu Glu Gln Leu Tyr Gly Arg Leu  
   1              5                  10                  15

gcg gcc ggc gtg ctc agt gcc ttc cac cac acg ctg cag ctg ggg ccg 96  
 Ala Ala Gly Val Leu Ser Ala Phe His His Thr Leu Gln Leu Gly Pro  
                   20                  25                  30

cgt gag cag gcg cgc aac gcg agc tgc ccg gca ggg ggc agg ccc gcc 144  
Arg Glu Gln Ala Arg Asn Ala Ser Cys Pro Ala Gly Gly Arg Pro Ala  
35 40 45

gac cgc cgc ttc cgg acg ccc acc aac ctg cgc agc gtg tcg ccc tgg	192	
Asp Arg Arg Phe Arg Thr Pro Thr Asn Leu Arg Ser Val Ser Pro Trp		
50	55	60

gcc tac aga atc tcc tac gac ccg gcg agg tac ccc agg tac ctg cct 240  
 Ala Tyr Arg Ile Ser Tyr Asp Pro Ala Arg Tyr Pro Arg Tyr Leu Pro  
 65 70 75 80

gaa gcc tac tgc ctg tgc cgg ggc tgc ctg acc ggg ctg ttc ggc gag 288  
 Glu Ala Tyr Cys Leu Cys Arg Gly Cys Leu Thr Gly Leu Phe Gly Glu  
                   85                  90                  95

gag gac gtg cgc ttc cgc agc gcc cct gtc tac atg ccc acc gtc gtc 336  
 Glu Asp Val Arg Phe Arg Ser Ala Pro Val Tyr Met Pro Thr Val Val  
                   100              105              110

ctg cgc cgc acc ccc gcc tgc gcc ggc ggc cgt tcc tcc gtc tac acc gag 384  
 Leu Arg Arg Thr Pro Ala Cys Ala Gly Gly Arg Ser Val Tyr Thr Glu  
 115 120 125

```

gcc tac gtc acc atc ccc gtg ggc tgc acc tgc gtc ccc gag ccg gag 432
Ala Tyr Val Thr Ile Pro Val Gly Cys Thr Cys Val Pro Glu Pro Glu
    130           135           140

```

aag gac gca gac agc atc aac t 454  
 Lys Asp Ala Asp Ser Ile Asn  
 145 150

<210> 18  
 <211> 151  
 <212> PRT  
 <213> rodent

<400> 18  
 Cys Ala Asp Arg Pro Glu Glu Leu Leu Glu Gln Leu Tyr Gly Arg Leu  
 1 5 10 15

Ala Ala Gly Val Leu Ser Ala Phe His His Thr Leu Gln Leu Gly Pro  
 20 25 30

Arg Glu Gln Ala Arg Asn Ala Ser Cys Pro Ala Gly Gly Arg Pro Ala  
 35 40 45

Asp Arg Arg Phe Arg Thr Pro Thr Asn Leu Arg Ser Val Ser Pro Trp  
 50 55 60

Ala Tyr Arg Ile Ser Tyr Asp Pro Ala Arg Tyr Pro Arg Tyr Leu Pro  
 65 70 75 80

Glu Ala Tyr Cys Leu Cys Arg Gly Cys Leu Thr Gly Leu Phe Gly Glu  
 85 90 95

Glu Asp Val Arg Phe Arg Ser Ala Pro Val Tyr Met Pro Thr Val Val  
 100 105 110

Leu Arg Arg Thr Pro Ala Cys Ala Gly Gly Arg Ser Val Tyr Thr Glu  
 115 120 125

Ala Tyr Val Thr Ile Pro Val Gly Cys Thr Cys Val Pro Glu Pro Glu  
 130 135 140

Lys Asp Ala Asp Ser Ile Asn  
 145 150

<210> 19  
 <211> 1143  
 <212> DNA  
 <213> rodent

<220>  
 <221> CDS  
 <222> (1)..(615)

<220>  
 <221> mat\_peptide  
 <222> (73)..(615)

<400> 19  
 atg ttg ggg aca ctg gtc tgg atg ctc ctc gtc ggc ttc ctg ctg gca 48  
 Met Leu Gly Thr Leu Val Trp Met Leu Val Gly Phe Leu Leu Ala  
 -20 -15 -10

ctg gcg ccg ggc cgc gcg ggc gcg ctg agg acc ggg agg cgc ccg 96  
 Leu Ala Pro Gly Arg Ala Ala Gly Ala Leu Arg Thr Gly Arg Arg Pro  
 -5 -1 1 5

gcg cgg ccg cgg gac tgc gcg gac cgg cca gag gag ctc ctg gag cag 144

Ala Arg Pro Arg Asp Cys Ala Asp Arg Pro Glu Glu Leu Leu Glu Gln			
10	15	20	
ctg tac ggg cggtcg ggc gtc acg gcc ttc cac cac acg		192	
Leu Tyr Gly Arg Leu Ala Ala Gly Val Leu Ser Ala Phe His His Thr			
25	30	35	40
ctg cag ctc ggg ccg cgc gag cag ggc cgc aat gcc agc tgc ccg gcc		240	
Leu Gln Leu Gly Pro Arg Glu Gln Ala Arg Asn Ala Ser Cys Pro Ala			
45	50	55	
ggg ggc agg gcc gac cgc cgc ttc cgg cca ccc acc aac ctg cgc		288	
Gly Gly Arg Ala Ala Asp Arg Arg Phe Arg Pro Pro Thr Asn Leu Arg			
60	65	70	
agc gtg tcg ccc tgg gcg tac agg att tcc tac gac cct gct cgc ttt		336	
Ser Val Ser Pro Trp Ala Tyr Arg Ile Ser Tyr Asp Pro Ala Arg Phe			
75	80	85	
ccg agg tac ctg ccc gaa gcc tac tgc ctg tgc cga ggc tgc ctg acc		384	
Pro Arg Tyr Leu Pro Glu Ala Tyr Cys Leu Cys Arg Gly Cys Leu Thr			
90	95	100	
ggg ctc tac ggg gag gag gac ttc cgc ttt cgc agc aca ccc gtc ttc		432	
Gly Leu Tyr Gly Glu Glu Asp Phe Arg Phe Arg Ser Thr Pro Val Phe			
105	110	115	120
tct cca gcc gtg gtg ctg cgg cgc aca gcg gcc tgc gcg ggc cgc		480	
Ser Pro Ala Val Val Leu Arg Arg Thr Ala Ala Cys Ala Gly Gly Arg			
125	130	135	
tct gtg tac gcc gaa cac tac atc acc atc ccg gtg ggc tgc acc tgc		528	
Ser Val Tyr Ala Glu His Tyr Ile Thr Ile Pro Val Gly Cys Thr Cys			
140	145	150	
gtg ccc gag ccg gac aag tcc gcg gac agt gcg aac tcc agc atg gac		576	
Val Pro Glu Pro Asp Lys Ser Ala Asp Ser Ala Asn Ser Ser Met Asp			
155	160	165	
aag ctg ctg ctg ggg ccc gac agg cct gcg ggg cgc tgatgccgg		625	
Lys Leu Leu Leu Gly Pro Ala Asp Arg Pro Ala Gly Arg			
170	175	180	
gactccccgc catggcccaag cttcctgcat gcattcaggc ccctggccct gacaaaaccc		685	
accccatgat ccctggccgc tgcctaattt ttccaaaagg acagctacat aagctttaaa		745	
tatatttttc aaagttagaca ctacatatct acaactattt tgaatagtgg cagaaactat		805	
tttcatatta gtaattttaga gcaagcatgt tgaaaaaaa cttctttgat atacaagcac		865	
atcacacaca tcccgttttc ctcttagtagg attcttgagt gcataattgt agtgctcaga		925	
tgaacttcct tctgctgac tgcgtccgt ccctgagtct ctccgtggc ccaagcttac		985	
taaggtgata atgagtgctc cggatctggg cacctaaggt ctccaggtcc ctggagaggg		1045	
agggatgtgg gggggctagg aaccaagcgc cccttggc tttagcttat ggatggctt		1105	
aactttataa agattaaagt ttttgtgtt attcttc		1143	

<210> 20  
<211> 205  
<212> PRT  
<213> rodent

<400> 20  
 Met Leu Gly Thr Leu Val Trp Met Leu Leu Val Gly Phe Leu Leu Ala  
 -20 -15 -10

Leu Ala Pro Gly Arg Ala Ala Gly Ala Leu Arg Thr Gly Arg Arg Pro  
 -5 -1 1 5

Ala Arg Pro Arg Asp Cys Ala Asp Arg Pro Glu Glu Leu Leu Glu Gln  
 10 15 20

Leu Tyr Gly Arg Leu Ala Ala Gly Val Leu Ser Ala Phe His His Thr  
 25 30 35 40

Leu Gln Leu Gly Pro Arg Glu Gln Ala Arg Asn Ala Ser Cys Pro Ala  
 45 50 55

Gly Gly Arg Ala Ala Asp Arg Arg Phe Arg Pro Pro Thr Asn Leu Arg  
 60 65 70

Ser Val Ser Pro Trp Ala Tyr Arg Ile Ser Tyr Asp Pro Ala Arg Phe  
 75 80 85

Pro Arg Tyr Leu Pro Glu Ala Tyr Cys Leu Cys Arg Gly Cys Leu Thr  
 90 95 100

Gly Leu Tyr Gly Glu Glu Asp Phe Arg Phe Arg Ser Thr Pro Val Phe  
 105 110 115 120

Ser Pro Ala Val Val Leu Arg Arg Thr Ala Ala Cys Ala Gly Gly Arg  
 125 130 135

Ser Val Tyr Ala Glu His Tyr Ile Thr Ile Pro Val Gly Cys Thr Cys  
 140 145 150

Val Pro Glu Pro Asp Lys Ser Ala Asp Ser Ala Asn Ser Ser Met Asp  
 155 160 165

Lys Leu Leu Leu Gly Pro Ala Asp Arg Pro Ala Gly Arg  
 170 175 180

<210> 21  
<211> 504  
<212> DNA  
<213> primate

<220>  
<221> CDS  
<222> (19)..(501)

<220>  
<221> mat\_peptide  
<222> (67)..(501)

<400> 21  
tgagtgtgca gtgccagc atg tac cag gtg gtt gca ttc ttg gca atg gtc 51  
Met Tyr Gln Val Val Ala Phe Leu Ala Met Val  
-15 -10

atg gga acc cac acc tac agc cac tgg ccc agc tgc tgc ccc agc aaa 99  
Met Gly Thr His Thr Tyr Ser His Trp Pro Ser Cys Cys Pro Ser Lys  
-5 -1 1 5 10

ggg cag gac acc tct gag gag ctg ctg agg tgg agc act gtg cct gtg 147  
Gly Gln Asp Thr Ser Glu Glu Leu Leu Arg Trp Ser Thr Val Pro Val  
15 20 25

cct ccc cta gag cct gct agg ccc aac cgc cac cca gag tcc tgt agg 195  
 Pro Pro Leu Glu Pro Ala Arg Pro Asn Arg His Pro Glu Ser Cys Arg  
 30 35 40

gcc agt gaa gat gga ccc ctc aac agc agg gcc atc tcc ccc tgg aga 243  
 Ala Ser Glu Asp Gly Pro Leu Asn Ser Arg Ala Ile Ser Pro Trp Arg  
 45 50 55

tat gag ttg gac aga gac ttg aac cgg ctc ccc cag gac ctg tac cac 291  
 Tyr Glu Leu Asp Arg Asp Leu Asn Arg Leu Pro Gln Asp Leu Tyr His  
 60 65 70 75

gcc cgt tgc ctg tgc ccg cac tgc gtc agc cta cag aca ggc tcc cac 339  
 Ala Arg Cys Leu Cys Pro His Cys Val Ser Leu Gln Thr Gly Ser His  
 80 85 90

atg gac ccc cgg ggc aac tcg gag ctg ctc tac cac aac cag act gtc 387  
 Met Asp Pro Arg Gly Asn Ser Glu Leu Leu Tyr His Asn Gln Thr Val  
 95 100 105

ttc tac cgg cgg cca tgc cat ggc gag aag ggc acc cac aag ggc tac 435  
 Phe Tyr Arg Arg Pro Cys His Gly Glu Lys Gly Thr His Lys Gly Tyr  
 110 115 120

tgc ctg gag cgc agg ctg tac cgt gtt tcc tta gct tgt gtg tgt gtg 483  
 Cys Leu Glu Arg Arg Leu Tyr Arg Val Ser Leu Ala Cys Val Cys Val  
 125 130 135

cgg ccc cgt gtg atg ggc tag 504  
 Arg Pro Arg Val Met Gly  
 140 145

<210> 22  
<211> 161  
<212> PRT  
<213> primate

<400> 22  
Met Tyr Gln Val Val Ala Phe Leu Ala Met Val Met Gly Thr His Thr  
-15 -10 -5 -1

Tyr Ser His Trp Pro Ser Cys Cys Pro Ser Lys Gly Gln Asp Thr Ser  
1 5 10 15

Glu Glu Leu Leu Arg Trp Ser Thr Val Pro Val Pro Pro Leu Glu Pro  
20 25 30

Ala Arg Pro Asn Arg His Pro Glu Ser Cys Arg Ala Ser Glu Asp Gly  
35 40 45

Pro Leu Asn Ser Arg Ala Ile Ser Pro Trp Arg Tyr Glu Leu Asp Arg  
50 55 60

Asp Leu Asn Arg Leu Pro Gln Asp Leu Tyr His Ala Arg Cys Leu Cys  
65 70 75 80

Pro His Cys Val Ser Leu Gln Thr Gly Ser His Met Asp Pro Arg Gly  
85 90 95

Asn Ser Glu Leu Leu Tyr His Asn Gln Thr Val Phe Tyr Arg Arg Pro  
100 105 110

Cys His Gly Glu Lys Gly Thr His Lys Gly Tyr Cys Leu Glu Arg Arg

115

120

125

Leu Tyr Arg Val Ser Leu Ala Cys Val Cys Val Arg Pro Arg Val Met  
130 135 140

Gly  
145

<210> 23  
<211> 620  
<212> DNA  
<213> rodent

<220>  
<221> CDS  
<222> (1)..(432)

<400> 23

```

cg1 c2 a3 g4 c5 g6 a7 a8 g9 c10 g11 a12 g13 a14 g15 t16 c17 t18 g19 c20 g21 t22 g23 a24 g25 c26 t27 c28 t29 g30 c31 g32 t33 g34 a35 g36 c37 t38 g39 c40 g41 t42 g43 a44 g45 c46 t47 c48 t49 g50 c51 g52 t53 g54 a55 g56 t57 g58 c59 g60 a61 g62 t63 g64 a65 g66 t67 g68 c69 t70 c71 t72 g73 c74 g75 t76 g77 a78 g79 t80 g81 c82 t83 c84 t85 g86 c87 g88 t89 g90 a91 g92 t93 g94 c95 g96 t97 g98 a99 g100 t101 g102 c103 t104 c105 t106 g107 c108 g109 t110 g111 a112 g113 t114 g115 c116 t117 c118 t119 g120 c121 g122 t123 g124 a125 g126 t127 g128 c129 t130 c131 t132 g133 c134 g135 t136 g137 a138 g139 t140 g141 c142 t143 c144 t145 g146 c147 g148 t149 g150 a151 g152 t153 g154 c155 t156 c157 t158 g159 c160 g161 t162 g163 a164 g165 t166 g167 c168 t169 c170 t171 g172 c173 g174 t175 g176 a177 g178 t179 g180 c181 t182 c183 t184 g185 c186 g187 t188 g189 a190 g191 t192 g193 c194 t195 c196 t197 g198 c199 g200 t201 g202 a203 g204 t205 g206 c207 t208 c209 t210 g211 c212 g213 t214 g215 a216 g217 t218 g219 c220 t221 c222 t223 g224 c225 g226 t227 g228 a229 g230 t231 g232 c233 t234 c235 t236 g237 c238 g239 t240 g241 a242 g243 t244 g245 c246 t247 c248 t249 g250 c251 g252 t253 g254 a255 g256 t257 g258 c259 t260 c261 t262 g263 c264 g265 t266 g267 a268 g269 t270 g271 c272 t273 c274 t275 g276 c277 g278 t279 g280 a281 g282 t283 g284 c285 t286 c287 t288 g289 c290 g291 t292 g293 a294 g295 t296 g297 c298 t299 c300 t301 g302 c303 g304 t305 g306 a307 g308 t309 g310 c311 t312 c313 t314 g315 c316 g317 t318 g319 a320 g321 t322 g323 c324 t325 c326 t327 g328 c329 g330 t331 g332 a333 g334 t335 g336 c337 t338 c339 t340 g341 c342 g343 t344 g345 a346 g347 t348 g349 c350 t351 c352 t353 g354 c355 g356 t357 g358 a359 g360 t361 g362 c363 t364 c365 t366 g367 c368 g369 t370 g371 a372 g373 t374 g375 c376 t377 c378 t379 g380 c381 g382 t383 g384 a385 g386 t387 g388 c389 t390 c391 t392 g393 c394 g395 t396 g397 a398 g399 t400 g401 c402 t403 c404 t405 g406 c407 g408 t409 g410 a411 g412 t413 g414 c415 t416 c417 t418 g419 c420 g421 t422 g423 a424 g425 t426 g427 c428 t429 c430 t431 g432 c433 g434 t435 g436 a437 g438 t439 g440 c441 t442 c443 t444 g445 c446 g447 t448 g449 a450 g451 t452 g453 c454 t455 c456 t457 g458 c459 g460 t461 g462 a463 g464 t465 g466 c467 t468 c469 t470 g471 c472 g473 t474 g475 a476 g477 t478 g479 c480 t481 c482 t483 g484 c485 g486 t487 g488 a489 g490 t491 g492 c493 t494 c495 t496 g497 c498 g499 t500 g501 a502 g503 t504 g505 c506 t507 c508 t509 g510 c511 g512 t513 g514 a515 g516 t517 g518 c519 t520 c521 t522 g523 c524 g525 t526 g527 a528 g529 t530 g531 c532 t533 c534 t535 g536 c537 g538 t539 g540 a541 g542 t543 g544 c545 t546 c547 t548 g549 c550 g551 t552 g553 a554 g555 t556 g557 c558 t559 c560 t561 g562 c563 g564 t565 g566 a567 g568 t569 g570 c571 t572 c573 t574 g575 c576 g577 t578 g579 a580 g581 t582 g583 c584 t585 c586 t587 g588 c589 g590 t591 g592 a593 g594 t595 g596 c597 t598 c599 t600 g601 c602 g603 t604 g605 a606 g607 t608 g609 c610 t611 c612 t613 g614 c615 g616 t617 g618 a619 g620 t621 g622 c623 t624 c625 t626 g627 c628 g629 t630 g631 a632 g633 t634 g635 c636 t637 c638 t639 g640 c641 g642 t643 g644 a645 g646 t647 g648 c649 t650 c651 t652 g653 c654 g655 t656 g657 a658 g659 t660 g661 c662 t663 c664 t665 g666 c667 g668 t669 g670 a671 g672 t673 g674 c675 t676 c677 t678 g679 c680 g681 t682 g683 a684 g685 t686 g687 c688 t689 c690 t691 g692 c693 g694 t695 g696 a697 g698 t699 g700 c701 t702 c703 t704 g705 c706 g707 t708 g709 a710 g711 t712 g713 c714 t715 c716 t717 g718 c719 g720 t721 g722 a723 g724 t725 g726 c727 t728 c729 t730 g731 c732 g733 t734 g735 a736 g737 t738 g739 c740 t741 c742 t743 g744 c745 g746 t747 g748 a749 g750 t751 g752 c753 t754 c755 t756 g757 c758 g759 t760 g761 a762 g763 t764 g765 c766 t767 c768 t769 g770 c771 g772 t773 g774 a775 g776 t777 g778 c779 t780 c781 t782 g783 c784 g785 t786 g787 a788 g789 t790 g791 c792 t793 c794 t795 g796 c797 g798 t799 g800 a801 g802 t803 g804 c805 t806 c807 t808 g809 c810 g811 t812 g813 a814 g815 t816 g817 c818 t819 c820 t821 g822 c823 g824 t825 g826 a827 g828 t829 g830 c831 t832 c833 t834 g835 c836 g837 t838 g839 a840 g841 t842 g843 c844 t845 c846 t847 g848 c849 g850 t851 g852 a853 g854 t855 g856 c857 t858 c859 t860 g861 c862 g863 t864 g865 a866 g867 t868 g869 c870 t871 c872 t873 g874 c875 g876 t877 g878 a879 g880 t881 g882 c883 t884 c885 t886 g887 c888 g889 t890 g891 a892 g893 t894 g895 c896 t897 c898 t899 g900 c901 g902 t903 g904 a905 g906 t907 g908 c909 t910 c911 t912 g913 c914 g915 t916 g917 a918 g919 t920 g921 c922 t923 c924 t925 g926 c927 g928 t929 g930 a931 g932 t933 g934 c935 t936 c937 t938 g939 c940 g941 t942 g943 a944 g945 t946 g947 c948 t949 c950 t951 g952 c953 g954 t955 g956 a957 g958 t959 g960 c961 t962 c963 t964 g965 c966 g967 t968 g969 a970 g971 t972 g973 c974 t975 c976 t977 g978 c979 g980 t981 g982 a983 g984 t985 g986 c987 t988 c989 t990 g991 c992 g993 t994 g995 a996 g997 t998 g999 c999 t1000 c1001 t1002 g1003 c1004 g1005 t1006 g1007 a1008 g1009 t1010 g1011 c1012 t1013 c1014 t1015 g1016 c1017 g1018 t1019 g1020 a1021 g1022 t1023 g1024 c1025 t1026 c1027 t1028 g1029 c1030 g1031 t1032 g1033 a1034 g1035 t1036 g1037 c1038 t1039 c1040 t1041 g1042 c1043 g1044 t1045 g1046 a1047 g1048 t1049 g1050 c1051 t1052 c1053 t1054 g1055 c1056 g1057 t1058 g1059 a1060 g1061 t1062 g1063 c1064 t1065 c1066 t1067 g1068 c1069 g1070 t1071 g1072 a1073 g1074 t1075 g1076 c1077 t1078 c1079 t1080 g1081 c1082 g1083 t1084 g1085 a1086 g1087 t1088 g1089 c1090 t1091 c1092 t1093 g1094 c1095 g1096 t1097 g1098 a1099 g1100 t1101 g1102 c1103 t1104 c1105 t1106 g1107 c1108 g1109 t1110 g1111 a1112 g1113 t1114 g1115 c1116 t1117 c1118 t1119 g1120 c1121 g1122 t1123 g1124 a1125 g1126 t1127 g1128 c1129 t1130 c1131 t1132 g1133 c1134 g1135 t1136 g1137 a1138 g1139 t1140 g1141 c1142 t1143 c1144 t1145 g1146 c1147 g1148 t1149 g1150 a1151 g1152 t1153 g1154 c1155 t1156 c1157 t1158 g1159 c1160 g1161 t1162 g1163 a1164 g1165 t1166 g1167 c1168 t1169 c1170 t1171 g1172 c1173 g1174 t1175 g1176 a1177 g1178 t1179 g1180 c1181 t1182 c1183 t1184 g1185 c1186 g1187 t1188 g1189 a1190 g1191 t1192 g1193 c1194 t1195 c1196 t1197 g1198 c1199 g1200 t1201 g1202 a1203 g1204 t1205 g1206 c1207 t1208 c1209 t1210 g1211 c1212 g1213 t1214 g1215 a1216 g1217 t1218 g1219 c1220 t1221 c1222 t1223
```

atc tgt atc ccc ccc aga gcc tct gag cca cac cca cca cgc aga atc 96  
 Ile Cys Ile Pro Pro Arg Ala Ser Glu Pro His Pro Pro Arg Arg Ile  
           20                 25                 30

ctg cag ggc cag caa gga tgg cct ctc aac agc agg gcc atc tct cct 144  
 Leu Gln Gly Gln Gln Gly Trp Pro Leu Asn Ser Arg Ala Ile Ser Pro  
                  35                 40                 45

tgg agc tat gag ttg gac agg gac ttg aat cggtcgcccaagac tgg 192  
 Trp Ser Tyr Glu Leu Asp Arg Asp Leu Asn Arg Val Pro Gln Asp Trp  
 50 55 60

tac cac gct cga tgc ctg tgc cca cac tgc gtc acg cta cag aca ggc . 240  
 Tyr His Ala Arg Cys Leu Cys Pro His Cys Val Thr Leu Gln Thr Gly  
       65              70              75              80

tcc cac atg gac ccg ctg ggc aac tcc gtc cca ctt tac cac aac cag 288  
 Ser His Met Asp Pro Leu Gly Asn Ser Val Pro Leu Tyr His Asn Gln  
                   85                  90                  95

acg gtc ttc tac cgg cgg cca tgc atg gcg agg aag gta ccc atc gcc 336  
 Thr Val Phe Tyr Arg Arg Pro Cys Met Ala Arg Lys Val Pro Ile Ala  
 100 105 110

gct act gct tgg agc gca ggt cta ccg agt ctc ctt ggc ttg tgt gtg 384  
 Ala Thr Ala Trp Ser Ala Gly Leu Pro Ser Leu Leu Gly Leu Cys Val  
     115              120              125

tgt gcg gcc ccg ggt cat ggc tta gtc atg ctc acc atc tgc ctg agg 432  
 Cys Ala Ala Pro Gly His Gly Leu Val Met Leu Thr Ile Cys Leu Arg  
     130                135                140

tgaatccgg gtgggagaga gggccaggt tacatcacct gccaatgcgg gccgggttca 492  
agcctgcaaa gcctaccta agcagcagg cccgggacag gatggagact tggggagaaa 552

<211> 144  
<212> PRT  
<213> rodent

<400> 24  
Arg His Arg Arg His Lys Ala Arg Arg Val Ala Glu Val Glu Leu Cys  
1 5 10 15  
Ile Cys Ile Pro Pro Arg Ala Ser Glu Pro His Pro Pro Arg Arg Ile-  
20 25 30  
Leu Gln Gly Gln Gln Gly Trp Pro Leu Asn Ser Arg Ala Ile Ser Pro  
35 40 45  
Trp Ser Tyr Glu Leu Asp Arg Asp Leu Asn Arg Val Pro Gln Asp Trp  
50 55 60  
Tyr His Ala Arg Cys Leu Cys Pro His Cys Val Thr Leu Gln Thr Gly  
65 70 75 80  
Ser His Met Asp Pro Leu Gly Asn Ser Val Pro Leu Tyr His Asn Gln  
85 90 95  
Thr Val Phe Tyr Arg Arg Pro Cys Met Ala Arg Lys Val Pro Ile Ala  
100 105 110  
Ala Thr Ala Trp Ser Ala Gly Leu Pro Ser Leu Leu Gly Leu Cys Val  
115 120 125  
Cys Ala Ala Pro Gly His Gly Leu Val Met Leu Thr Ile Cys Leu Arg  
130 135 140

<210> 25  
<211> 985  
<212> DNA  
<213> rodent

<220>  
<221> CDS  
<222> (1)..(507)

<220>  
<221> mat\_peptide  
<222> (49)..(507)

<400> 25  
atg tac cag gct gtt gca ttc ttg gca atg atc gtg gga acc cac acc 48  
Met Tyr Gln Ala Val Ala Phe Leu Ala Met Ile Val Gly Thr His Thr  
-15 -10 -5 -1  
gtc agc ttg cgg atc cag gag ggc tgc agt cac ttg ccc agc tgc tgc 96  
Val Ser Leu Arg Ile Gln Glu Gly Cys Ser His Leu Pro Ser Cys Cys  
1 5 10 15  
ccc agc aaa gag caa gaa ccc ccg gag gag tgg ctg aag tgg agc tct 144  
Pro Ser Lys Glu Gln Glu Pro Pro Glu Glu Trp Leu Lys Trp Ser Ser  
20 25 30  
gca tct gtg tcc ccc cca gag cct ctg agc cac acc cac cac gca gaa 192  
Ala Ser Val Ser Pro Pro Glu Pro Leu Ser His Thr His His Ala Glu  
35 40 45  
tcc tgc agg gcc agc aag gat ggc ccc ctc aac agc agg gcc atc tct 240  
Ser Cys Arg Ala Ser Lys Asp Gly Pro Leu Asn Ser Arg Ala Ile Ser  
50 55 60

cct tgg agc tat gag ttg gac agg gac ttg aat cgg gtc ccc cag gac Pro Trp Ser Tyr Glu Leu Asp Arg Asp Leu Asn Arg Val Pro Gln Asp 65 70 75 80	288
ctg tac cac gct cga tgc ctg tgc cca cac tgc gtc agc cta cag aca Leu Tyr His Ala Arg Cys Leu Cys Pro His Cys Val Ser Leu Gln Thr 85 90 95	336
ggc tcc cac atg gac ccg ctg ggc aac tcc gtc cca ctt tac cac aac Gly Ser His Met Asp Pro Leu Gly Asn Ser Val Pro Leu Tyr His Asn 100 105 110	384
cag acg gtc ttc tac ccg cgg cca tgc cat ggt gag gaa ggt acc cat Gln Thr Val Phe Tyr Arg Arg Pro Cys His Gly Glu Gly Thr His 115 120 125	432
cgc cgc tac tgc ttg gag cgc agg ctc tac cga gtc tcc ttg gct tgt Arg Arg Tyr Cys Leu Glu Arg Arg Leu Tyr Arg Val Ser Leu Ala Cys 130 135 140	480
gtg tgt gtg cgg ccc cgg gtc atg gct tagtcatgct caccacctgc Val Cys Val Arg Pro Arg Val Met Ala 145 150	527
ctgaggctga tgcccggttg ggagagaggg ccaggtgtac aatcaccttg ccaatgcggg 587	
ccgggttcaa gccctccaaa gccctacctg aagcagcagg ctcccggac aagatggagg 647	
acttggggag aaactctgac ttttgcactt ttttggaaactt cttttggaa ggagcagg 707	
ccgcttgtgc tgcttagagga tgctgttgtg gcatttctac tcaggaacgg actccaaagg 767	
cctgctgacc ctggaagcca tactcctggc tcctttcccc tgaatcccc aactcctggc 827	
acaggcactt tctccacctc tcccccttg cctttgttg tgtttggaa tgcatgccaa 887	
ctctgcgtgc agccagggt aattgccttg aaggatggtt ctgaggtgaa agctgttatac 947	
gaaagtgaag agatttatcc aaataaacat ctgtgttt 985	
 <b>&lt;210&gt; 26</b>	
<b>&lt;211&gt; 169</b>	
<b>&lt;212&gt; PRT</b>	
<b>&lt;213&gt; rodent</b>	
 <b>&lt;400&gt; 26</b>	
Met Tyr Gln Ala Val Ala Phe Leu Ala Met Ile Val Gly Thr His Thr -15 -10 -5 -1	
Val Ser Leu Arg Ile Gln Glu Gly Cys Ser His Leu Pro Ser Cys Cys 1 5 10 15	
Pro Ser Lys Glu Gln Glu Pro Pro Glu Glu Trp Leu Lys Trp Ser Ser 20 25 30	
Ala Ser Val Ser Pro Pro Glu Pro Leu Ser His Thr His His Ala Glu 35 40 45	
Ser Cys Arg Ala Ser Lys Asp Gly Pro Leu Asn Ser Arg Ala Ile Ser 50 55 60	
Pro Trp Ser Tyr Glu Leu Asp Arg Asp Leu Asn Arg Val Pro Gln Asp 65 70 75 80	

Leu Tyr His Ala Arg Cys Leu Cys Pro His Cys Val Ser Leu Gln Thr  
85 90 95

Gly Ser His Met Asp Pro Leu Gly Asn Ser Val Pro Leu Tyr His Asn  
100 105 110

Gln Thr Val Phe Tyr Arg Arg Pro Cys His Gly Glu Glu Gly Thr His  
115 120 125

Arg Arg Tyr Cys Leu Glu Arg Arg Leu Tyr Arg Val Ser Leu Ala Cys  
130 135 140

Val Cys Val Arg Pro Arg Val Met Ala  
145 150

<210> 27

<211> 784

<212> DNA

<213> primate

<220>

<221> CDS

<222> (3)...(281)

<400> 27

tc gtg ccg tat ctt ttt aaa aaa att att ctt cac ttt ttt gcc tcc	47
Val Pro Tyr Leu Phe Lys Lys Ile Ile Leu His Phe Phe Ala Ser	
1 5 10 15	

tat tac ttg tta ggg aga ccc aat ggt agt ttt att cct tgg gga tac	95
Tyr Tyr Leu Leu Gly Arg Pro Asn Gly Ser Phe Ile Pro Trp Gly Tyr	
20 25 30	

ata gta aat act tca tta aag tcg agt aca gaa ttt gat gaa aag tgt	143
Ile Val Asn Thr Ser Leu Lys Ser Ser Thr Glu Phe Asp Glu Lys Cys	
35 40 45	

gga tgt gtg gga tgt act gcc gcc ttc aga agt cca cac act gcc tgg	191
Gly Cys Val Gly Cys Thr Ala Ala Phe Arg Ser Pro His Thr Ala Trp	
50 55 60	

agg gag aga act gct gtt tat tca ctg att aag cat ttg ctg tgt acc	239
Arg Glu Arg Thr Ala Val Tyr Ser Leu Ile Lys His Leu Leu Cys Thr	
65 70 75	

aac tac ttt tca tgt ctt atc tta att ctc ata aca gtc att	281
Asn Tyr Phe Ser Cys Leu Ile Leu Ile Leu Ile Thr Val Ile	
80 85 90	

tgatatttta aaaaacccca gaaatctgag aaagagataa agtggttgc tcaaggttat 341

agaacagact accatgtgtt gtatttcaga ttttaattca tgtttgtctg attttaagtt 401

ttgttcgctt gccagggtac cccacaaaaa tgccaggcag ggcattttca tgatgcacct 461

gagataacctg aaatgacagg gtagcatcac acctgagagg ggtaaaggat gggAACCTAC 521

cttccatggc cgctgcttg cagtctcttgc ctgcatgcta gcagagccac tgtatatgtg 581

ccgaggctct gagaattaac tgcttaaaga actgccttct ggagggagaa gagcacaaga 641

tcacaattaa ccatatacac atcttactgt gcgaggtcat tgagcaatac aggaggatt 701

ttatacattt tagcaactat cttcaaaacc tgagctatag ttgtattctg ccccccttcct 761

ctgggcaaaa gtgtaaaagt ttg

784

<210> 28  
<211> 93  
<212> PRT  
<213> primate

<400> 28  
Val Pro Tyr Leu Phe Lys Lys Ile Ile Leu His Phe Phe Ala Ser Tyr  
1 5 10 15  
Tyr Leu Leu Gly Arg Pro Asn Gly Ser Phe Ile Pro Trp Gly Tyr Ile  
20 25 30  
Val Asn Thr Ser Leu Lys Ser Ser Thr Glu Phe Asp Glu Lys Cys Gly  
35 40 45  
Cys Val Gly Cys Thr Ala Ala Phe Arg Ser Pro His Thr Ala Trp Arg  
50 55 60  
Glu Arg Thr Ala Val Tyr Ser Leu Ile Lys His Leu Leu Cys Thr Asn  
65 70 75 80  
Tyr Phe Ser Cys Leu Ile Leu Ile Leu Ile Thr Val Ile  
85 90

<210> 29  
<211> 460  
<212> DNA  
<213> primate

<220>  
<221> CDS  
<222> (1)...(189)

<400> 29  
gtg act gta ttg tgg gga cag gaa gca caa att ccc atg tgg atc act 48  
Val Thr Val Leu Trp Gly Gln Glu Ala Gln Ile Pro Met Trp Ile Thr  
1 5 10 15  
agg aga gat aat aag tgg ggt cat ttc acc cct tgg tcc cct gct tcc 96  
Arg Arg Asp Asn Lys Trp Gly His Phe Thr Pro Trp Ser Pro Ala Ser  
20 25 30  
aga ccc aaa gag gcc tac atg gca ttg tgc ttc ctt ctt agt tgt agg 144  
Arg Pro Lys Glu Ala Tyr Met Ala Leu Cys Phe Leu Leu Ser Cys Arg  
35 40 45  
agg tgt gag ata caa tca ttt gcc tct gac ttt gag ggt tgg tcc 189  
Arg Cys Glu Ile Gln Ser Phe Ala Ser Asp Phe Glu Gly Trp Ser  
50 55 60

tagcatcccc ctgaccagta gccccttaaa tacttcattg atatggaaagg tctctgaatc 249  
ttcgtggct taatctacca ctctctgaag ttcttatgtc tttcaaaggc ctctaaaatc 309  
tctgccatgt cttgctcatc cagttgttag catgatgtca ttgatacagt ggactttgga 369  
atctaagtgg ggagacactg gtaagtgacc aattacttca cctgtggtgt gcaagccaga 429  
tcaggaagcc tctacctgca cgacaacaca t 460

<210> 30  
<211> 63  
<212> PRT  
<213> primate

<400> 30  
Val Thr Val Leu Trp Gly Gln Glu Ala Gln Ile Pro Met Trp Ile Thr  
1 5 10 15  
Arg Arg Asp Asn Lys Trp Gly His Phe Thr Pro Trp Ser Pro Ala Ser  
20 25 30  
Arg Pro Lys Glu Ala Tyr Met Ala Leu Cys Phe Leu Leu Ser Cys Arg  
35 40 45  
Arg Cys Glu Ile Gln Ser Phe Ala Ser Asp Phe Glu Gly Trp Ser  
50 55 60

<210> 31  
<211> 150  
<212> PRT  
<213> rodent

<400> 31  
Met Cys Leu Met Leu Leu Leu Leu Asn Leu Glu Ala Thr Val Lys  
1 5 10 15  
Ala Ala Val Leu Ile Pro Gln Ser Ser Val Cys Pro Asn Ala Glu Ala  
20 25 30  
Asn Asn Phe Leu Gln Asn Val Lys Val Asn Leu Lys Val Ile Asn Ser  
35 40 45  
Leu Ser Ser Lys Ala Ser Ser Arg Arg Pro Ser Asp Tyr Leu Asn Arg  
50 55 60  
Ser Thr Ser Pro Trp Thr Leu Ser Arg Asn Glu Asp Pro Asp Arg Tyr  
65 70 75 80  
Pro Ser Val Ile Trp Glu Ala Gln Cys Arg His Gln Arg Cys Val Asn  
85 90 95  
Ala Glu Gly Lys Leu Asp His His Met Asn Ser Val Leu Ile Gln Gln  
100 105 110  
Glu Ile Leu Val Leu Lys Arg Glu Pro Glu Lys Cys Pro Phe Thr Phe  
115 120 125  
Arg Val Glu Lys Met Leu Val Gly Val Gly Cys Thr Cys Val Ser Ser  
130 135 140  
Ile Val Arg His Ala Ser  
145 150

<210> 32  
<211> 147  
<212> PRT  
<213> rodent

<400> 32  
Met Leu Leu Leu Leu Ser Leu Ala Ala Thr Val Lys Ala Ala Ala  
1 5 10 15

Ile Ile Pro Gln Ser Ser Ala Cys Pro Asn Thr Glu Ala Lys Asp Phe  
 20 25 30

Leu Gln Asn Val Lys Val Asn Leu Lys Val Phe Asn Ser Leu Gly Ala  
 35 40 45

Lys Val Ser Ser Arg Arg Pro Ser Asp Tyr Leu Asn Arg Ser Thr Ser  
 50 55 60

Pro Trp Thr Leu His Arg Asn Glu Asp Pro Asp Arg Tyr Pro Ser Val  
 65 70 75 80

Ile Trp Glu Ala Gln Cys Arg His Gln Arg Cys Val Asn Ala Glu Gly  
 85 90 95

Lys Leu Asp His His Met Asn Ser Val Leu Ile Gln Gln Glu Ile Leu  
 100 105 110

Val Leu Lys Arg Glu Pro Glu Ser Cys Pro Phe Thr Phe Arg Val Glu  
 115 120 125

Lys Met Leu Val Gly Val Gly Cys Thr Cys Val Ala Ser Ile Val Arg  
 130 135 140

Gln Ala Ala  
 145

<210> 33  
<211> 155  
<212> PRT  
<213> primate

<400> 33  
Met Thr Pro Gly Lys Thr Ser Leu Val Ser Leu Leu Leu Leu Ser  
1 5 10 15

Leu Glu Ala Ile Val Lys Ala Gly Ile Thr Ile Pro Arg Asn Pro Gly  
20 25 30

Cys Pro Asn Ser Glu Asp Lys Asn Phe Pro Arg Thr Val Met Val Asn  
35 40 45

Leu Asn Ile His Asn Arg Asn Thr Asn Thr Asn Pro Lys Arg Ser Ser  
50 55 60

Asp Tyr Tyr Asn Arg Ser Thr Ser Pro Trp Asn Leu His Arg Asn Glu  
65 70 75 80

Asp Pro Glu Arg Tyr Pro Ser Val Ile Trp Glu Ala Lys Cys Arg His  
85 90 95

Leu Gly Cys Ile Asn Ala Asp Gly Asn Val Asp Tyr His Met Asn Ser  
100 105 110

Val Pro Ile Gln Gln Glu Ile Leu Val Leu Arg Arg Glu Pro Pro His  
115 120 125

Cys Pro Asn Ser Phe Arg Leu Glu Lys Ile Leu Val Ser Val Gly Cys  
130 135 140

Thr Cys Val Thr Pro Ile Val His His Val Ala  
145 150 155

<210> 34

<211> 151  
<212> PRT  
<213> viral

<400> 34  
Met Thr Phe Arg Lys Thr Ser Leu Val Leu Leu Leu Leu Ser Ile  
1 5 10 15  
Asp Cys Ile Val Lys Ser Glu Ile Thr Ser Ala Gln Thr Pro Arg Cys  
20 25 30  
Leu Ala Ala Asn Asn Ser Phe Pro Arg Ser Val Met Val Thr Leu Ser  
35 40 45  
Ile Arg Asn Trp Asn Thr Ser Ser Lys Arg Ala Ser Asp Tyr Tyr Asn  
50 55 60  
Arg Ser Thr Ser Pro Trp Thr Leu His Arg Asn Glu Asp Gln Asp Arg  
65 70 75 80  
Tyr Pro Ser Val Ile Trp Glu Ala Lys Cys Arg Tyr Leu Gly Cys Val  
85 90 95  
Asn Ala Asp Gly Asn Val Asp Tyr His Met Asn Ser Val Pro Ile Gln  
100 105 110  
Gln Glu Ile Leu Val Val Arg Lys Gly His Gln Pro Cys Pro Asn Ser  
115 120 125  
Phe Arg Leu Glu Lys Met Leu Val Thr Val Gly Cys Thr Cys Val Thr  
130 135 140  
Pro Ile Val His Asn Val Asp  
145 150

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/00005

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 C12N15/24 C07K14/54 A61K38/20 C07K16/24 G01N33/68  
 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 18826 A (SCHERING CORP ; INST NAT SANTE RECH MED (FR)) 13 July 1995 (1995-07-13) the whole document especially sequences ID no.6 and 9 ---	1-20
A	YAO Z ET AL: "HUMAN IL-17: A NOVEL CYTOKINE DERIVED FROM T CELLS" JOURNAL OF IMMUNOLOGY, US, THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 155, no. 12, 15 December 1995 (1995-12-15), pages 5483-5486, XP000602481 ISSN: 0022-1767 cited in the application ---	1-20 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

8 June 2000

Date of mailing of the international search report

29/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Le Cornec, N

## INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 00/00005

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 60127 A (CHEN JIAN ;GENENTECH INC (US); LI HANZHONG (US); FILVAROFF ELLEN () 25 November 1999 (1999-11-25) The whole document especially sequences ID no. 3,4,13 and 24 * 100% identity with sequences ID no.4 and 5 *	1-20
P,X	WO 99 61617 A (HUMAN GENOME SCIENCES INC ;EBNER REINHARD (US); RUBEN STEVEN M (US) 2 December 1999 (1999-12-02) the whole document especially figures 6A-B	1-20
E	WO 00 20593 A (GLASEBROOK ANDREW L ;SU ERIC W (US); LILLY CO ELI (US); LIU LING () 13 April 2000 (2000-04-13) the whole document especially sequences ID no.1 and 2 and the claims * 100% identity with sequences ID no.4 and 5 *	1-20
T	H. LI ET AL: "Cloning and characterization of the iL-17B and iL-17C, two members of the iL-17 cytokine family" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 97, no. 2, 18 January 2000 (2000-01-18), pages 773-778, XP002139729 NATIONAL ACADEMY OF SCIENCE. WASHINGTON., US ISSN: 0027-8424	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/00005

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9518826 A	13-07-1995	AU 1520895 A EP 0733069 A JP 11276171 A JP 2919974 B JP 9501572 T			01-08-1995 25-09-1996 12-10-1999 19-07-1999 18-02-1997
WO 9960127 A	25-11-1999	AU 3993799 A WO 9946281 A			06-12-1999 16-09-1999
WO 9961617 A	02-12-1999	AU 4208799 A			13-12-1999
WO 0020593 A	13-04-2000	NONE			